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Abstract 
 
 
Purpose: Sarcoidosis is a diverse condition. The condition currently has a limited body 
of knowledge surrounding the effect and role of physical activity and exercise on 
quality of life and disease management. Therefore, this project aimed to preliminarily 
establish trends and correlations in relationship to quality of life and disease 
management through environmental and lifestyle factors.  
Methods: The project involved a systematic review into physical activity, exercise 
capacity and muscle strength, two online epidemiological studies looking at 
environmental and lifestyle factors alongside type and symptoms of the condition. In 
addition to qualitative questions helping understand the views of patients. While a 
final study compared an objective (triaxial accelerometery) measure of physical 
activity against a standardised self-reported measure (IPAQ), in addition to their 
relationships with physiological and mental measures of sarcoidosis. 
Results: Sarcoidosis is typically associated with reduced exercise capacity and muscle 
strength with reductions more profound in patients reporting fatigue. Although 
physical activity has been found to be above and below recommended levels. Chapter 
five found quality of life, number of symptoms and fatigue were predictors (R2=.094) 
of perceived categories physical activity while accelerometer MVPA found calories 
burned per day and BMI as predictors (R2=.968). Fatigue was found to be a major 
issue within the population with number of symptoms and physical activity since 
diagnosis as predictors within chapter five (R2 =.238) and the SHQ within chapter 
seven (R2=.797). 
Conclusions: This was the first study to look at the role of sarcoidosis effects on work-
life balance. A large number of patients (41.5%) reported changing or stopping work 
due to sarcoidosis and thus the role and effects of physical activity needs further 
investigation, although the findings suggest MVPA cannot be used as the only form 
of physical activity measure and others such as steps per day; and light activity should 
be considered, physical activity is shown to be diverse within the population. Exercise 
rehabilitation can improve associated symptoms and deconditioning within 
sarcoidosis, while taught coping methods may be beneficial. 
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1. INTRODUCTION/LITERATURE REVIEW 
1.1. Sarcoidosis  
Sarcoidosis is a non-caseating granulomatous disease (Morand et al., 2015), it is a 
condition that involves the inflammation of organs and tissues (NHS, 2015a). 
Sarcoidosis is pulmonary in up to 90% of cases although the condition can affect 
numerous other locations, such as, the liver and heart, with 25% of cases affecting the 
skin (Saidha et al., 2012). The granulomas form due to the clustering of lymphocytes 
cells (Loke et al., 2013; National Heart, Lung and Blood Institute, 2013a), specifically 
T-cells due to an impaired immunosuppressive function (Broos et al., 2013). The 
mechanism(s) behind this is not clear, however, regulatory T Cells (Treg) have been 
shown to have increased apoptosis, which is thought to contribute to the impairment 
(Broos et al., 2015). The granulomas cause pulmonary fibrosis in 25% of cases 
(Iannuzzi et al., 2007). Pulmonary fibrosis is the most common mechanism for 
pulmonary hypertension within sarcoidosis (Handa et al., 2006), pulmonary 
hypertension involves high blood pressure within the pulmonary arteries (NHS, 2017) 
and is defined by mean pulmonary artery pressure of ≥25mm Hg at rest during right 
heart catheterisation (Hoeper et al., 2013). Other major symptoms include fatigue, 
muscle weakness and dyspnoea (Wirnsberger et al., 1998; Baughman, 2013). 
Commonly, patients with pulmonary sarcoidosis present with reduction in maximal 
breathing capacity, lung volume and diffusing capacity of the lung (DL) as well as 
increased airway resistance and hypnocapnea (Ting and Williams, 1965). Lung 
capacity has been shown to differ by 16% between those with the condition versus a 
healthy population (Baydur et al., 2001). Baughman et al. (2001) found 46.9% of 
sarcoidosis patients had a forced expiratory volume in 1 second/forced vital capacity 
(FEV1/FVC) ratio of > 80% of predictive and a further 13.2% scored >50-69% of 
predictive. The mechanisms behind the lung function reductions are multiple; they 
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include fibrotic scarring to the bronchial walls caused by the formation or granulomas 
and bronchial hyperactivity (Martinez & Flaherty, 2006; Martusewicz-Boros et al., 
2012), suggested as being related to granulomatous inflammation of the bronchial 
mucosa (Drent & Costabell, 2005), increased body composition as a result of fat mass 
and a decline in muscle strength (Ostrowski & Barud, 2006) linked to deconditioning.  
 
The ‘definitive’ aetiology of sarcoidosis remains unknown (Dubrey et al., 2014), 
however there has been numerous proposed mechanisms, the current research supports 
the hypothesis that the immune response within sarcoidosis is caused by a putative 
antigen in an individual with genetic susceptibility (Loke et al., 2013).  Sarcoidosis is 
diagnosed following the exclusion of other probable causes (Judson, 2008), as such, 
several tests are utilised to diagnose sarcoidosis, which are dependent on assessing the 
affected organs (NHS, 2015a). Tests include chest X-ray’s, computerised tomography 
(CT), lung function tests, tissue biopsy, blood tests and electrocardiogram (ECG) 
(National Heart, Lung and Blood Institute, 2013a). This task is a histopathologic and 
clinical dilemma due to a lack of distinction between sarcoidosis and sarcoid-type 
tissue reactions (Tchernev et al., 2015) such as lymph node metastases (Nag, 2011). 
Muller-Quernheim et al. (2006) states in up to 40% of cases of chronic beryllium 
disease has been misdiagnosed as sarcoidosis. Potential triggers of the disease include 
environmental and occupational factors (Dubrey et al., 2014; Iannuzzi et al., 2007; 
Newman & Newman, 2012). Kucera et al. (2003) found metal work, education, 
transportation industry and high humidity occupations were associated with 
sarcoidosis, whilst Newman et al. (2004) found those exposed within agricultural 
employment were at higher risk of sarcoidosis. Specific-work related exposures 
associated with sarcoidosis included vegetable dust, insecticides, mold and titanium 
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(Kucera et al., 2003; Newman et al., 2004). Kucera et al. (2003) also highlighted the 
limitations of using job titles as substitutes for exposure to specific agents. This point 
is further backed by Barnard et al. (2005), stating employees of building, gardening 
and hardware materials having a positive association to sarcoidosis whilst occupations 
involving exposure to metal fumes and dust being negatively associated with 
sarcoidosis. Newman & Newman (2012) stated there is a growing body of research 
supporting multiple causes including inorganic triggers and foreign antigens. Rybicki 
et al. (2004) suggested the risk of sarcoidosis increases with exposure to a photocopier, 
more specifically to toner dust i.e. an inorganic particle. On top of this Liu et al. (2016) 
found a significant difference for sarcoidosis morality due to occupational exposure 
based on gender and ethnicity with females and Afro-Caribbean’s at higher risk, which 
conforms to other research in the area (Baughman & Lower, 2011) however the 
reasoning for this remains unclear. This research highlights the multifactorial nature 
of sarcoidosis and why such a diverse approach to the disease is needed. Alongside 
this, an infectious communicable agent has been suggested as an initiating factor 
within the disease (Du Bois et al., 2003), although literature still lacks a definitive 
answer, Mycobacterium spp has been implicated the most, to date (Saidha et al., 2012). 
Edmondstone (1988) found UK nurses had a greater number with sarcoidosis, standing 
at 7.5 times more than expected. Although it is not clear if this is down to greater 
proximity to those with Sarcoidosis and therefore the communicable agent or if it 
relates to occupational and environmental factors associated with the health care 
profession and hospitals such as mold, mildew and high internal humidity (Newman 
et al., 2004). Another common variable associated to this is seasonal variations, 
showing peak clustering within spring months (Bardinas et al., 1989; Panayeas et al., 
1991), furthermore this seasonal clustering has been recorded in both northern and 
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southern hemispheres (Wilsher, 1998). Additionally, DNA and RNA of mycobacterial 
and Propionibacterium acnes has been found within sarcoid tissues (Iannuzzi et al., 
2007). Eishi et al. (2002) states P. acnes had an increased chance of being involved 
with the aetiology of sarcoidosis than mycobacterium in both European and Japanese 
sufferers, whilst the only microorganism found within lesions caused by sarcoidosis 
is P. acnes (Eishi, 2013). Saidha et al. (2012) suggests the combination of infection 
followed by an environmental agent such as Mycobacterium spp in a genetically 
predisposed individual as the causation of the disease.  
 
Although anyone can be affected by sarcoidosis, the highest incident rates have been 
recorded in Scandinavia and Japanese ethnicities (Iannuzzi et al., 2007). The reason 
for this is unknown, however northern Japan which typically has cold winters and mild 
summers; much like Scandinavia, has a higher incidence rate than the mild winters 
and warm summers of southern Japan (Yamaguchi et al., 1989). It is also noteworthy 
that those of Afro-Caribbean descent also have a higher incident rate than their 
Caucasian counterparts (Gerke, 2015). Rybicki et al. (1997) reported the incident rate 
of African-Americans as being three times that of Caucasian-Americans, along with 
higher chronic rates (Baughman et al., 2001) and a mortality rate 12-times higher than 
Caucasians when adjusted for age (Mirsaeidi et al., 2015). Although the NHS (2015a) 
suggests sarcoidosis is not inherited, this is primarily down to a lack of consensus and 
understanding of the genetic makeup of patients, as well as the current understanding 
among researchers that an external trigger is required in tandem with a predisposition 
to the disease (Iannuzzi & Rybicki, 2007; Loke et al., 2013). Therefore, it cannot be 
conclusively stated that there is no familial link. In contrast to this, Rybicki et al. 
(2001) found significantly heightened risk of the disease among first and second-
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degree relatives of sarcoidosis relatives. Monozygotic twins have also been noted as 
having a higher incidence rate in comparison to other siblings (Sverrild et al., 2008). 
On the other hand, Leil et al. (2013) suggests familial clustering may be due to shared 
environmental exposures and should not be overlooked due to shared genes. Current 
research supports the notion that human leukocyte antigen (HLA) class I and II are 
associated with sarcoidosis (Grunewald et al., 2004; Iannuzzi & Ryibicki, 2007) and 
can affect sarcoidosis disease risk as well as severity and phenotype (Grunewald, 
2008). An example of this is, the HLA-DRB1*03 & DQB1*0201 alleles being 
associated with acute onset and resolving sarcoidosis, while HLA-DRB1*15 & 
DQB1*0601 have been associated with chronic sarcoidosis (Berlin et al., 1997; Sato 
et al., 2002. Grunewald et al., 2004). However, Grunewald (2008) also states 
sarcoidosis is affected by multiple genes, unfortunately there is a lack of consensus of 
these other genes due to discrepancies among research to date (Iannuzzi & Ryibicki, 
2007). Nevertheless, Spagnolo & Grunewald (2013) states genetics not only 
determines overall disease susceptibility but also plays a key role in influencing 
phenotypic expression. However, it is worth noting the suggestion from Rybicki and 
Iannuzzi (2007) that genes influencing phenotypes may be separate from the genes 
affecting susceptibility, thus highlighting once again the range and complexity of this 
disease. 
The NHS (2015a) state “most people” with the condition suffer from acute sarcoidosis, 
where they develop symptoms abruptly and unexpectedly that then clear within a few 
months-years, the National Heart, Lung and Blood Institute (2013a) state more than 
half will enter remission within three years of diagnosis, which increases to two-thirds 
at 10 years of diagnosis with relapse occurring in less than 5% of patients. 
Unfortunately, there is still a significant number of patients who suffer chronically 
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from the disease (n=33% at 10 years+), which may be due to the persistence of 
granulomas leading to fibrotic scarring, which in turn leads to/worsens several 
debilitating symptoms of the disease (Broos et al., 2013). 
1.2. Treatment 
Currently, steroids are the predominant form of treatment for all forms of sarcoidosis 
(Judson, 2012; NHS, 2015a) usually taken in bouts varying from 6-24 months 
(Jennifer & Rashcovsky, 2004). Of the steroids used, corticosteroids are the 
predominant drug class (Grutters and Van der Bosch, 2006) with prednisone as the 
chief prescribed drug (National Heart, Lung and Blood Institute, 2013b). Despite 
steroids being used as a treatment to improve the condition, they have also been 
associated with a poorer quality of life (QOL; Judson et al., 2015) as well as lower 
exercise tolerance; demonstrated through a reduced six-minute walk distance 
(6MWD) following a six-minute walk test (6MWT) (Alhamad et al., 2010). The exact 
reasons for this, much like the aetiology of sarcoidosis itself are unknown; however, 
it has been suggested as another possible side effect of steroid use (Grutters & Van der 
Bosch, 2006). Other side effects include weight gain, increased blood pressure, 
cataracts, osteoporosis, increased risk of infection and suppressed hormone production 
from the adrenal gland (Poetker & Reh, 2010; Liu et al., 2013). These side effects lead 
to a further prescription of drugs which in-turn lead to a wider range of negative side 
effects, for example osteoporosis increasing the risk of fractures (Kanis et al., 2000). 
Typically, vitamin D supplementation is used to aid the elevation of this risk and help 
maintain healthy bones (Stovall, 2013) however Baughman & Lower (2014) found 
hypercalcuria and hypercalcemia can result due to this within sarcoidosis patients. 
Other side effects associated with prednisolone use include increased blood pressure 
that can lead to hypertension which if left untreated can lead to a stroke or heart attack 
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among other serious health conditions (NHS, 2016) as well as increased appetite, 
thinned skin and greater susceptible to to bruising (Judson, 2012). Due to the damaging 
side effects and the current limitations in treating sarcoidosis, novel therapies varying 
in their approach are required. One example of this is exercise rehabilitation (Naz et 
al., 2018). Outside of specific novel treatments, improvements of current systems such 
as better integration between a patient’s different specialist doctors and GP is another 
possible avenue for improving some primary and secondary symptoms. Bird et al. 
(2010) found chronic obstructive pulmonary disease (COPD) patients’ quality of life 
and symptoms improved following a patient focused integrated care facilitation model 
which involved identifying unmet health care needs and then providing the relevant 
information and advice. However, as mentioned above, lack of information regarding 
the cause, flare-up and mechanisms as well as the perceptions of those with the 
condition is a major limitation to the treatment area. Due to this, greater knowledge is 
required to aid the formation of better, sarcoidosis tailored treatments. Current 
research into Sarcoidosis is often narrowly focussed on one aspect and a wider 
perceptive is needed due to the multi-dimensional nature of the condition. Multiple 
factors compiled together may lead to a trend being discovered that can be utilised to 
advance research, diagnosis and treatment of the condition. Patients often have their 
own views regarding triggers of flare ups and how to best minimise the symptoms 
however research thus far has overlooked their insight opting for a more clinical focus 
with lung function often the main measure; although lung function has been shown to 
not correlate with quality of life (Wirnsberger et al., 1998; De Boer & Wilsher, 2012) 
as well as not predicting an individual’s functional limitations (Kallianos et al., 2015).  
 
1.3. The role of non-pharmacological rehabilitation 
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Reis et al. (2007) argues that exercise capacity, breathlessness and quality of life can 
be improved significantly with appropriate rehabilitation such as upper and lower 
extremity exercise training in numerous pulmonary diseases, such as COPD, cystic 
fibrosis, thoracic cage abnormalities and bronchiectasis (Foster & Thomas, 1990; Reis 
et al., 2007), however little has been noted in sarcoidosis (Marcelis et al., 2015; 
Strookappe et al., 2015; Naz et al., 2018).  Drent et al. (2015) argues due to wide 
ranging effects of sarcoidosis a multidisciplinary approach to its management is 
required. Generally, “high-frequency, low-impact” exercise can be recommended 
(Strookappe et al., 2016a), however further studies to fine tune the training parameters 
are required. As with any chronic condition, modifications of the duration, frequency 
and intensity of exercise programs are vital to achieve physical benefits (Spruit et al., 
2005a; Swigris et al., 2011; Boots et al., 2011; Strookappe et al., 2015).  
 
Deconditioning often occurs within sarcoidosis patients (Mitchell et al., 2012; 
Fleischer et al., 2014). The typical symptoms of sarcoidosis; fatigue, muscle weakness 
and dyspnea (Wirnsberger et al., 1998; Baughman, 2013), have been suggested as 
being pivotal in the deconditioning process (Spruit et al., 2005b; Fleischer et al., 
2014). Fatigue has been reported in up to 70% of cases of sarcoidosis (Drent et al., 
2014) and cited as decreasing quality of life (Drent et al., 2014; De Boer et al., 2014). 
The symptoms lead to a decrease in an individual’s daily activities (Mitchell et al., 
2012) and increased perception of dyspnoea (O’Donnel 2006) that further limits 
patients’ participation to activities or structured exercise programmes. Dyspnoea is 
also associated with a lower quality of life (De Boer et al., 2014), however, the ACSM 
(2014) argues that a correct training regime can help decrease severity and 
inflammation of the disease. Each symptom of sarcoidosis typically impacts on 
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another, where muscle weakness causes increased dyspnoea and this combination has 
a significant effect on exercise tolerance (Spruit, 2005b). Due to these reasons exercise 
is not always a possible initial treatment method, or it requires a longer time to take 
effect than the 6-12 weeks suggested (Reis et al., 2007). These factors and the current 
limited research in this population, suggest that further studies into improving 
sarcoidosis patients’ exercise tolerance and thusly quality of life are required.  
 
1.4. Exercise Rehabilitation 
Exercise is essential for the maintenance and improvement of respiratory function 
(Cheng et al., 2003; ACSM, 2014). However, reduced physical activity is common 
among those with sarcoidosis (Spruit et al., 2005a; Marcellis et al., 2013a). The 
respiratory system’s ability to function effects everything an individual does from 
walking up a flight of stairs to jogging (Battaglia et al., 2015). A reduction in lung 
function can be the result of numerous reasons, such as; aging, chronic disease, 
smoking, obesity and muscular disorders such as muscular dystrophy (Ostrowski & 
Barud, 2006; Sharma & Goodwin, 2006). Reduced lung function has been linked to a 
decrease in physical activity (Serres et al., 1998), which may be due to a diminished 
supply of oxygen delivery, and as such results in greater exertion for the same level of 
work and causes increased fatigue (Boutellier & Piwko, 1992). Additionally, reduced 
lung function results in an increase in cardiovascular mortality (Sin et al., 2005); 
although the mechanisms are not fully known, reduced forced expiratory volume 
(FEV1) has been associated with atherosclerosis and chronic low-grade systemic 
inflammation (Sin et al., 2005). 
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Exercise has also been shown to improve dyspnoea, exercise tolerance, perceived 
fatigue and quality of life (Taylor et al., 2014). Dyspnoea is the feeling of 
breathlessness (Antoniu, 2010); it consists of a number of sensations including 
tightness of the chest, increased effort to breath and air hunger (Nishino, 2011). 
Exercise tolerance relates to an individual’s ability to exercise (Casaburi, 2006; Belfer 
& Reardon, 2009) and intolerance to exercise has been shown to be a strong predictor 
of poor quality of life (Belfer & Reardon, 2009; Drent et al., 2014). The quality of life 
of an individual has been linked to an individuals’ exercise tolerance (Drent et al., 
2014) however intolerance to exercise is a major symptom of pulmonary sarcoidosis 
(Hildebrand et al., 2012), with it being the first physiological parameter impaired 
(Akkoca et al., 2005), with a number of studies have shown sarcoidosis patients to 
have a decreased perceived quality of life (Hinz et al., 2012; Heer et al., 2013; Drent 
et al., 2014). Vries and Wirnsberger (2005) suggest that the age range may be a factor, 
older populations are better at coping with chronic diseases (Loddenkemper et al. 
1998) but as sarcoidosis peaks between 20-40 years of age (Lenner et al., 2002), there 
is a greater struggle associated with a decline in quality of life. A limitation of quality 
of life testing is that it reflects someone’s perception of their limitations and therefore 
changes between individuals (De Vries & Wirnsberger, 2005). In addition, fatigue has 
been recognised as a disabling symptom within sarcoidosis and listed as a reason for 
decreased quality of life (Drent et al., 2014); it has also been found to be strongly 
associated to depression and therefore linked to a decreased quality of life (Leone, 
2010). The NHS (2015a) argues that because fatigue cannot be physically identified, 
it can lead to loneliness. quality of life is made up of a number of categories and 
therefore any decrease/increase is multidisciplinary, an example is corticosteroid 
therapy used to treat sarcoidosis often increases fatigue and thus decreases quality of 
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life (Drent et al., 2014). The NHS (2015a) state fatigue, joint pains, weight loss and 
night sweats are all symptoms associated with a decrease in quality of life. Therefore, 
therapies are required to help the condition but also prevent further reductions in 
quality of life. 
Despite sarcoidosis affecting a significant amount of people globally and being second 
only to asthma in young adults for respiratory diseases (Morgenthau & Iannuzzi, 
2011), there is a short supply of research into the condition as well as novel treatments 
such as with exercise to alleviate the primary and secondary symptoms. 
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2. AIMS AND OBJECTIVES 
2.1. Aims 
The aim of this thesis was to establish the impact of physical activity on sarcoidosis 
and establish trends between environment, physical activity, forms and symptoms of 
sarcoidosis and medical history. The project aimed to better understand sarcoidosis in 
relation to multiple internal & external factors such as types and symptoms of 
sarcoidosis (self-reported), physical activity, length of condition, quality of life, 
exercise performance and muscle strength.  
Firstly, a systematic review (chapter four) aimed to group and better understand the 
outcome effects of sarcoidosis on exercise capacity, muscle strength and physical 
activity. 
Chapters five and six aimed to establish trends in relation to environment, physical 
activity and personal views of day-to-day experiences. Patient involvement helped to 
develop priorities in clinical care and the work aimed to identify patient-reported 
outcome measures to establish further understanding of the phenotype and exercise 
capacity of patients.  
The primary aim of chapter seven was to ascertain the physical activity patterns in 
those with pulmonary sarcoidosis with regards to perceived physical activity and 
actual physical activity. While the secondary aim of the study was to understand the 
effect of pulmonary sarcoidosis in relation to muscle strength and exercise capacity 
against physical activity, lung function quality of life as well as how this differs to 
normative values. 
2.2. Objectives 
• To establish multifactorial patterns within pulmonary sarcoidosis considering 
environment, physical activity and medical history as well as patient 
perceptions. 
• To determine the influence and relation of real-world physical activity versus 
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self-reported physical activity as well as too exercise performance (aerobic) 
and muscle strength on symptoms and physiological outcomes. 
 
3. GENERAL METHODOLOGIES  
This chapter outlines the justification of the quantitative and qualitative research 
design and methods employed with consideration of research rigor and ethics. 
 
3.1. Participants 
Participants with medically diagnosed pulmonary sarcoidosis were selected, all 
pulmonary radiographic stages (0-IV) and length of time since diagnosis were 
accepted. All radiographic stages were accepted for several reasons, firstly within 
chapter five and six all forms of sarcoidosis were accepted and as such participants 
may not have had pulmonary involvement (stage 0), Siltzbach et al., (1974) states 
5-10% have stage 0. Furthermore, pulmonary function abnormalities have been 
shown not to correlate with the radiographic stage (Criado et al., 2010) while 
radiographic stage effect on symptom severity is also unknown. A diagnosis of 
sarcoidosis was accepted provided the participant had been clinically diagnosed 
ascertained by self-reporting, self-reported sarcoidosis was accepted due to the 
online approach of chapter five and six as well as the population size and not 
wanting to discourage any potential participants. However, individuals with 
diagnosis of other significant respiratory disorders (asthma, COPD, lung cancer, 
cystic fibrosis) were excluded. For all experimental studies, participants were 
recruited initially through support groups and online forums from the known 
sarcoid population. 
Exclusion Criterion was altered appropriately between the different studies’, 
within chapter seven the inability to perform physical and/or exercise tests such as 
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cardiovascular disease or an injury in the past six months that inhibits their ability 
to perform the tests determined through completion of a sub-maximal fitness test 
(Appendix 1). Other exclusion factors for chapter seven included pregnancy and 
an inability to obtain informed consent and cognitive failure making them unable 
to give consent or understand questionnaires or instruction. 
3.2. Equipment and Procedures 
3.2.1. Physical Activity 
Physical activity was assessed in several different ways across the experimental three 
studies’ (chapters five, six and seven). Within Chapter five physical activity was based 
purely on self-perception and whether they considered themselves to be physically 
active based on the question “What are your current physical activity levels?” (adapted 
from current NHS guidelines of 30 minutes moderate physical activity being 
considered physical activity for the related day) with a follow-up question to 
understand whether patients considered themselves to have increased/decreased or 
remained the same since diagnosis of sarcoidosis (Appendix 2). For chapter six and 
seven the validated questionnaire of International Physical Activity Questionnaire 
(IPAQ; Craig et al., 2003) was utilised (Appendix 3). The IPAQ comprises of 27 items 
across five activity domains asked independently, the domains include job-related 
physical activity, transportation physical activity, housework/maintenance, 
recreation/leisure-time physical activity and sitting time. Benefits and thus reasons for 
the use of the IPAQ were multiple, firstly it has been validated across a range of 
diverse countries including the U.K and USA (Craig et al., 2003) where the majority 
of online participants had selected as their nationality and current country of residence 
within chapter five. Additionally, Craig et al. (2003) found strong correlations of test-
retest reliability (mean .80) across the populations too. Further research into the IPAQ 
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also found similar findings of acceptable validity and test-retest ability in both healthy 
populations (Hagstromer et al., 2006; Oyeyemi et al., 2014) and lung diseases 
including asthma (Varlaet et al., 2013) and COPD (Liao et al., 2014). For chapter 
seven real world physical activity was also reported on top of self-reported physical 
activity (IPAQ) via a tri-axial accelerometer (GT3X+ accelerometer, Actigraph). The 
device was worn on the right hip for five days the following morning from participants 
first lab visit, sample rate was set to 100Hz and all participant information (gender, 
stature, mass, age, ethnicity) was entered including whether the right was their 
dominant side or not and the data was uploaded and analysed using the Freedson 1998 
adult bouts algorithm within the ActiLife programme (Actigraph). Currently there is 
no consensus of minimum wear time required for accelerometer data (Trost et al., 
2005). Due to the population size and length of time with the device (five), a minimum 
of seven hours wear time per day was required when analysing the data, as too not 
discourage participation within the study and still allow for an accurate representation 
of a participant’s day, these factors were set within the ActiLife programme before 
analysis to allow for the removal of any of did not meet the set criterion. The 
accelerometer was selected due to its accuracy of measuring real world physical 
activity (Sallis, 2010; Lee & Shrioma, 2014), ease of use for participants (Murphy, 
2009; Sallis, 2010) and advantages over self-reporting methods such as the IPAQ 
(O’Neill et al., 2017). Advantages included no need for participant recall and thus no 
over/underestimation of activity (Sylvia et al., 2014). Accelerometers have also been 
used in previous studies within sarcoidosis (Korenromp et al., 2011; Saligan, 2014) 
and compared/correlated against the IPAQ (Hagstromer et al., 2010; Wanner et al., 
2016). 
3.2.2. Quality of life, Depression and Fatigue 
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Quality of life, depression and fatigue were measured via three methods across the 
three experimental studies’ (chapters five, six and seven). The sarcoidosis health 
questionnaire (SHQ; Cox et al., 2003; Appendix 4) for quality of life, the center for 
epidemiologic studies depression scale for depression (CES-D; Eaton et al., 2004; 
Appendix 5) and the fatigue assessment scale for fatigue (FAS; Michielsen et al., 2003; 
Appendix 7) Firstly, the SHQ was selected as it has been shown to be a reliable 
indicator of quality of life as well as having been created and developed specifically 
for the condition (sarcoidosis) that the studies’ focussed on (Cox et al., 2003). The 
questionnaire comprised of 29 questions separated into three categories daily 
functioning, physical functioning and emotional functioning and is based on a 7-point 
likert scale (Cox et al., 2003). Furthermore, the SHQ has been utilised across the 
literature too (Cox et al., 2004; De Vries & Drent, 2008; De Boer & Wilsher, 2012) 
and as such allowed for comparison of the new findings against published literature. 
While the CES-D was selected due to its validity within the general population 
(Radloff, 1977) and prior use within sarcoidosis for indicating depressive symptoms 
(Chang et al., 2001; Cox et al., 2003; Elfferich et al., 2011). The CES-D questionnaire 
involved 20 questions on a 4-point likert scale. Fatigue has been noted as being 
significant within sarcoidosis (Baughman, 2013) in terms of its affect and incidence 
(Drent et al., 2014) and therefore was included within this study. The fatigue 
assessment scale was chosen due to its use within previous sarcoidosis research 
(Marcellis et al., 2013a; Drent et al., 2014; Saligan, 2014; Strookappe et al., 2015) and 
validity within the required population (De Vries et al., 2004). The FAS is a 10-item, 
5-point likert scale questionnaire split equally into physical and mental fatigue 
questions. 
3.2.3. Muscle Strength and exercise performance (aerobic) 
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Muscle strength was measured in two ways within chapter seven. The first was 
handgrip strength (HGS) and the second isokinetic dynamometer. Handgrip strength 
is a widely used method for measuring muscle strength in a range of populations, 
healthy and ill (Burtin et al., 2015; Leong et al., 2016). The reason for its regular use 
is its strong associations with numerous variables including mortality (Oksuzyan et 
al., 2017), functional ability (Taekema et al., 2010) and quality of life (Jakobsen et al., 
2010). In addition to its test-rest reliability (Haward & Griffin, 2002), as well as 
previously being used within sarcoidosis populations (Korenromp et al., 2011; 
Strookappe et al., 2015; Strookappe et al., 2016b). Within chapter seven participants 
were required to hold the hand grip device with a straight arm above their head as the 
start position and then squeeze the device as hard as they could when bringing the 
device down towards their body in a side motion while maintaining a straight arm. 
This was conducted three times per arm (swapping sides for each test) with the mean 
of the three being recorded. The other method of isokinetic dynamometry was selected 
due to its ability to isolate specific muscle(s) (Osternig, 1986) such as quadriceps and 
hamstrings along with its ability to pre-set a desired speed of motion (Nimbarte et al., 
2009). The measurements utilised within chapter seven were based on the systematic 
review (Chapter four, Morton-Holtham et al., ndA) with elbow flexor muscle strength 
(EFMS), quadricep peak torque (QPT) and hamstring peak torque (HPT) all 
commonly measured within the sarcoidosis literature (Korenromp et al., 2011; 
Marcellis et al., 2013b; Drent et al., 2014; Marcellis et al., 2015; Strookappe et al., 
2015; Strookappe et al., 2016b). For EFMS the isokinetic dynamometry was set up as 
per the biodex manual (Biodex System 4, Biodex Corporation, NY, USA), this 
involved the attachment of the elbow adapter, aligning the shaft red dot with the 
relevant R or L (based on participants dominant side) and seating the participant. 
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Following this, the participant was aligned and moved into position before the device 
range of motion was recorded (maximal flexion and extension of the elbow), the 
device was set to 120 degrees per second due to the unknown muscle strength of 
participants taking part. QPT and HPT were set up in a similar fashion with their 
relevant adapters, again following the biodex manual. For QPT and HGS the device 
was set to 180 degrees per second. Across the three measurements participants were 
required to complete five repetitions as fast and as hard as they could, three times with 
a rest period between. Participants highest score were recorded. The six-minute walk 
distance (6MWD) is often utilised in clinical populations (Kowalska et al. 2012; 
Marcellis et al., 2013a; Drent et al., 2014; Zieleznik et al., 2015), and is recorded via 
a six-minute walk test (6MWT) (Butland et al., 1982; American Thoracic Society, 
2002).  The 6MWT was performed along a straight flat 30 metre course indoors, 
participants walked as fast as they felt able to for 6 minutes (Butland et al., 1982). No 
warm-up is required, however participants were seated and rested for a minimum of 
20 minutes following their muscle strength tests based on exercise-based pulmonary 
rehabilitation research (Vainshelboim et al., 2014), additional heart rate (bpm) was 
checked after the 20 minutes and then at two-minute intervals until heart rate returned 
to baseline (ACSM, 2014). The 6MWT has been used in a wide range of studies 
(Alhamad et al., 2010; Baughman et al., 2007; Kallianos et al., 2015), this is due to 
the increased safety in comparison to an aerobic capacity test (V̇O2max) as well as its 
ease of use and incorporation of low-cost equipment (American Thoracic Society, 
2002).  
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3.2.4. Chapter five and six questionnaire development 
Both chapter five (appendix 2) and six involved (appendix 6) online based 
questionnaires conducted via Qualtrics. An online approach was utilised due to the 
incidence of sarcoidosis in the U.K. (1 in 10,000; NHS, 2015a) as this allowed us to 
reach a wider portion of the population via a low-cost method within the U.K. and 
across the globe. Additionally, the majority of recruitment was via online platforms 
and therefore continuing the research online removed another barrier of difficulty as 
participants could start and complete the questionnaires direct from whatever device 
(smartphone, tablet, PC etc.) they saw our information on. Development of both 
surveys took a wide and complex approach; validated questionnaires such as the 
IPAQ, SHQ and FAS (Appendix 3, 4 & 8) were utilised where possible due to their 
validity and the ability to directly compare previous and current findings. Standardised 
closed ended questions such as participants smoking status, age, gender and ethnicity 
(appendix 2) were also utilised alongside the validated questionnaires. Participants had 
the ability to skip any question barring validated questionnaires once they had been 
started but were offered the opportunity to skip before starting them, with the 
questionnaire explained prior to their commitment.   
Within chapter five, open-ended qualitative questions (appendix 2) were also included 
allowing for a further reaching and more comprehensive understanding of patients 
views on both barriers since sarcoidosis diagnosis as well as factors they feel are 
beneficial and detrimental to their health.  
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4. CHAPTER FOUR SYSTEMATIC REVIEW 
4.1. A Systematic Review of Physical Activity and Physical Fitness in 
Sarcoidosis.  
4.1.1. Chapter four Abstract 
Background: Individuals with sarcoidosis are at risk of deconditioning and heightened 
non-communicable diseases through decreased muscle strength and physical activity 
levels. The purpose of this systematic review was to analyse published data to provide 
an overview of the effects of sarcoidosis on physical activity and physical fitness. 
Methods: A systematic search of PubMed and Science Direct, was conducted in 
February 2018 following PRISMA guidelines, to determine the effects of sarcoidosis 
on physical activity and fitness. Experimental studies of patients with sarcoidosis in 
which exercise capacity, physical activity and/or strength were measured were 
selected.  
Results: A total of twenty-two trials with 1488 participants met the inclusion criteria. 
These studies (published between 1986-2018) found a reduced exercise capacity, 
physical activity level and muscle strength within sarcoidosis patients, with those with 
fatigue affected more than non-fatigued sarcoidosis patients. 
Conclusions: Physical activity is reduced in sarcoidosis compared to normative values, 
including sedentary healthy individuals. In addition, muscle strength and exercise 
capacity are reduced, with a large portion of individuals affected by fatigue. However, 
three exercise intervention trials demonstrated improved muscle strength and six-
minute walk distance alongside decreased fatigue scores. Further well-designed trials 
with exercise prescription are needed to establish standardised exercise 
recommendations specific to sarcoidosis.  
 
4.2. Introduction 
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Physical activity and, by extension, exercise should be a key component of everyone’s 
life for numerous health reasons, including improved quality of life and reduced risk 
of non-communicable diseases (NHS, 2015b). The need for physical activity and/or 
exercise within chronic disease(s) is amplified due to its ability to reduce symptoms 
and therefore improve the health of individuals (Gleeson et al., 2011). However, 
within chronic disease, specifically interstitial lung diseases (ILD) such as asthma, 
Chronic Obstructive Pulmonary Disease (COPD) and sarcoidosis (Korenromp et al., 
2011; Watz et al., 2011; Saligan, 2014), physical activity has been recorded as lower 
than healthy counterparts, despite the known public health benefits for both healthy 
and chronically ill populations (Durstine et al., 2000; Warbuton et al., 2006). For 
example; regular physical activity within COPD has been shown to reduce not just 
admissions to hospital, but also all-cause mortality, as well as specifically, respiratory 
mortality (Garcia-Aymerich et al., 2006), while physical inactivity is the fourth 
biggest killer across the world’s population (Kohl et al., 2012). 
Sarcoidosis is a non-caseating granulomatous disease (Morand et al., 2015), a 
condition that involves the inflammation of organs and tissues (Kobak, 2015). The 
granulomas form as a result of lymphocyte cells clustering together (Loke et al., 2013). 
Up to 90% of sarcoidosis cases are pulmonary; however, the condition can affect 
numerous other locations, such as the liver, heart and skin (Saidha et al., 2012). 
Despite sarcoidosis affecting a significant number of people globally (sarcoidosis 
affects 1 in 10,000 in the UK; NHS, 2015a) and being second only to asthma in young 
adults for respiratory diseases (Morgenthau & Iannuzzi, 2011), there is a short supply 
of research into the condition, as well as non-pharmacological treatments to alleviate 
the primary and secondary symptoms. Unfortunately, the typical sarcoidosis 
symptoms including fatigue, dyspnoea and chronic cough (Wirnsberger et al., 1998; 
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Baughman, 2013), often lead to decreased levels of physical activity and the negative 
side effects associated with this, such as muscular atrophy like sarcopenia or cachexia 
(Cremers et al., 2013), and as such the symptoms have been suggested as being pivotal 
within the deconditioning process (Fleicher et al., 2014). The loss of muscle mass and 
strength is a major problem in sarcoidosis (Baughman, 2013) as this leads to reduced 
quality of life caused by an impairment of day-to-day functional abilities such as stair 
climbing or carrying shopping. High levels of fatigue and decreased lung function 
(Martuseeqicz-Boros et al., 2012; Baughman, 2013; Drent et al., 2014) cause greater 
exertion during physical tasks such as stair climbing or walking (Kallianos et al., 
2015), which aids in the faster progression of the deconditioning process and thus 
compounds the above (Durstine et al., 2013). Although, it is worth noting that within 
healthy adolescent males, only vigorous physical activity was positively associated 
with lower body muscle strength (Moliner-Urdiales et al., 2010). Despite these 
findings (Moliner-Urdiales et al., 2010), it is unclear whether this trend is consistent 
across all demographics such as age, fitness level and disease severity as those with 
greater muscular strength/endurance would need to elicit greater effort to improve on 
current levels such as progressive overloading within bodybuilders seeking increased 
muscle mass (Helms et al., 2014). Although, physical activity and exercise, as well as 
muscle strength due to its relevance to physical health, have a growing body of 
knowledge in relation to sarcoidosis (Strookappe et al., 2016a), still much remains 
unknown, including the effect of sarcoidosis on muscle in terms of strength and mass 
and the mechanism behind any decrease in terms of how much can be directly 
associated with sarcoidosis rather than other compounding factors such as reduced 
physical activity. 
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Therefore, better understanding of exercise, physical activity and muscle strength 
within sarcoidosis and the other factors such as lung function and heightened 
inflammation that may induce changes, may help to improve the treatment and 
guidance available to patients and thus lead to improved health status and quality of 
life. A better understanding through compiling all currently available research on 
exercise, physical activity and muscle strength within sarcoidosis is therefore required, 
with the aim of drawing insight and defining future directions for new research and 
potential treatment strategies for the condition. The purpose of this systematic review, 
therefore, was to analyse published data to provide an overview of the effects of 
sarcoidosis on physical activity and physical fitness. 
 
4.3. Methodology 
4.3.1. Data Sources and Searches 
Standardised systematic review methodology based on PRISMA (Moher et al., 2009; 
Shamseer et al., 2015) was utilised throughout this review. A search of PubMed and 
Science Direct was conducted in February 2018 and all duplicate documents found 
were removed from the results. Additionally, a hand search of the reference lists of 
articles included in the final analysis that were identified via the database search was 
conducted, as were the first twenty “related articles” of those included database search 
articles on PubMed. A hand search of other reviews, commentaries, letters, PhD 
dissertations, and reference lists of original articles was also conducted. The search 
terms chosen to aid this review were constructed based on the PICOT framework 
(Population, intervention, comparison, outcome, time; Shamseer et al., 2015). Terms 
utilised included: “Sarcoidosis” OR “Pulmonary”, AND “Physical Activity” OR 
“Rehabilitation”, OR “Exercise Prescription”, OR “Exercise Training”, OR “Muscle 
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Strength”, OR “Aerobic”, “Aerobic Capacity”, OR “Cardiopulmonary Exercise 
Testing (CPET)”, OR “Handgrip”, OR “Isokinetic dynamometry”. 
 
4.3.2. Study Selection 
Inclusion criterion included sarcoidosis being researched individually and not as part 
of a wider group such as interstitial lung disease (ILD). Exercise testing of sarcoidosis 
participants including aerobic, muscle strength and physical activity and included both 
real-world data (i.e. accelerometer) and questionnaires (i.e. international physical 
activity questionnaire; IPAQ).  
Exclusion criterion extended to mixed ILD studies, lack of exercise testing, case 
studies and other systematic reviews/meta-analysis as well as use of inspiratory 
muscle training (IMT). The reviewer was not blinded to study authors, institutions or 
journals of publication. If a decision on the relevance of a paper could not be made 
from the title and abstract, full text was obtained and checked.  
 
4.3.3. Data Extraction, Synthesis and Analysis 
Data extraction was carried out via two Microsoft Office tables, and studies were 
placed in order of publication year. The data extraction results were summarised into 
two structured tables one focussing on research with rehabilitation programmes and 
the other including those measuring exercise, physical activity and muscle strength.  
Meta-analysis was not performed due to the differences between the studies. 
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4.4. Results 
4.4.1. Summary of Studies 
In total, 1088 studies were identified following the literature search (Figure 1). Of 
these studies, 22 articles were included within the review following record screening 
and having met the inclusion criteria. A total of 1488 sarcoidosis participants were 
included with studies ranging from 14 – 160 participants (Table 1; Table 2). Of the 22 
studies considered, 18 measured lung function, 18 conducted a form of 
cardiopulmonary exercise testing (CPET; six-minute walk test (6MWT), symptom 
linked bicycle test etc.), nine assessed muscle strength, eight evaluated fatigue and, 
two considered physical activity levels within pulmonary sarcoidosis through direct 
measurement, utilising an accelerometer (Korenromp et al., 2011; Saligan, 2014). 
Four studies also looked at depression/depressive symptoms (Spruit et al., 2005; 
Korenromp et al., 2011; Saligan, 2014; Naz et al., 2018), and four studies used healthy 
matched controls alongside sarcoidosis participants (Spruit et al., 2005a; Korenromp 
et al., 2011; Kowalska et al., 2012; Braam et al., 2013), while three evaluated the 
effects of rehabilitation treatment programmes (Marcellis et al., 2015; Strookappe et 
al., 2015; Naz et al., 2018; Table 2). 
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22 total articles selected for 
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Figure 1. Flow diagram of systematic review search process of study selection. 
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4.4.2. Exercise Testing 
Some form of exercise testing was conducted in 18 of the studies (Table 1; Table 2). 
Exercise testing included standardised testing such as the six-minute walk test, 
modified shuttle test, symptom limited bicycle test and symptom limited maximal 
exercise test (peak ?̇?𝑉O2) but some studies reported as generic “cardiopulmonary 
exercise test”. Limitations of many of the studies were that most lacked detailed 
descriptive methods of how the exercise test was conducted beyond providing a name, 
and potential confounding factors such as warm-up protocol, nutrition intake prior to 
testing and verbal encouragement frequency and volume were not adjusted for. 
However, this latter aspect should be noted as a general limitation within sarcoidosis 
research, due to the lack of specific knowledge regarding confounding factors. 
Additionally, across the evaluated studies, the outcomes of the exercise testing were 
measured in different ways thereby increasing the difficulty of determining any trends 
in the findings. Overall, it can be deemed that pulmonary sarcoidosis negatively affects 
exercise performance and impairs gas exchange but the extent to which this occurs, 
and the specific impact is unclear. The quality of evidence was moderate, though the 
differing tests and measurements used make it hard to draw clear meaningful 
conclusions from the exercise testing beyond pulmonary sarcoidosis having a 
detrimental effect on exercise/functional performance. 
4.4.3. Physical Activity 
Only two studies measured physical activity both via accelerometer’s (Korenromp et 
al., 2011; Saligan, 2014), where one (Saligan, 2014) compared sarcoidosis patients to 
age, gender and race-matched, sedentary healthy controls and found sarcoidosis 
patients to be less physical active and more fatigued in addition to lower functional 
performing outcomes. The second study (Korenromp et al., 2011) found physical 
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activity to be reduced in fatigued sarcoidosis patients against non-fatigued sarcoidosis 
patient values and reduced in both fatigued and non-fatigued sarcoidosis patients when 
compared to a healthy control population (Table 1). While the mechanism(s) behind 
this remain unclear, fatigue was found to be associated with reduced physical activity 
(Korenromp et al., 2011) and participants grouped as fatigued following a self-
reported questionnaire recorded lower physical activity than their non-fatigued peers. 
Additionally, confounding factors were eluded to, but never fully explained, likely due 
to shortcomings in the body of knowledge, as previously discussed in relation to 
exercise testing.  
4.4.4. Muscle Strength 
Of the nine studies associated with measurement of muscle strength, elbow flexor 
muscle strength and quadricep peak torque (Spruit et al., 2005a; Korenromp et al., 
2011; Marcellis et al., 2013b; Marcellis et al., 2015; Strookappe et al., 2015; 
Strookappe et al., 2016b) received the most attention, although hamstring peak torque 
and handgrip strength were also measured and reported within one (Marcellis et al., 
2013b) and three studies (Spruit et al., 2005; Korenromp et al., 2011; Strookappe et 
al., 2015), respectively (Table 1). Three different methods (Isokinetic dynamometry, 
back and leg dynamometer and MicroFET) were generally used to measure muscle 
strength. This means that some discrepancies between the findings can be expected, 
however there was much more consistency in reported variables than observed in the 
exercise testing. Muscle strength was shown to be reduced in comparison to normative 
values for those with sarcoidosis across all of the nine studies. Marcellis et al. (2013b) 
found quadricep peak torque (QPT) was reduced by 21.3% and 18% respectively, after 
a two-year follow-up, compared against normative values. However, studies exploring 
efficacy of rehabilitation (Marcellis et al., 2015; Strookappe et al., 2015; Naz et al., 
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2018) suggest a possibility of reversing this trend within the defined population. 
Fatigue has been associated with this detrimental symptom of reduced muscle strength 
within sarcoidosis, for example (Korenromp et al., 2011) found fatigued participants 
scored significantly lower than their non-fatigued counter-parts although other 
confounding factors have not been effectively determined. All rehabilitation studies 
(Marcellis et al., 2015; Strookappe et al., 2015; Naz et al., 2018) showed statistically 
significant improvements to fatigue scores (FAS and fatigue severity scale; FSS) and 
six-minute walk distance (6MWD), in addition to their respected muscle strength 
scores, quadricep (Marcellis et al., 2015), leg strength (Naz et al., 2018) and elbow 
flexion percentage (Strookappe et al., 2015), despite differing approaches to 
rehabilitation.  
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Table 1. Exercise Capacity, Physical Activity and Muscle Strength studies within Sarcoidosis. 
References Participants 
(N=) 
Age 
Mean age or 
Range (yrs) 
Factors studied Main Findings Summary of Findings 
Athos et al. 
(1986) 
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Male = 12 
Female = 27 
Mean: 39 
Range: 21-75 
 
 
• Lung Function 
(FVC, FEV1, 
MVV, DLCO). 
• Exercise 
Capacity 
(Incremental 
symptom limited 
exercise test 
(?̇?𝑉O2)) 
• Dyspnoea 
(MRC) 
• Pulmonary limitation to 
exercise occurred in 29% 
(stage 0 & 1) and 95% 
(stage 2 & 3). 
• ?̇?𝑉O2 was not reported. 
• 89% reported dyspnoea. 
• Severe abnormalities of gas 
exchange occurred more frequently 
from submaximal exercise studies.  
• No single test or combination of lung 
function, arterial blood gas, or 
pulmonary symptom tests could 
precisely predict pulmonary 
limitation to exercise.  
Sietsema et 
al. (1992) 
20  
 
Male = 6 
Female = 14 
Mean: 43 
Range: 24-58 
 
 
• Lung function 
(FVC) 
• Exercise 
capacity 
(Symptom 
limited maximal 
exercise testing 
(peak ?̇?𝑉O2)) 
• Heart rate 
• Forced vital capacity 
averaged 88±12% of 
predicted value. 
• 11 of 20 patients failed to 
reach > 80% of predicted 
maximum ?̇?𝑉O2, although 
all but 3 of them met 
criteria for maximal or 
near-maximal effort.  
• 7 of the 11 had one or more 
abnormal ?̇?𝑉O2 response to 
exercise. 
• Impairment in the rate of delivery 
and utilisation of oxygen during 
exercise, despite normal lung 
functions.  
• Reduced maximal exercise capacity, 
abnormal efficiency of pulmonary 
gas exchange. 
• Exertional symptoms and their 
absence predicted neither normal or 
abnormal results of exercise testing. 
Medinger 
et al. (2001) 
48 
 
Mean: 41  • Lung function 
(FEV1, FVC), 
• Exercise 
Capacity (6min 
• No significant association 
between radiographic stage 
and FEV1/FVC%, ?̇?𝑉O2 
• Gas exchange changes with exercise 
may be the most sensitive 
physiologic measurements to assess 
the extent of disease in stages (0-2). 
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progressive 
bicycle exercise 
(?̇?𝑉O2 max)) 
 
max, AT, HRR, BR, or 
VEe/?̇?𝑉CO2 AT.  
• 11 participants exercise 
blood gas measurement 
was not recorded due to 
technical issues regarding 
arterial access. 
• Remains a lack of a true non-
invasive “gold standard” for 
measuring the extent of disease. 
Akkoca et 
al. (2005) 
29 
 
Groups 
defined by 
radiographic 
stage. 
 
Stage 1 
mean: 42 
 
Stage 2 
mean: 42 
 
Stage 3 
mean: 44 
• Lung function, 
• Exercise 
Capacity (CPET) 
 
• Moderate decrease 
reported between stages 2 
& 3, with significant 
difference between 1 & 3. 
• Limitation of exercise 
capacity correlated with 
radiographic stage. 
• Radiographic stage 
increases were 
significantly observed with 
decreases to ?̇?𝑉O2 /kg 
(p<0.05). 
• Exercise capacity is the earliest 
impaired physiological parameter.  
• Intolerance to exercise is correlated 
with radiological stage and 
worsened by HRR to exercise and 
circulatory impairment, an effect 
more prominent in the advanced 
radiological stages. 
Spruit et al. 
(2005) 
25 fatigued 
sarcoidosis  
Male = 15 
Female = 10 
 
21 healthy 
control 
Male = 13 
Female 8 
Mean: 42 • Lung function 
(FVC, FEV1, 
TLC) 
• Muscle Strength 
(HGS, QPT) 
• Exercise 
Capacity 
(6MWT, 
maximal 
incremental 
exercise test) 
• The controls scored 
significantly (P<0.05) 
better for all measurements 
than the sarcoidosis group.  
 
• Sarcoidosis: 
• HGF%pred = 87 
• QPT%pred = 67 
• 6MWD =605 
 
• Muscle weakness occurs within 
sarcoidosis (mechanism(s) currently 
unknown) but associated with 
fatigue. 
• Fatigue is also associated with 
diminished QOL and exercise 
capacity. 
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• QOL (SF-36. 
EQ-5D) 
• Depression 
(HADS) 
Alhamad et 
al. (2010) 
59 
 
Male = 17 
Female = 42 
Mean: 48 
 
 
• Lung function 
(FVC, FEV1, 
TLC) 
• Exercise 
Capacity 
(6MWT) 
 
• Mean lung function 
parameters for FVC, FEV1 
and TLC results, as 
percentages of predicted 
values, were 77.6 ± 22.2, 
77.1 ± 22.8 and 78.7 ± 16.1, 
respectively. 
• Female 6MWD = 324.1m. 
• Male 6MWD = 409.4m. 
• DSP is correlated with more factors 
linked to reduced 6MWD than 
6MWD alone, therefore DSP 
appears to be a useful indictor for 
functional status within the 
sarcoidosis population. 
• Pulmonary hypertension and fibrosis 
associated with reductions to 
6MWD. 
Korenromp 
et al. (2011) 
 
75 patients in 
clinical 
remission 
 
Male = 33 
Female = 42  
 
Non-fatigued 
mean: 48 
 
Fatigued 
mean: 46 
 
 
 
 
 
• Lung Function 
• Muscle Strength 
(HGS & QPT) 
• Physical Activity 
(Accelerometer) 
• Fatigue (CIS)  
• QOL (sf-36) 
• Depression(BDI) 
• Anxiety (SCL-
90) 
• Lung function within 
normal range for all 
participants. 
• HGS mean score lower 
among fatigued group. 
• Weekday = 75.14 
(fatigued) vs. 82.06 (non-
fatigued) accelerations / 
day.  
• Weekend = 66.93 
(fatigued) vs. 79.81 (non-
fatigued) accelerations / 
day. Norm score = 91 
(healthy). 
• Fatigue = 30.5, with 15.5 
on the subscale fatigue 
severity.  
• Fatigue is a frequent severe and 
chronic issue within clinical 
remission patients. 
• Psychologic distress and reduced 
QOL are associated with fatigue in 
addition to, reduced physical activity 
and muscle weakness in fatigued 
patients. 
• On all tests, the mean score of the 
fatigued group was signiﬁcantly 
lower than the mean of the non-
fatigued group. 
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• Significantly worse 
depression and QOL scores 
among fatigued 
participants. 
Kowalska 
et al. (2012) 
47 (22 with 
cardiac 
involvement) 
 
Males = 19 
Females = 28 
 
As well as 18 
healthy 
volunteers 
for control 
Mean: 48 
 
 
 
• Exercise 
Capacity 
(6MWT 
oxygen 
saturation, 
heart rate) 
• Cardiac sarcoidosis 
with treatment: 6MWD 
= 514.81 ± 91.22m. 
• Maximum desaturation 
= 3.5±3.7%. 
• Cardiac sarcoidosis (no 
treatment): 6MWD = 
567.09 ± 119.06. 
• Maximum desaturation 
= 1.9±1.7%. 
• No cardiac 
involvement (no 
treatment): 6MWD = 
20.8± 96.22. 
• Maximum desaturation 
= 2.36 ± 2.87. 
• Participants with cardiac 
involvement and treatment had a 
lower heart rate during the first 
minute of the 6MWT as well as 
desaturating more than the no 
cardiac involvement group.  
• Treatment with prednisone 
decreased both 6MWD and 
oxygen saturation in comparison 
to no treatment. 
• The healthy control group 
recorded better 6MWD than 
sarcoidosis groups. 
Marcellis et 
al. (2013b) 
92  
 
Male = 62 
Female = 28 
Mean: 46 
 
 
• Exercise 
Capacity 
(6MWT) 
• Muscle strength 
(EFMS, HPT, 
QPT)  
Fatigue (FAS). 
• Reduced 6MWT (41.6 vs. 
34.8 %) at baseline and 
follow-up,  
• EFMS (6.7 vs. 14.6 %),  
• QPT (21.3 vs. 18 %),  
• HPT (13.5 vs. 12.4 %)  
Fatigue reported in 86 and 77% 
of participants. 
• Decreased measurements at baseline 
and follow-up for participants 
compared to control. 
• The physical impairments remained 
stable across baseline and follow-up. 
• Exercise intolerance, muscle 
weakness, and fatigue are frequent 
problems in sarcoidosis patients. 
Suggests a rehabilitation program 
should be considered as adjunct 
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therapy in the multidisciplinary 
management of sarcoidosis. 
Marcellis et 
al. (2013c) 
160 
 
Male = 97 
Female = 63 
Mean: 41 
 
 
• Lung Function 
(DLCO) 
• Exercise 
Capacity (CPET 
blood gas 
analysis) 
 
• DLCO (mean = 83.2 ± 18.0 
%)  
• < 80 % of predicted DLCO 
in 38 % of participants. 
• DLCO < 60% indicates 
significant impairment of 
gas exchange.  
• 59% failed to reach 83% of 
predicted ?̇?𝑉O2 max. 
• Symptomatic patients with normal 
DLCO appeared to have pulmonary 
gas exchange impairment at 
maximal exercise 
• Results suggest that normal DLCO 
at rest is an inappropriate predictor 
of abnormal pulmonary gas 
exchange during exercise.  
• CPET appeared to offer added value 
in detecting impaired gas exchange 
during exercise in patients with 
unexplained disabling symptoms. 
Braam et al. 
(2013) 
20 
sarcoidosis 
and 10 
healthy 
volunteers 
for control  
 
Male = 16 
Female = 14 
Healthy 
Control: 35 
 
Sarc Mod 
fatigue: 41 
 
Sarc severe 
fatigue: 37 
 
 
• Exercise 
Capacity (CPET, 
Symptom limited 
incremental 
exercise test 
(?̇?𝑉O2, RER)) 
• Blood pressure, 
HR, pulse 
oximetry, 
cytokines, stress 
hormones, ACE 
and CK (before, 
after and 3 days 
after).  
• Sarcoidosis w/Mod fatigue: 
?̇?𝑉O2 max = 270±67.4 
• Sarcoidosis w/Severe 
fatigue: ?̇?𝑉O2 max = 
187±54.2 
• Severe fatigue is not correlated with 
biomarkers nor a reduction of 
exercise capacity and is only 
consistently measured via self-
reported patient feedback/outcomes. 
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de Boer et 
al. (2014) 
33 
 
Male = 17 
Female = 16 
Mean: 48 
 
 
• Lung Function 
(FEV1, FVC, 
DLCO) 
• Exercise 
Capacity 
(MSWT, CPET)  
• Mean FEV1 = 75.7% 
predicted 
• Mean FVC = 88.7% 
predicted 
• Mean DLCO = 71.4% 
predicted 
 
• MSWT correlated with 
peak oxygen update during 
CPET 
• Both FVC and DLCO correlated 
with the two exercise measures. 
• MSWT is a symptom-limited 
maximal exercise test comparable 
with full CPET in assessing 
functional capacity in sarcoidosis. 
• Peak ?̇?𝑉O2  during CPET correlated 
with MSWT distance. 
 
 
Drent et al. 
(2014) 
88 
Sarcoidosis 
 
Male = 61 
Female = 28 
 
62 healthy 
controls 
Mean: 46 
 
 
• Lung Function 
(FEV1, FVC, 
DLCO) 
• Exercise 
capacity 
(6MWT) 
• Muscle strength 
(EFMS, HPT, 
QPT) 
• Fatigue (FAS) 
• QOL 
(WHOQOL-
BREF)  
• Sarcoidosis: FEV1 (%pred) 
= 84 
• FVC (%pred) = 98. 
• DLCO (%pred) = 76. 
• 6MWD Female = 551. 
• 6MWD Male = 606. 
• EFMS (%pred) Female = 
97.7. 
• EFMS (%pred) Male = 
89.9. 
• QPT180 (%pred) Female = 
84.9. 
• QPT180 (%pred) Male = 
81.4. 
• HPT180 (%pred) Female = 
86.4. 
• HPT180 (%pred)  Male = 
81.9. 
• FAS = 28.6. 
• Males scored lower than female 
across all muscle strength tests 
however performed better during the 
6MWT. 
• QOL is diminished and associated 
with both exercise capacity and 
fatigue especially within the 
physical health domain. 
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• QOL reduced in 
comparison to healthy 
controls. 
Saligan 
(2014) 
14 
pulmonary 
sarcoidosis 
participants 
as well as 13 
age, sex and 
race matched. 
Not stated • Exercise 
Capacity 
(6MWT) 
• Muscle Strength 
(MVC/kg) 
• Physical activity 
(Accelerometer) 
• Fatigue (FAS) 
• Depression 
(HAM-D) 
• Sarc:  
6MWD - 502±84. 
MVC/kg – 26.06. 
Mean Energy Expenditure – 
1324. 
Mean FAS – 27.4±5.7. 
HAM – D - 8.6+5.0. 
 
• Control: 
6MWD - 607±77. 
MVC/kg – 32.71. 
Mean Energy Expenditure – 
1748. 
Mean FAS – 14.2±3.5. 
HAM – D - 2.5+2.2. 
• There were significant differences in 
physical activity, exercise capacity, 
muscle strength, depression and 
fatigue scores between sarcoidosis 
patients and healthy control. 
Zieleznik et 
al. (2015) 
74 
Sarcoidosis 
 
Male = 53 
Female = 21 
 
30 Healthy 
controls 
Mean: 45 
 
Range: 29-71 
 
 
• Lung function 
(FEV1, FVC) 
• Exercise 
Capacity 
(6MWT) 
• Fatigue (FAS) 
• FEV1 = 3.18±0.82. 
• FEV1 (%) = 90.4±13.1. 
• FVC = 4.16±1.1. 
• FVC (%) = 98.9±13.9. 
• 6MWD (m) = 555.9±91.5. 
• FAS = 22.9±7.3. 
• Fatigue did not correlate with lung 
function scores or 6MWD. 
• 43.06% sarcoidosis participants 
reported no fatigue compared to 
76.67% for the control group. 
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Kallianos et 
al. (2015) 
83  
 
Male = 31 
Female = 52 
 
Patients were 
grouped 
according to 
their 
radiological 
stages: Stage 
I (n=43), 
Stages II–III 
(n=31), and 
Stage IV 
(n=9). 
Mean: 58 
 
Range: 36-84 
 
 
• Lung function 
FEV1, FVC, TLC 
DLCO) 
• Exercise 
Capacity (CPET 
Standard 
protocol). 
• FEV1, FVC, TLC were 
found to be mildly 
impaired solely in stage IV 
(means ± standard 
deviation: 72.44±28.00, 
71.33±26.70, and 
59.78±21.72, respectively). 
• DLCO was reduced in 
stages 2-4.  
• Peak oxygen consumption 
during exercise was 
decreased and varied by 
stage; Stage 1: 48%, Stages 
2–3: 52%, Stage 4: 78%. 
• Only stage 1 and 4 reported 
as having a significant 
difference. 
• Exercise capacity is the first 
impaired physiological parameter in 
sarcoidosis, with it being found to be 
limited from stage I.  
• The mechanisms responsible for 
exercise limitation are multifactorial 
and correlated with the radiological 
extent of the disease. 
• Exercise limitation may be attributed 
to both ventilatory and 
cardiocirculatory impairment. 
 
Strookappe 
et al. 
(2016b) 
146  
 
Male = 89 
Female = 57 
Mean: 47 
 
 
• Lung Function 
(FEV1, FVC, 
DLCO) 
• Exercise 
Capacity 
(6MWT, SRT) 
• Muscle strength 
(EFMS, HGS) 
• Fatigue (FAS) 
 
 
 
• FEV1 (%pred) - 87.6 ± 
19.7. 
• FVC (%pred) - 94.7 ± 18.7. 
• DLCO (%pred) - 79.3 ± 
18.0. 
• 6MWD 536±104. 
• SRT 26.8±6.3. 
• HGS (pred%) 91.1±22.7. 
• EFMS (pred%) 
100.5±20.4. 
• FAS 30.2±9.0. 
• Exercise capacity partly predicts 
fatigue. 
• Fatigue is a substantial problem 
among sarcoidosis patients, which is 
affected by many variables.  
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Chenivesse 
et al. (2016) 
 
130  
 
Male = 78 
Female = 52 
Mean: 49 
 
Range: 26-78 
 
 
• Lung Function 
(FEV1, FVC, 
TLC, DLCO) 
• Exercise 
Capacity 
(6MWT) 
 
• FEV1(% pred) – 80. 
• FVC (% pred) – 92. 
• TLC (% pred) – 90. 
• DLCO (% pred) – 71. 
• 6MWD – 450. 
 
• Normal DLCO is a good predictor of 
the absence of severe gas exchange 
impairment.  
• The stage 4 group had lower FEV1, 
FVC, DLCO scores, in addition to a 
reduced ?̇?𝑉O2 Peak compared to the 
other stages. 
Mirsaeidi et 
al. (2016) 
108  
 
Male = 21 
Female = 87 
Mean: 54 
 
 
• Lung function 
(FEV1, FVC, 
DLCO, VC, 
TLC, FRC) 
• Exercise 
Capacity 
(6MWT) 
• FEV1%   74.3±28.5.  
• FVC%   83.5±25.3. 
• DLCO%     61±18.6. 
• VC%     88±23.9. 
• TLC%   84.3±17.1. 
• FRC% 101.6±20.6. 
• 6MWD – 364.4±77.3. 
• These tests are useful for tracking 
the progression of pulmonary 
hypertension associated with 
sarcoidosis. 
Definition of abbreviations: 6MWT- 6 minute walk test; 6MWD – 6 minute walk distance; QOL - quality of life, DLCO- diffusing capacity of the lungs for carbon monoxide; 
CPET – Cardiopulmonary exercise testing; FAS – fatigue assessment scale; FVC – Forced vital capacity; TLC – total lung capacity; FEV1 – forced expiratory volume in one 
second; VC – vital capacity; FRC – functional residual capacity; MVV – Maximal voluntary ventilation; Ve/Vco2 AT - ventilatory equivalent for carbon dioxide at anaerobic 
threshold; HRR – heart rate reserve; BR – breathing reserve; DSP – distance saturation product; CIS – checklist individual strength; SCL-90 – symptom checklist 90 ; BDI – 
beck depression inventory for primary care ; SF-36 – Medical outcomes study 36-item health survey; QPT – quadricep peak torque; HPT – hamstring peak torque; EFMS – 
elbow flexor muscle strength; ACE - angiotensin converting enzyme; CK – creatine kinase; RER – respiratory exchange ratio; HR – heart rate; MSWT - Modified shuttle walk 
test; HGS – handgrip strength; SRT – steep ramp test; MRC – Medical Research Council Dyspnoea Scale; HAM – D – Hamilton Depression Rating Scale; MVC – Maximum 
voluntary contraction; %pred – Percent of Predicted.
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Table 2. Exercise intervention Studies. 
References Study Design Sample Size 
(age / gender) 
Factors studied Exercise programme Main Findings 
Marcellis et 
al. (2015) 
Intervention: 
pre/post 
measurement 
design. 
24 patients with 
fatigue complaints 
and/or exercise 
intolerance. 
 
18 patients 
completed 
(50.3±10.4years / 4 
females & 14 males). 
• Lung function (FVC, FEV1, 
DLCO) 
• Exercise Capacity (6MWT, 
Submaximal bicycle test) 
• Muscle Strength (X-RM leg 
extension, elbow flexor 
microFET)  
• Fatigue (FAS) 
• QOL (WHOWOL-BREF),  
• Dyspnoea (MRC, Borg 
RPE) 
13-week programme 
(1h x 3 / week)  
Aerobic endurance:  
60% maximal walking speed 
of 6MWT or cycling at 50% 
Wmax for 20-30 minutes, 
increased 3%/ week. 
Strength Training: 
3 sets of 8-10 reps, at 40% 
multiple-repetition 
maximum increased 3% 
/week. 
• Lung function not 
reported post-
treatment. 
• ↑ 6MWD. 
• ↑HR (submaximal).  
• ↑ Quadricep 
strength. 
• ↓ FAS score. 
• ↑MRC and 
WHOQOL-BREF. 
 
 
Strookappe 
et al. (2015) 
Intervention: 
pre/post 
measurement 
design. 
90 participants (49 
completing 
treatment, 41 opted 
not partake in 
treatment). 
• Lung function (FVC, FEV1, 
DLCO) 
• Exercise Capacity (SRT, 
6MWT) 
• Muscle strength (HGS, 
EFMS via microFET) 
• Fatigue (FAS) 
• Borg RPE, Dyspnoea 
(modified Borg) 
12-week programme 
(1h x 2 / week) 
Aerobic endurance: 
Treadmill or stationary 
cycling at 50-60% peak 
work.  
Strength Training:  
3 sets of 15-20 reps on 6-8 
different exercises at 13-15 
Borg RPE. 
• Lung function 
unchanged. 
• ↑ 6MWD. 
• ↑SRT. 
• ↑ Elbow flexion.  
• ↑ HGS. 
• ↓ FAS Score. 
• RPE & Dyspnoea 
scores stable. 
Naz et al. 
(2018) 
Intervention: 
pre/post 
measurement 
design. 
18 participants (9 
undergoing 
intervention, 9 
controls with usual 
care). 
• Lung function (FVC & 
FEV1) 
• Exercise Capacity (6MWT) 
• Muscle Strength (back and 
leg dynamometer) 
• Fatigue (FSS) 
12-week programme (2 x 
week) 
Aerobic endurance:  
Treadmill and stationary 
cycling at 80% & 70% peak 
speed of 6MWT, increased 
within symptom tolerance 
• Lung function 
unchanged. 
• ↑ 6MWD. 
• ↑ Leg Strength. 
• ↓ FSS Score. 
• ↑ SGRQ. 
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• QOL (SF-36, SGRQ) 
• Borg Dyspnoea (modified 
Borg) 
• Depression and Anxiety 
(HADS) 
when continuous 15min 
exercise achieved 
Strength Training: 
Amount of sets not stated, 8-
10 reps on 8 exercises at 4-6 
modified Borg, increased 2-
10% following ability of 1-2 
extra reps. 
• SF-36 unchanged. 
• ↓Dyspnoea. 
• ↓HADS. 
Definition of abbreviations: QOL - quality of life, SRT – steep ramp test; Borg RPE – Borg rating of perceived exertion; FAS – fatigue assessment scale; FSS – fatigue severity 
scale; HGS – handgrip strength; EFMS – elbow flexor muscle strength;  6MWT – six minute walk test; DLCO – diffusing capacity of the lungs for carbon monoxide;  FVC – 
Forced vital capacity; FEV1 – forced expiratory volume in one second; MRC – medical research council dyspnoea scale; WHOWOL-BREF - World Health Organization 
Quality of Life Instruments; SF-36 –  36-item Short Form survey ; SGRQ -  St. Georges respiratory questionnaire; HADS – Hospital depression and anxiety scale. 
50 
 
4.5. Discussion 
This systematic review identified 22 studies that investigated the influence or levels 
of physical fitness, physical activity and muscle strength of people with sarcoidosis. 
The key findings of the review are decreased levels of exercise capacity, physical 
activity and muscle strength within the sarcoidosis population compared to a healthy 
population or predicted normative data, with those recorded as fatigued showing 
greater impairment than non-fatigued sarcoidosis patients (table 1). Unfortunately, 
there is yet to be an extensive range of controlled and standardised research focussing 
on exercise within pulmonary sarcoidosis from which clear outcomes can be utilised 
for treatment policy and to optimise future direction of research. However, key 
findings from the available literature relating to exercise and sarcoidosis, emphasise 
the requirement for further research that aims to overcome these constraints. All 22 
studies recorded some sign of impairment as recorded by the variables tested in terms 
of exercise capacity and physical activity (table 1 & 2). Most prevalent were the 
reduction in lung function (Alhamad et al., 2010), and by extension ?̇?𝑉O2 peak 
(Chenivesse et al., 2016), and reduced distance within the six-minute walk test 
(Marcellis et al., 2013b) or other exercise test performance outcome such as modified 
shuttle walk test (de Boer et al., 2014) and ?̇?𝑉O2 max (Medinger et al., 2001). The lack 
of consensus between the studies in terms of the choice of exercise tests, led to 
discrepancies across the research and reduced the ability to form clear conclusions as 
different exercise tests have varying pros and cons, an example, the use of cycling 
which leads to fatigue of the quadriceps (Fletcher et al., 2001) a known muscle group 
reduced within sarcoidosis (de Boer et al., 2014), with cycling inexperienced 
participants recording ?̇?𝑉O2 max 10-15% lower than treadmill testing (Fletcher et al., 
2001). Whereas, ramp protocols on a treadmill rely on estimating functional capacity 
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via an activity scale and can lead to under- and over-estimating of functional capacity 
and lead to premature termination of the exercise test (Fletcher et al., 2001). One issue 
across the current literature is the lack of understanding of the mechanisms associated 
with the decreased findings in comparison to predicted and normative values, where 
the research reported thus far, lacks sufficient depth in the analysis of the findings. For 
example, Kallianos et al. (2015) found exercise capacity to be limited and the first 
physiological parameter impaired, yet the mechanism(s) responsible for this 
impairment were not investigated despite the researchers noting both ventilatory and 
cardiocirculatory factors may attributed to the exercise limitation. However, impaired 
diffusing capacity of the lungs and/or increased dead space related to pulmonary 
hypertension were considered as possible reasons for ventilatory factors. Impaired 
defusing capacity may result in a knock-on detrimental effect on the delivery of 
oxygen, Sietsema et al. (1992) found impairment of oxygen delivery and utilisation 
within sarcoidosis participants with normal lung function. Those who recorded 
abnormal oxygen consumption responses patterns (nine participants) had 
echocardiographic studies undertaken due to the association with cardiovascular 
disease. Five participants at rest or during exercise recorded right ventricular systolic 
dysfunction with four of them also showing hypertrophy of the right ventricular, 
however, another factor may be, impaired utilisation of oxygen at the muscle due to 
granulomatous lesions, which was not investigated (Sietsema et al., 1992). 
Furthermore, contradictory findings surrounding the diffusing capacity of the lungs 
for carbon monoxide (DLCO) were reported, with the DLCO suggested as a good 
predictor of the absence of pulmonary gas exchange impairment (Chenivesse et al., 
1995) despite Marcellis et al. (2013c) suggesting that pulmonary gas exchange 
impairment occurs at maximal exercise in a substantial number of the participants, 
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despite normal resting DLCO. The reasons for these differences observed remain 
unknown but could be associated with the lack of consistency in the disease states 
within this condition. Despite the lack of understanding regarding the mechanisms of 
the observed alterations to exercise capacity, lung function, physical activity and 
muscle strength, key findings which may aid in directing future work are those of the 
various exercise parameters (?̇?𝑉O2 max, gas exchange, total lung capacity, exercise 
heart rate response) that were typically more detrimentally affected as the radiographic 
stage increased (Sietsema et al., 1992; Medinger et al., 2001). 
 
4.5.1. Fatigue 
A factor that became prominent within this review, despite not being a primary search 
term, was fatigue. Fatigue has been recognised as a major symptom within pulmonary 
sarcoidosis (Baughman, 2013) and has been reported to occur in up to 70% of cases 
(Korenromp et al., 2011). Fatigue is compounded by the secondary effects it has, such 
as decreased quality of life (Korenromp et al., 2011; Marcellis et al., 2013c) and 
psychological distress (Korenromp et al., 2011). This is likely, in part, caused by the 
isolating effect of fatigue, and worsened by the lack of a physical manifestation for 
others to see. Korenromp et al. (2011) found fatigue to be a chronic symptom within 
sarcoidosis, despite clinical remission, associated with reduced muscle strength and 
physical activity in comparison to both healthy control and self-reported non-fatigued 
pulmonary sarcoidosis participants. While Zieleznik et al. (2015) found fatigue not to 
correlate with lung function or distance covered within the six-minute walk test. In 
addition to this, Saligan (2014) found sedentary healthy controls scored statistically 
significantly lower (P<0.01) than the sarcoidosis group and had a higher daily energy 
expenditure (1748 kcal) than fatigued sarcoidosis patients (1324 kcal). The control 
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group also outperformed on the six-minute walk test. It is worth noting, however, 
despite the control group being age, gender and ethnicity matched, they were not 
matched for body mass index (BMI) or body composition, which is a key limitation 
within the research, as body composition differences (i.e. the muscle mass of 
participants) may in part explain the differences between daily energy expenditure 
(Lassek et al., 2009). Much like the mechanisms behind the reduction in exercise 
performance, the understanding of the mechanisms behind fatigue remain unknown. 
Strookappe et al. (2016b) states fatigue within sarcoidosis is multifaceted and as such, 
further research needs to be conducted to understand these diverse effects and their 
implications. Despite this, the three rehabilitation interventions (Marcellis et al., 2015; 
Strookappe et al., 2015; Naz et al., 2018) found that the exercise programmes 
significantly improved fatigue, by scores of 2.7 and 4.2 respectively, via the fatigue 
assessment scale (FAS) (Marcellis et al., 2015; Strookappe et al., 2015) and 7, via the 
fatigue severity scale (FSS) (Naz et al., 2018). 
4.5.2. Physical Activity  
Physical inactivity even within healthy populations has been shown to be a complex 
and a serious issue (Sparling et al., 2000). Research into physical activity is severely 
limited within pulmonary sarcoidosis at present, despite the known benefits for the 
general population including decreased levels of non-communicable diseases as well 
as lower risk of depression (NHS, 2015b), although physical activity within 
sarcoidosis has been associated with fatigue (Korenromp et al., 2011) as a confounding 
factor. Garcia-Aymerich et al. (2006) found even COPD patients with low self-
reported physical activity levels had lower hospital admissions and mortality rates than 
those reporting very low levels. Low was classified as engaging in light physical 
activity including walking or biking for less than two hours per week, while very low 
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was classed as sedentary activities such as sitting during working hours and no leisure 
time activity, jogging or cycling (Garcia-Aymerich et al., 2006). Many physical 
inactivity factors are known or suggested and thus implementing changes to improve 
physical activity over a sustained period of time remains difficult (Kohl et al., 2012). 
Interestingly, Egan et al. (2012) found despite pulmonary rehabilitation in COPD 
improving exercise capacity, physical activity remained unchanged from baseline. The 
combination of a chronic disease coupled with, in some cases, severe fatigue, is likely 
to only increase the difficulty in achieving the desired behaviour. Korenromp et al. 
(2011) found higher levels of physical activity on weekdays for both fatigued and non-
fatigued sarcoidosis participants than on weekends, however fatigued participants 
showed a bigger drop in physical activity levels on the weekends compared to their 
non-fatigued peers. This is very a useful insight into sarcoidosis patients’ lives and 
suggests having to work might increase physical activity although job status, hours, or 
industry occupation were not recorded within the study. A limitation of Saligan’s 
(2014) study was the exclusion of recording physical activity on weekends opting for 
three consecutive days during the week therefore leading to a more limited view than 
Korenromp et al. (2011) study. 
4.5.3. Muscle Strength  
Muscle strength is associated with functional limitations (Hairi et al., 2010). Handgrip 
strength is a useful indicator of quality of life in the elderly (Musalek et al., 2017) as 
well as young adults (Jakobosen et al., 2010), it is also correlated with mobility 
(Jakobosen et al., 2010) with poor handgrip strength correlated with lower functional 
scores Taekema et al. (2010). A number of studies demonstrated a reduction in muscle 
strength within pulmonary sarcoidosis (Spruit et al., 2005a; Korenromp et al., 2011; 
Marcellis et al., 2013b; Saligan, 2014). Marcellis et al. (2013c) found reductions at 
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both baseline, and follow-up against normative values, for elbow ﬂexor muscle 
strength (reduction of 6.7 and 14.6 %), quadriceps peak torque (reduction of 21.3 and 
18 %) and hamstrings peak torque (reduction of 13.5 and 12.4 %). In contrast, 
Strookappe et al. (2016b) found elbow flexor muscle strength to be 100.5±20.4% of 
the predicted value using normative data for a healthy population. Handgrip strength 
also showed mixed results ranging from 87% to 96.8% predicted (Spruit et al., 2005a; 
Strookappe et al., 2016b) and thus highlights again the complexity and variability of 
the condition and the need for more detailed research addressing the differing 
severities of the condition. It would also be beneficial to have comparable data through 
use of a standardised method for testing muscle strength in sarcoidosis. This review 
found both isokinetic dynamometry (Marcellis et al., 2013b), back and leg 
dynamometer (Naz et al., 2018) and microFET (Marcellis et al., 2015; Strookappe et 
al., 2015) were utilised within the current literature. Muff et al. (2016) found the 
different methods correlated strongly within healthy adults for knee extensor and 
flexor muscle strength however a limitation of the microFET is the flexor/extensor 
ratio with correlations against the isokinetic ranging from -0.04 to 0.46. Again, the 
research stopped short of providing answers into why muscle strength was and was 
not negatively affected by pulmonary sarcoidosis, nevertheless, Marcellis et al. 
(2015), Strookappe et al. (2015) and Naz et al. (2018) did show significant 
improvements in muscle strength following completion of their intervention 
programmes. Participants within Marcellis et al.’s (2015) study demonstrated 
quadricep strength lift ability increased by 10.7kg compared to baseline, Naz et al., 
(2018) showed a median improvement of 10kg for leg strength while Strookappe et 
al. (2015) recorded a 7.2% increase in elbow flexor muscle strength. Based on this, it 
can be suggested deconditioning plays a key role in the reduction of muscle strength. 
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4.5.4. Exercise Rehabilitation  
Although exercise-based rehabilitation also referred to as pulmonary rehabilitation 
(Evans et al., 2010) is known to be beneficial within COPD and asthma, there is a 
shortage of research into its effect on sarcoidosis. McCarthy et al. (2015) systematic 
review found rehabilitation improved quality of life and exercise capacity in addition 
to dyspnoea and fatigue within COPD with the improvements clinically significant. It 
is worth noting however, no difference has been attributed between exercise only 
programs and more complex pulmonary rehabilitation programmes based on the 
current body of knowledge. At present, only three studies have investigated exercise 
as a potential rehabilitation strategy to improve the symptoms and quality of life of 
sarcoidosis patients (Marcellis et al., 2015; Strookappe et al., 2015; Naz et al., 2018). 
These three studies showed promising results with improvements in quality of life, 
muscle strength and exercise performance, as measured via six-minute walk test, as 
well as reductions in self-reported fatigue. Additionally, Marcellis et al. (2015) 
recorded an initial 72.2% continuation rate of a similar exercise programme following 
completion of the study, which highlights the value placed on the programme and the 
results by the participants themselves. Unfortunately, no follow-up to check on the 
outcome measures or exercise adherence was implemented within any of the studies, 
barring Marcellis et al. (2015) check immediately following completion of the 
structured programme. However, Forkan et al. (2006) found prescribed home exercise 
programs had a 37% adherence for elderly people with impaired balance, with time 
since discharge not found to affect adherence within the population, where no 
difference was reported between those discharged 12 or 24 months prior. It is worth 
noting all three studies (Marcellis et al., 2015; Strookappe et al., 2015; Naz et al., 
2018) had differing methodologies for the exercise programme; Marcellis et al. (2015) 
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evaluated a 13-week programme featuring both aerobic (60% maximal walking speed 
of 6MWT via treadmill/cycling on an ergometer) and resistance training (40% 
multiple-repetition maximum, increasing 3% weekly, 8-10 reps, 3 sets) for one hour 
three times a week, whereas Strookappe et al. (2015) used an intervention consisting 
of one hour twice a week involving aerobic exercise at 50-60% peak work calculated 
from the steep-ramp test and resistance training of  3 sets consisting of 15-20 reps with 
the weight set by participants own 13-15 rating on Borg RPE per session. While Naz 
et al. (2018) used an intervention involving two sessions a week on a 12-week 
programme, involving both aerobic (walking and cycling, 15 mins continuously at 
80% speed of 6MWT and 70% estimated work rate via the 6MWT, increasing within 
symptom tolerance when goals met) and resistance training (selected through 4-6 
rating on the modified Borg scale, starting at 8 reps and progressing to 10, once 
participant would achieve 1-2 reps on top of this, workload increased by 2-10%). All 
strategies produced statistically significant improvements, and therefore an optimal 
exercise programme for improvements is yet to be known and should be a future 
research aim. However, Strookappe et al. (2015) participants 6MWD improved 
greater (70m) than Naz et al. (2018) and Marcellis et al. (2015) participants (40m and 
34.6m). Strookappe et al. (2015) study also recorded a decrease of 3.8 for their FAS 
score compared with 2.7 by participants of Marcellis et al. (2015) while Naz et al. 
(2018) use of the FSS is not directly comparable, the FAS is more widely used 
(Marcellis et al., 2013c; de Boer et al., 2014; Saligan, 2014; Zieleznik et al., 2015; 
Strookappe et al., 2016b). Additionally, Marcellis et al. (2015) study found a 
statistically nonsignificant (P>0.05) improvement in elbow flexor muscle strength, 
which cannot be attributed to the programme due to the limited improvement, whereas 
Strookappe et al. (2015) participants did significantly improve (P<0.05) with an 
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increase of 7.8 of percentage of predicted value (Strookappe et al., 2015). The reasons 
are unclear, however may be partly explained by working at a higher peak work load 
aerobically throughout the programme as well as during strength training with Borg 
RPE used as the measure than 40% multiple-repetition maximum. A limitation of Naz 
et al. (2018) study was the exclusion of upper limb muscle strength testing although 
their respective measure (leg strength) did improve statistically significantly by 10kg 
(P<0.05), much like Marcellis et al. (2015), which reported a quadricep strength 
increase of 10.7kg. 
4.5.5. Future Directions 
The results of the present systematic review can help to direct future research. Due to 
the current lack of knowledge and evidence regarding sarcoidosis and exercise, there 
are a number of desirable areas to be explored. One key factor to explore is exercise 
and physical activity as a potential rehabilitation option outside of the current 
pharmacological routes, based on the promising outcomes reported thus far (Marcellis 
et al., 2015; Strookappe et al., 2015; Naz et al., 2018). Additionally, a future aim 
should be to identify and create optimised non-pharmacological treatment plan, ideally 
personalised to each individual, due to the evidence of the complex, varied and 
individual nature of the condition and in keeping with other trends within the 
healthcare sector (NICE, 2017). To achieve these aims, future research will need to be 
conducted to explore the mechanisms behind the reduction of muscle strength, lung 
function and exercise performance, as well as any other associated confounding 
variables such as fatigue (De Kleijn et al., 2009 and impaired heart rate response to 
exercise (Delobbe et al., 2002). There is a need to determine and understand trends in 
fatigue and lifestyle factors with the aim to utilise this information to improve quality 
of life, by understanding the mechanisms, and strategies to address resulting factors 
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such as impaired gas exchange and heart rate, can be developed. Another useful future 
direction would be the research supported creation of a standardised set of exercise 
tests for aerobic capacity and muscle strength within sarcoidosis, that could be used to 
assess and inform treatment strategies, as currently the wide range of tests employed 
make it difficult to draw clear conclusions across the current research.  
4.6. Conclusion 
In conclusion, the current review has identified that sarcoidosis has been shown to 
have a detrimental effect on various factors related to exercise such as lung function, 
quality of life, exercise capacity and physical activity, to name a few. The mechanisms 
behind these negative effects are complex and remain unknown at resent. There is a 
need for further in-depth studies looking at these variables and their mechanisms as 
well as greater focus on exercise rehabilitation for improved patient care. 
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5. CHAPTER FIVE 
5.1. Investigation of Factors Related to Quality of Life, Depression and 
Physical Activity within Sarcoidosis. 
5.1.1. Chapter five Abstract 
Background: Individuals with sarcoidosis are at risk of numerous mental and 
physical detriments compared to their healthy counterparts, due to multifactorial 
reasons. An online cross-sectional observational survey was undertaken to 
investigate factors influencing these detriments such as fatigue, dyspnoea & 
deconditioning aiming to provide participant-specific characteristics. These 
included opinions on current and future treatment options, alongside their fatigue 
and physical activity levels, including reference to changes in their physical 
activity due to sarcoidosis. Analysis aimed to inform future direction for 
sarcoidosis research. 
Methods: A online survey using Qualtrics, comprising of validated questionnaires 
measuring quality of life and depression, in addition to closed quantitative and 
open-ended qualitative questions surrounding physical activity, employment, 
smoking and other related daily life questions. 
Results:  Multiple regression revealed the CES-D and number of symptoms as 
predictors of quality of life (R2 = .509). The mean number of symptoms reported 
was 3.79, females reported lower levels of quality of life and higher depressive 
scores via the CES-D. The majority of both genders reported being either inactive 
(no activity) or less than two bouts of physical activity a week, in addition 73.79% 
of the study participants reported decreased levels of physical activity since 
diagnosis, 41.55% also changed jobs or stopped working due to the disease. While 
only 38.36% and 25% of the population had been suggested physical activity or 
diet as a potential treatment method, themes identified as potential improvement 
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to current care and quality of life were more knowledgeable doctors regarding the 
condition and better understanding of lifestyle factors such as diet, physical 
activity and smoking status. 
Conclusions: Quality of life appears to be affected by depression and number of 
symptoms a patient has, physical activity is also detrimentally affected following 
diagnosis of sarcoidosis and affects both personal and professional life, patient’s 
themes identified included poor lifestyle and heightened levels of stress and 
anxiety as areas that worsened symptoms and quality of life. More research is 
required looking at the role and effect of lifestyle on the condition including the 
number of and severity of the disease as well as depression and quality of life. 
Taught coping methods for stress and anxiety may also be beneficial for patients 
and thus needs investigation within the population. 
5.2. Introduction 
Sarcoidosis involves granulomatous inflammation of organs and tissues (Saidha et al., 
2012), which is pulmonary in the majority of cases (90%) but can affect any part of 
the body (Saidha et al., 2012). Sarcoidosis involves the formation of granulomas via 
the clustering of lymphocyte cells (National institute of Health, 2013a). The symptoms 
of sarcoidosis are wide-ranging and can be severe and disabling (Drent et al., 2014), 
with typical symptoms including fatigue, dyspnoea, chronic cough and muscle 
weakness (Baughman, 2013). Unfortunately, sarcoidosis suffers from a chronic 
shortage of research, when compared to other interstitial lung diseases such as asthma 
or COPD, especially with regards to alternative treatment strategies such as exercise 
and physical activity. This lack of research is coupled with current researchers’ focus 
solely on results of tests such as lung function, at the expense of patient feedback on 
the condition, despite lung function being shown to be a poor indicator of overall 
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health including primary and secondary symptoms within sarcoidosis (Karetzky & 
McDonough, 1996). Therefore, the objective of the current study and its outcomes are 
driven by informed patient experiences from a wide range of patients from numerous 
geographical locations and backgrounds, thus allowing for an improved perspective 
and understanding of the issues experienced by those with sarcoidosis, including 
issues related to quality of life and the negative affect of symptoms. Exercise is 
frequently suggested as a method to improve sarcoidosis symptoms and boost overall 
health (Marcellis et al., 2015; Strookappe et al., 2015), however both these 
suggestions currently suffer the same pitfall of limited to no research, both within 
pulmonary sarcoidosis and the other forms of sarcoidosis (Morton-Holtham et al., 
ndA). The ACSM (2014) argues that a correct training regime can help decrease 
severity and inflammation of the disease, with preliminary studies supporting this 
statement (Holland et al., 20013; Marcellis et al., 2015). However, these specialised 
training regimes currently have numerous limitations including the lack of an 
optimised regime/different regimes for the vast range of population with sarcoidosis, 
the need for further empirical proof across a larger range of the population, the need 
for qualified practitioners for substantial amounts of the regimes and the current lab-
based approach for participants. For exercise to be seriously considered as a “Miracle 
Cure” as stated by the NHS (2015b) further research must be conducted across a wider 
range of the population with varying type, time and intensity. The individual must also 
be considered with regards to their preferences for a truly effective long-term 
treatment due to the difficulties of people adhering to exercise regimes despite 
knowing the benefits and consequences. Seefeldt et al. (2002) notes successful 
interventions individualised, accounting for a participant’s personal views of fitness, 
their needs and outcomes as well as allowing for their control of an activity. 
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Physical inactivity is common among those with sarcoidosis (Spruit et al., 2005a; 
Korenromp et al., 2011). Saligan (2014) found sarcoidosis participants had 
statistically significant lower levels (P<0.05) of physical activity than their healthy 
age, gender and race matched controls despite the recognised benefits for chronically 
ill populations (Durstine et al., 2000; Warburton et al., 2006), although one limitation 
of Saligan’s research is the exclusion of physical activity being recorded on weekends 
and thus leaves an area for future research. However, it is too simplistic to single out 
sarcoidosis alone as the reason for this as physical activity has been shown to be a 
complex issue across all populations including healthy and ill, alike (Sparling et al., 
2000). Currently sarcoidosis patients’ views on physical activity, exercise, diet and 
their potential benefits are unknown, with exercise and diet often marginalized within 
this disease to off the cuff remarks therefore collecting participant views alongside 
current and prior-to-diagnosis levels of physical activity and diet across this period is 
key to building a platform for future research based on empirical data over the current 
hearsay. Alongside physical inactivity those with sarcoidosis have been shown to have 
a higher incidence rate of depression than the general population (Hinz et al., 2012), 
Saligan (2014) found higher depression scores for sarcoidosis participants than healthy 
age, gender and race matched controls. Much like physical inactivity, depression is a 
complex and multifaceted issue, which is likely to be contributed to by both 
sarcoidosis and non-sarcoidosis factors. One possible contributing factor is frequent 
hospital visits (Kersnik et al., 2001) such as those associated with steroid treatment 
due to the required monitoring of a patient. Another factor is the reduced skeletal 
muscle strength within sarcoidosis (Marcellis et al., 2013a; Saligan, 2014; Marcellis 
et al., 2015; Strookape et al., 2015) which has been linked to depression and decreased 
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quality of life (Spruit et al., 2005b). A further sarcoidosis factor is fatigue; a major 
issue within sarcoidosis (Baughman, 2013). Fatigue has been associated with 
depression (Leone, 2010) and decreased quality of life (Drent et al., 2014). Korenromp 
et al. (2011) found sarcoidosis patients with fatigue scored worse for depression and 
quality of life than their non-fatigued counterparts despite both groups being in clinical 
remission and thus highlights the importance of patient feedback, as fatigue is a self-
reported variable (Gawron, 2017). Chang et al. (2001) found following adjustments 
of steroid treatment and non-sarcoidosis factors such as race and income, increased 
dyspnoea scores predicted depression as a sarcoidosis factor. Whereas the external 
factors predicting depression were the female gender and limited access to medical 
care. Currently, there is a lack of knowledge regarding the effect physical activity 
and/or exercise would have on depression and whether depression scores would 
improve primarily due to increased physical activity/exercise or whether the 
improvements of other symptoms associated with depression, such as fatigue, muscle 
strength and dyspnoea due to higher levels of physical activity/exercise, would then 
lead to improved depression as a secondary factor. This research will allow for the 
gathering of the views and thoughts of physical activity and exercise within the 
population and thus aid in the understanding of the complex role of physical activity 
and exercise and therefore inform on future research which potentially improve the 
implementation and maintenance of physical activity and exercise. 
 
Treatment is currently predominantly focused on the use of steroids (Jennifer & 
Rashcovsky, 2004) and corticosteroid use within sarcoidosis has been linked with 
diminished quality of life (Cox et al. 2004; Drent et al., 2014), with prednisone the 
most used drug (National institute of Health, 2013). Alongside a decreased quality of 
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life there are numerous other side effects including osteoporosis, weight gain and 
increased risk of infection (Poetker & Reh, 2010; Liu et al., 2013). In addition to this, 
Alhamad et al. (2010) found sarcoidosis patients receiving corticosteroids had a 
decreased exercise performance via the six-minute walk test than their peers not on 
medication. The reasons for this are unclear, i.e. are they on a treatment of steroids 
due to needing them and thus already have a decreased exercise performance than the 
study’s counter parts or has the use of the steroids decreased their exercise 
performance further, nonetheless Grutters and Van der Bosch (2006) suggest the 
decreased performance is another side effect of the corticosteroid use. There are 
numerous issues and limitations associated with current treatment practices with 
uncertainty surrounding the best treatment plan for the different symptoms/issues 
within the populations, further worsened by the complex nature of the condition. 
Therefore, research is needed focusing on limiting the side effects of steroid use as the 
current treatment method while there needs to be a drive towards better treatment 
methods through the creation of new and novel methods as well as optimizing other 
treatments currently available. Greater understanding of the symptoms and side effects 
caused by both sarcoidosis and treatment via patient feedback combined with 
quantitative scores will allow for a more informed approach to future research. 
Therefore, this study aims to establish trends within the quality of life of sarcoidosis 
in relation to environment, diet, PA and personal views of day-to-day experiences. 
This is the first study to seek future direction and areas of research via qualitative 
feedback, patient involvement will help prioritise clinical care and we aim to identify 
patient-reported outcome measures to establish improved understanding of the 
condition including, nutritional status and exercise capacity of patients.  
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5.3. Methodology 
5.3.1. Participants 
An online survey of 149 participants with self-reported sarcoidosis were voluntarily 
recruited via online sarcoidosis forums and support groups. Exclusion criteria 
extended to anyone with an additional interstitial lung disease such as asthma and 
chronic obstructive pulmonary disease (COPD) as well as those unable to give 
consent. The study consisted of 189 participants, 40 participants were removed due to 
incomplete surveys (<50% survey completion removed), 149 participants answers 
were analysed (n = 44 male, n = 103 female, n = 2 unanswered), ethnicity was also 
recorded (n = 143 Caucasian, n = 3 Afro-Caribbean, n = 3 mixed Caucasian and Afro-
Caribbean). 
5.3.2. Design, Equipment and Procedures 
The study design was a cross-sectional online observation study investigating quality 
of life in sarcoidosis and the relationship to the different factors affecting it such as 
symptoms, types of sarcoidosis, physical activity level and anthropometric data. 
Questions were formed of likert scales, multiple selection and open-ended questions 
(Appendix 2). The participants firstly had to read and accept the informed consent for 
the study, this then lead them onto self-reported anthropometric questions for them to 
answer including age (Years) mass (kg), stature (cm), gender and ethnicity. Following 
this they answered independent questions on their symptoms, length & types of 
sarcoidosis, mould status of their homes, smoking status, medication, physical activity 
as well as whether physical activity or diet had been suggested as a potential treatment 
method, two example questions are “Considering your condition, on average, what are 
the main symptoms you experience. Please select all that apply.” and “Has physical 
activity been mentioned to you as an option for improving your symptoms by a 
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physician / GP?” quality of life was measured via the sarcoidosis health questionnaire 
(SHQ; Cox et al., 2003; Appendix 4) and the presence of depressive symptoms via 
center for epidemiologic studies depression scale (CES-D; Eaton et al., 2004; 
Appendix 5). In the section following the two validated questionnaires participants 
answered close-ended questions on their geographical location, property and 
employment status & history. The concluding section of the survey comprised of 
open-ended qualitative questions (Appendix 2) involving the effect of sarcoidosis on 
their life, what they believe improves as well as negatively affects their symptoms and 
their ideas regarding which areas of sarcoidosis would most benefit from further 
support, one example question is “What factors do you believe improve your 
sarcoidosis symptoms?”. 
5.3.3. Data Analysis 
The data were analysed via SPSS 24.0 (IBM Corp, Armonk, New York). An 
exploratory data analysis was first completed; the data were normally distributed and 
therefore met parametric assumptions, following this a multiple regression was 
conducted between the different variables. Content analysis was conducted viva 
NVivo Pro 11 (QRS International, Doncaster, Australia) for the qualitative elements 
of this study. The content analysis involved the compiling and reviewing of all 
statements, firstly all questions and their answers were uploaded into Nvivo, the 
answers to individual questions were then all analysed separately, and their answers 
highlighted and labelled as nodes (sub-categories) following this the different nodes 
were grouped based on their overall theme.  
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5.4. Results 
5.4.1. Participant’s Characteristics 
Of the 189 participants who started the study, 40 were removed due to incomplete 
surveys. Table 3 displays the characteristics of the participants who partook in the 
study. Only two participants were aged 30 or younger while the most populous age 
range was 51-60 (35%). The vast majority of participants self-identified as Caucasians 
(95%) and female participants outnumbered males by more than double the male quota 
(69% versus 30%). 
Table 3. Characteristics of Participants. 
Age (Yrs) No. Percentage (%) 
21-30 2 1.34 
31-40 28 18.79 
41-50 45 30.20 
51-60 52 34.90 
61+ 22 14.77 
Total 149 100.00 
Gender   
Male 44 29.53 
Female 103 69.12 
Not reported 2 1.34 
Total 149 100.00 
Ethnicity   
Caucasian 143 96.00 
Afro-Caribbean 3 2.00 
Mixed Caucasian & Afro-Caribbean 3 2.00 
Total 149 100.00 
 
Table 4 highlights the lifestyle and employment of the population overall as well as 
by gender. Inactive was the most selected level of physical activity for both genders 
(39%), with the percentage of selected category decreasing as the level of physical 
activity increased. The majority of participants reported decreased levels of physical 
activity since diagnosis (73.79%) however males reported a higher percentage of 
stable physical activity levels than females (32.56 and 12%, respectively) although no 
significant difference was found (P>0.05). Physical activity and diet were not 
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suggested as a treatment to the majority of participants (61.64 & 75%, respectively). 
Smoker was the least populous selection (5.59%) in the smoking status category, 
however there was only a 1% difference between ex-smokers and non-smokers (46 & 
47%, respectively), while ‘15-19 cigarettes per day’ was the most selected for males 
(31.25%) and ‘10-14 per day’ for females (22.64%). People’s homes never having 
mould (61.38%) was close to double its nearest group of ‘sometimes’ (33.79%).  
 
Table 4. Physical activity and lifestyle factor data. 
 All* Male Female 
Physical Activity No. 
Percen
tage 
(%) No. 
Perce
ntage 
(%) No. 
Percen
tage 
(%) 
Inactive 56 38.62 17 39.53 38 38.38 
< twice week 39 26.90 12 27.91 26 26.26 
3-5 week 38 26.21 10 23.26 28 28.28 
5+ Week 12 8.28 4 9.30 7 7.07 
Total 144 100 43 100 99 100 
Change in PA since diagnosis       
Increased 12 8.28 3 6.98 9 9.00 
Decreased 107 73.79 26 60.47 79 79.00 
Same 26 17.93 14 32.56 12 12.00 
Total 145 100.00 43 100 100 100 
PA suggested as treatment       
Yes 56 38.36 18 41.86 38 37.62 
No 90 61.64 25 58.14 63 62.38 
Total 146 100.00 43 100 101 100.00 
Diet suggested as treatment       
Yes 36 25.00 8 18.60 28 27.72 
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No 110 75.00 35 81.40 73 72.78 
Total 146 100.00 43 100 101 100 
Smoke Status       
Smoker 8 5.59 1 2.33 7 7.00 
Ex-Smoker 63 44.06 17 39.53 46 46.00 
Non-smoker 72 50.35 25 58.14 47 47.00 
Total 143 100.00 43 100 100 100.00 
Amount per day       
1 to 4 11 15.49 1 6.25 9 16.98 
5 to 9 13 18.31 2 
 
12.50 10 18.86 
10 to 14 16 22.54 4 25.00 12 22.64 
15-19 15 21.13 5 31.25 10 18.87 
20-24 11 15.49 2 12.50 9 16.98 
25+ 5 7.04 2 12.50 3 5.66 
Total  71 100.00 16 100.00 53 100.00 
Mould Status       
Always 7 4.83 3 7.14 4 3.96 
Sometimes 49 33.79 13 30.95 36 35.64 
Never 87 61.38 26 61.90 61 60.40 
Total 145 100.00 42 100 101 100 
Asterisk (*) two participants included within all did not report their gender. PA = Physical Activity. 
 
Table 5 highlights the employment status and change since diagnosis. Full-time 
employment was confirmed for less than half of the population (47.92%) despite being 
the most selected answer, although over a fifth (23.24%) had indicated that they had 
stopped working due to the sarcoidosis. 
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Table 5. Showing employment status and change since diagnosis. 
Current employment       
Employed full time 69 47.92 22 52.38 47 47.00 
Employed part time 16 11.11 0 0.00 16 16.00 
Unemployed looking for work 4 2.78 1 2.38 3 3.00 
Unemployed not looking for work 8 5.56 3 7.14 5 5.00 
Unemployed receiving disability 
living allowance or equivalent 26 18.06 9 21.43 16 16.00 
Student 1 0.69 0 0.00 1 1.00 
Retired 20 13.89 7 16.67 12 12.00 
Total 144 100 42 100.00 100 100.00 
Employment change since diagnosis       
Stayed the same 69 48.59 19 46.34 50 50.51 
Changed due to Sarcoidosis 26 18.31 9 21.95 17 17.17 
Changed non-related to Sarcoidosis 14 9.86 3 7.32 10 10.10 
Stopped working due to Sarcoidosis 33 23.24 10 24.39 22 22.22 
Total 142 100 41 100.00 99 100.00 
 
As seen in Table 6, the types and symptoms of the population are presented overall 
and by gender. Pulmonary was the most common form of sarcoidosis (97.97%) with 
lymph nodes and skin, second and third (49.32% & 33.11%, respectively). Fatigue, 
dyspnoea and joint/bone pain were the most selected symptoms (92.62%, 77.18% & 
70.47%, respectively).  
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Table 6. Showing the type and symptoms of Sarcoidosis. 
 All* Male   Female 
Type of Sarcoidosis No. Percentage (%) No. 
Percentage 
(%) No. 
Percentage 
(%) 
Pulmonary 145 97.97 42 95.45 101 99.02 
Skin 49 33.11 10 27.73 37 36.27 
Heart 14 9.46 1 2.27 13 12.75 
Eye 29 19.54 9 20.45 19 18.63 
Endocrine 5 3.38 3 6.82 2 1.96 
Nervous 18 12.16 3 6.82 14 13.73 
Bone/Joint 43 29.05 11 25.00 30 29.41 
Lymph 73 49.32 1 2.27 49 48.04 
Organ 23 15.54 4 9.09 19 18.63 
Other 17 11.49 2 4.56 15 14.71 
Total  148 100.00 44 100.00 102 100.00 
Symptoms       
Fatigue 138 92.62 40 90.91 96 93.20 
Chronic Cough 71 47.65 25 56.81 45 43.69 
Dyspnoea 115 77.18 35 79.55 79 76.70 
Joint/bone pain 105 70.47 27 61.36 77 74.76 
Rashes 54 36.24 11 25.00 41 39.8` 
Sore eyes 52 34.90 12 27.27 39 37.86 
Other 30 20.13 9 20.45 21 20.39 
Total 149 100 44 100.00 103 100.00 
Asterisk (*) two participants included within all did not report their gender. 
 
Table 7 highlights the quality of life as measured by the sarcoidosis health 
questionnaire (SHQ) and the sub-scales of emotional, physical and daily functioning 
(score range 1-7), as well as depression score, measured via the center for 
epidemiologic studies depression scale (CES-D). A mean score of 3.41 was recorded 
for the SHQ while CES-D mean score was 25.75, females however scored lower on 
the SHQ and CES-D (3.34 & 26.14) than their male counterparts (3.58 & 24.86) and 
both genders scored lowest on emotional functioning (3.31 & 3.08, respectively) out 
of the three domains for the SHQ. 
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Table 7. Showing the quality of life and depression scores as well as standard 
deviation split by gender (No significant difference between genders; P>0.05; n= 145 
for SHQ & 141 for CES-D). 
 
Gender EF ±SD PF ±SD DF ±SD SHQ ±SD CES-D 
±SD 
Male 
3.31 ±1.11 3.88 ±1.01 3.56 ±1.07 3.58 ±0.94 
24.86 
±10.64 
Female 3.08 ±0.88 3.64 ±0.80 3.28 ±0.93 3.34 ±0.75 26.14 ±9.46 
Combined 3.15 ±0.96 3.71 ±0.88 3.37 ±0.98 3.41 ±0.82 25.75 ±9.85 
EF = Emotional Functioning, SD = standard deviation, PF = Physical Functioning, DF = Daily Functioning, SHQ = Sarcoidosis Health 
Questionnaire, CES-D = Center for Epidemiologic Studies Depression Scale. 
 
Table 8 highlights the multiple regression findings for the number of symptoms self-
reported. Quality of life, fatigue, number of types of sarcoidosis and self-reported 
physical activity levels were found to be significant predictors of number of 
symptoms, accounting for 46.1% of the variance. 
Table 8. Showing the multiple regression findings with number of symptoms as the 
dependent variable. 
Model R2 B Sig. 
1    
Constant  6.89 .001 
QOL .287 -.91 .001 
2    
Constant  8.17 .001 
QOL  -.76 .001 
Fatigue .380 -1.67 .001 
3    
Constant  7.46 .001 
QOL  -.70 .001 
Fatigue  -1.67 .001 
No. Types .420 .18 .003 
4    
Constant  7.10 .001 
QOL  -.75 .001 
Fatigue  -1.77 .001 
No. Type  .19 .001 
PA levels .461 .30 .002 
QOL = quality of life, No. Types = number of types of sarcoidosis, PA levels = physical activity levels. Dependent variable = 
number of symptoms. 
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Table 9 shows quality of life, number of symptoms and self-reported fatigue were 
found to be significant predictors of self-reported physical activity levels, accounting 
for 9.4% of the variance within the data. 
Table 9.  Multiple regression predictors of self-reported physical activity levels. 
Model R2 B Sig. 
1    
Constant  1.32 .001 
QOL .031 .20 .037 
2    
Constant  .27 .637 
QOL  .34 .003 
No. Symptoms .066 .15 .023 
3    
Constant  -.61 .386 
QOL  .33 .004 
No. Symptoms  .21 .004 
Fatigue .094 .67 .040 
QOL = quality of life, No. Symptoms = number of symptoms. Dependent variable = physical activity levels. 
 
Table 10 shows the R squared, beta and the significance of the variable within the 
model. The CES-D was the biggest predictor of quality of life (R2 = .397) while both 
variables CES-D and number of symptoms had a significant effect on the model (P = 
0.001). 
Table 10. Displaying the predictors of quality life via multiple regression findings. 
Model R2 B Sig. 
1    
Constant  4.76 .001 
CES-D .397 -.05 .001 
2    
Constant  5.29 .001 
CES-D .509 -.04 .001 
No. Symptoms  -.21 .001 
CES-D = Center for Epidemiologic Studies Depression Scale, No. Symptoms = number of symptoms. Dependent variable = 
quality of life. 
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Table 11 highlights the findings of the multiple regression into predictors of self-
reported fatigue. Number of symptoms and physical activity change since diagnosis 
were found to be significant predictors, explaining 23.8% of the variance within the 
data. 
Table 11. Multiple regression predictors of self-reported fatigue. 
Model R2 B Sig. 
1    
Constant  1.40 .001 
No. Symptoms .196 -.08 001 
2    
Constant  1.25 001 
No. Symptoms  -.08 001 
PA change .238 .09 006 
No, Symptoms = number of symptoms, PA change = physical activity change since diagnosis. Dependent variable = fatigue. 
 
 
QOL = Quality of Life, CES-D = Centre for Epidemiologic Studies Depression Scale 
Figure 2. Correlation between quality of life and CES-D (P = 0.001). 
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QOL = Quality of Life 
Figure 3. Correlation between number of symptoms and quality of life. 
 
5.4.2. Content analysis 
Table 12 highlights the key themes identified via the content analysis as well as 
interesting quotes surrounding these themes. 
Table 12. Showing themes identified via content analysis alongside definitions and 
quotes. 
Themes Quotes 
Limiting of 
activities/tasks 
- I am unable to do most/all of my hobbies 
- unable to complete many normal day to day tasks 
- The slightest effort results in struggling to breathe. 
- I am less active and I have barely enough energy to 
accomplish necessary tasks 
- Physically I am not able to work or do many normal 
things. 
Exercise, Physical 
activity and Diet 
- I sought help from the hospital dieticians while 
receiving treatment and this was successful 
- Advice on mobilisation exercise programs that would 
help inflamed joints 
- Swimming has helped immensely 
- On good days I get in as much as physically possible 
- Swimming has helped my breathing, 
- Light exercise seems to help improve some of my pain 
Poor Lifestyle - Poor diet. Physical inactivity 
- Smoking and I don’t know how to quit 
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- I don’t have the money to eat the way I should be eating 
on a better diet 
- Irregular eating patterns  
- Airborne particles such as icing sugar, flour, dust if 
sweeping 
Lack of Understanding - Friends and family have no idea of all the problems 
related to sarcoidosis 
- Poor understanding from employer who is an NHS 
trust 
- Lack of clear information on the web/from medical 
professionals  
- Consultants, I never get to see the same one and I 
always feel that they are winging it 
- Family's lack of understanding can be awful as are 
doctors  
- The lack of awareness in society 
- Dr who treats the disease and understands the 
complexity 
Anxiety and Stress - Mindfulness is helping control anxiety and stress 
responses 
- Staying away from stress 
- Absence of stress 
- Stress has major impact on my Sarcoid symptoms 
- Stress also exasperates my symptoms 
Importance of Sleep - Feel that if I could sleep properly I would feel better 
able to cope 
- Lack of sleep due to pain 
- Minimum of 7 1/2 hours sleep a night 
- More sleep during the day. 
- Sleep and the right care 
The Role of Medication - Prednisolone has helped reduce problems  
- If I feel more symptomatic or get an infection, I double 
my steroids for 48 hours which helps 
- The higher dose of steroids but would rather not take 
them cause of the side effects 
- Put on prednisolone my symptoms have improved 
massively 
- Higher dose steroids but don’t want them as weight 
ballooned literally 
 
5.5. Discussion 
The primary aim of this study was to determine and better understand trends relating 
to the quality of life of sarcoidosis patients in terms of their physical activity, diet and 
environment and their personal views of living with the disease. 
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5.5.1. Participant characteristics  
Only two participants within this study identified as being under 30 years of age, 
Bresnitz et al., 1983) states 20-40 years old as the age range for the predominant onset 
period of sarcoidosis, however a later study by Baughman et al. (2001) found peak 
onset of sarcoidosis associated with 35-45 years of age. The data collected better 
supports Baughman et al. (2001) with the age range 41-50 and 51-60 being the most 
selected (30.20% & 34.90%, respectively). Although, no definitive answers can be 
made from the data as the analytics of the support groups used for recruitment remains 
unknown and this elder population selection may simply represent the make-up of the 
support groups. One limitation of this study is the lack of depth around age and better 
understanding may have been achieved through participants stating their current age 
or using smaller age ranges. Additionally, age at diagnosis was not recorded and thus 
this is a limitation as the recorded time since diagnosis lacks the required depth 
although age at diagnosis itself does not necessarily associate or correlate with the age 
of sarcoidosis onset due to various reasons. Reasons include misdiagnosis as well as a 
lack of symptoms on onset (Belfer & Stevens, 1998), however the data collected (time 
since diagnosis) still has value and aids in the analysis and understanding of other 
relevant variables. Of note, a greater proportion of females participated in the research 
(69.12%). Birnbaum and Rifkin (2014) state females are more likely to develop 
sarcoidosis and although the reasons for this are unknown, hormones have been 
suggested to be a compounding factor (Birnbaum & Rifkin, 2014). However, the 
representation of the genders within this study are likely to have been affected due to 
the recruitment methods as women may make up a greater proportion of the support 
groups approached. Deans et al. (1998) and Krizek et al. (1999) both found that 
females were more likely to join cancer support groups, outnumbering males 3 to 1 
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(Dean et al., 1998) and these findings may be applicable to sarcoidosis support groups 
too. Much like age and gender, ethnicity may also have been influenced by the 
demographic of the support groups. 96% self-identified as Caucasian despite the 
incidence rate being suggested as 10 times higher for the black population than their 
white counterparts (Birnbaum & Rifkin, 2014), although Kamangar et al. (2017) state 
much more conservative figures with 11 per 100,000 for Caucasians, rising to 34 per 
100,000 in black populations, specifically African-Americans. The utilised support 
groups were based within the United Kingdom and the United states of America and 
this may in part explain the predominant Caucasian selection, as Northern Europeans 
and African Americans have been suggested as having the highest incident rate 
globally (Iannuzzi et al., 2007; Sharma, 2008). Within breast cancer, those of higher 
socio-economic status are more likely to seek health information regarding their 
condition online (McMullan, 2006) and this trend may transfer across to other 
conditions including sarcoidosis and warrants further investigation. Following 
demographic (ethnicity, gender & age) adjustments, lower socio-economic status has 
been linked to increased severity at presentation despite socio-economic status not 
affecting sarcoidosis risk (Iannuzzi et al., 2007).  
5.5.2. Types of sarcoidosis and symptoms  
The majority of participants selected pulmonary sarcoidosis (97.97%), with lymph 
node involvement second (49.32%) and skin third (33.11%), and despite nine 
categories listing different forms of sarcoidosis, 11.49% still selected “other”. The 
mean number of types of sarcoidosis recorded was 2.83, highlighting the varied and 
complex nature of the condition and thus the difficulty in understanding and treating 
it. This study’s findings are consistent with current literature as Iannuzzi et al. (2007) 
state that more than 90% of sarcoidosis cases have pulmonary, lymph node, skin 
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involvement or a combination of these different types. The complexity of sarcoidosis 
is further represented through the recorded symptoms. Fatigue as a symptom was 
reported at higher than expected levels (92.62%) among the participants, Drent et al. 
(2012) states 50-70% of patients report fatigue, dyspnoea (77.18%) was also found to 
be higher than previous studies. Yeager et al. (2005) reported dyspnoea in 51% of the 
population while de Boer et al. (2014) reported the symptom in 64% of participants, 
joint involvement has been reported between 14-38% (Wilcox et al., 2000; Awada et 
al., 2003). However, within this study joint/bone pain was recorded at 70.47% and 
made up one of the top three selected symptoms, while 20.13% selected “other” in 
addition to the six other listed symptoms. It is unclear why symptoms have been 
reported with higher frequency than reported in previous literature, however the 
increased levels of reported symptoms may be the reason itself as participants with 
greater severity and number of symptoms may be more inclined to participate than 
those with milder manifestations of the disease. The mean number of symptoms was 
3.79, following a stepwise multiple regression quality of life was shown to be best 
predictor of number of symptoms (R2 = .287; R = .536, P = .001). Quality of life, 
fatigue, number of types of sarcoidosis and self-reported physical activity levels 
accounted for 46.1% of the variance within the data (R2 = .461) and that the model 
was a significant predictor of number of symptoms, F (4, 137) = 29.29, P = .001. All 
variables contributed significantly to the model (P < 0.05). Therefore, a decrease in 
symptoms or symptom severity is a possible method for improving the quality of life 
of those with sarcoidosis. Fatigue has been shown to be associated with quality of life, 
Korenromp (2014) found patients identified as fatigued scored significantly worse for 
quality of life (short form-36) than non-fatigued patients. Following a stepwise 
multiple regression patient reported fatigue was found not to be a predictor of quality 
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of life and via a bivariate correlation between the two variables shown to have only a 
weak correlation. It is worth noting however that fatigue was not quantified such as 
by completing the fatigue assessment scale (FAS) and was simple selected from a 
range of symptoms, therefore the level of fatigue may vary widely between 
participants. Boer et al. (2014) found dyspnoea was also associated with a lower 
quality of life score, although both symptoms have been shown not to be predicted by 
lung function (Boer et al., 2014; Strookappe et al., 2016b). However, fatigue has been 
correlated with dyspnoea and stated as being a valid indicator for dyspnoea level 
within sarcoidosis (Jastrzebski et al., 2015). Fatigue is known to be a multifactorial 
issue (Strookappe et al., 2016b), causes include treatment (e.g. corticosteroid use), 
inflammation and comorbidities  (Gerke et al., 2015), and the other symptoms listed 
are also known to be multifactorial (Jastrzebski et al., 2015), therefore the relationship 
and interaction between the number of symptoms and quality of life is likely to be 
multifaceted by both primary and secondary outcomes of the symptoms such as 
physical activity (Korenromp, 2011) and depression (Chang et al., 2001). 
5.5.3. Lifestyle  
Despite the known benefits of physical activity and a healthy balanced diet, sarcoidosis 
patients are not being suggested these as a way to better manage and treat their 
condition from qualified professionals, with only 38.36% having been suggested 
utilising physical activity/exercise while suggestion of diet as a method drops to 25% 
of the study’s population. The majority of participants reported being sedentary and 
physically inactive, participants selected inactive or active twice or less a week for 
65.52% of the study’s population (Table 4), which is consistent with previously 
reported findings for the general population, such that 33% of 19-64-year olds in the 
U.K. in 2016 did not meet current U.K. physical activity guidelines (British Heart 
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Foundation, 2017). This figure however does not take into account people’s health and 
therefore may overestimate levels of inactivity for healthy individuals. The reasons for 
this are numerous and complex, involving those associated with sarcoidosis, such as 
symptoms including fatigue and dyspnoea (Korenromp et al., 2011; Baughman, 2013), 
and general population issues, including both environment and social factors such as 
childcare and support from family and friends ((Seefeldt et al., 2002). A limitation of 
this study was the lack of space for participant views on their physical activity habits. 
A multiple regression did not reveal physical activity levels or physical activity change 
since diagnosis as predictors of quality of life. Although, following a bivariate 
correlation physical activity change since diagnosis did produce a weak correlation 
(.374, P = .001). One possible reason for this could be that the ability to perform 
physical activity has a greater effect on someone’s perceived quality of life than 
current levels of physical activity. Physical activity is an area where there is a need for 
greater focus and insight within sarcoidosis and the general population as physical 
inactivity currently is the fourth biggest cause of mortality globally (Kohl et al., 2012). 
The need for greater focus on understanding physical inactivity and methods to 
increase activity levels is further shown when considering 73.79% of this study’s 
sarcoidosis population reported a decrease in physical activity since diagnosis. While 
the decrease is unlikely to be attributed solely to the onset of sarcoidosis, due to 
external factors affecting the general population such as age (Milanovic et al., 2013), 
it does however demonstrate the need for a disease-specific physical activity 
programme to aid in the maintenance and improvement of physical activity. 
Additionally, health-related behaviours have been shown to track from childhood into 
adulthood thus highlighting the need for early intervention in relation to physical 
activity and attitudes towards it (Kohl & Cook, 2013). Self-efficacy, for example has 
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been shown to be a predictor of physical activity participation (Park et al., 2014) and 
as such has been suggested as a focus for improving physical activity over a sustained 
time period (Green et al., 2006; Park et al., 2014). As such, self-efficacy within 
sarcoidosis should have a greater focus to aid understanding and development of a 
disease specific physical activity questionnaire. Seefeldt et al. (2002) note that 
successful interventions are? individualised, accounting for a participant’s personal 
views of fitness, their needs and outcomes as well as allowing for their control of an 
activity. Sarcoidosis does play an important role as highlighted by Saligan’s (2014) 
study showing lower levels of physical activity than age, gender and race-matched, 
sedentary healthy controls. The reduction in physical activity levels comparatively 
against healthy controls and pre-sarcoidosis levels, is likely affected by a combination 
of primary and secondary symptoms of the condition, such as fatigue (Korenromp et 
al., 2011) and deconditioning (Fleischer et al., 2014). Within this study, quality of life, 
number of symptoms and fatigue were found to be predictors of physical activity 
levels, accounting for 9.4% (R2 = .094, P < 0.05)   of the variance within the data. All 
variables contributed significantly to the model (< 0.05). While number of symptoms 
and physical activity change since diagnosis were found to be predictors of fatigue, 
accounting for 23.8% (R2 = .24, P < 0.001) of the variance. Number of symptoms (B 
= -.08) and physical activity change since diagnosis (B= .09) both contributed 
significantly to the model (P = 0.001 and P = 0.006, respectively). Although, this may 
be down to the unvalidated method employed for data collection of perceived activity 
levels. It is also worth noting that improving exercise capacity appears not to be 
enough in raising activity levels. Egan et al. (2012) found despite improvements to 
exercise capacity following pulmonary rehabilitation within COPD, physical activity 
post-treatment remained unchanged from baseline data. Through the content analysis 
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of the patient’s qualitative feedback from open questions regarding barriers, 
detriments, beneficial factors relating to sarcoidosis and future areas for treatment and 
care of the condition. Poor lifestyle alongside stress and anxiety were identified as 
themes for worsening management of symptoms and quality of life. Barriers included 
a lack of understanding of peers, family and employers, limitation of previous ability 
to conduct activities such as exercise, housework, work, playing with children, 
exemplified through the quote “I am unable to do most/all of my hobbies” in addition 
to poor integration of medical care, a major issue due to the diverse nature of the 
condition Themes identified as future areas for improving patients care, symptoms and 
quality of life were lifestyle improvements including diet, physical activity, smoking 
status and hours of sleep, more knowledgeable doctors regarding the condition in 
terms of specialists and initial GP care and a reduction of stress and anxiety. One 
patient noted “Mindfulness is helping control anxiety and stress responses” and as 
such is an area that requires attention and could potentially improve treatment in a 
relatively short period of time in comparison to the development of better suited 
medication. Merkes (2010) found mindfulness-based stress reduction improved 
patients’ ability to cope with symptoms, quality of life and enhanced health outcomes 
in chronic diseases including rheumatoid arthritis, chronic fatigue syndrome and type 
2 diabetes. 
 
While smoking status falls outside of diet into lifestyle, it is an area with interesting 
findings within sarcoidosis as the incidence rate of the disease has been stated as being 
higher among non-smokers (Valeyre et al., 1988), although within this study non-
smokers made up 50.35% while ex and current smokers consisted of 49.65% (table 4). 
It has been suggested that smoking provides some form of protective role against 
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developing the disease (Peros-Golubicic & Ljubic, 1995), alternatively, smoking may 
reduce the severity of the disease (Valeyre et al., 1988). The reasons for this remain 
unknown however the immunosuppressive properties of tobacco have been suggested 
(Sopori, 2002) as a potential reason, additionally the recognised detrimental effects of 
smoking may lead to smokers not seeking medical help and therefore leading to their 
under representation within the sarcoidosis population (Peros-Golubicic & Ljubic, 
1995). However, within this study incident rate between non-smokers and ex/current 
smokers varies by 0.35%, no correlation or significant difference (P>0.05) was 
reported between amount smoked per day and quality of life including the three sub-
scales and thus questions the above research, a larger population sample may lead to 
a clearer understanding. This lack of consensus highlights the need for further study 
within the condition with regards to smoking status.  Due to the lack of knowledge 
about the formation and development of the condition as well as its progression, an 
extensive multi-dimensional outlook is required to build an initial base of information. 
 
Several environmental factors have been identified within sarcoidosis and suggested 
as increasing the risk of the disease, despite the mechanisms behind this remaining 
unclear. Such factors include metal work, education, transportation industry and high 
humidity occupations (Kucera et al., 2003). Kucera et al. (2003) stated mould as an 
occupational factor, although mould is associated with both work buildings and 
homes. Terceli et al. (2011) found fungal exposure in the homes of Slovenian 
sarcoidosis patients to be significantly higher than their control counter parts, for both 
newly diagnosed and recurrence groups, (33.6 N-acetylhexosaminidase (NAHA) 
U/m3 and 39.9 NAHA U/m3, respectively versus 10.0 NAHA U/m3). The current study 
reported participants as ‘always’ or ‘sometimes having’ mould within their homes 
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38.62% of the time (Table 4). A limitation however is the lack of testing to confirm 
amount and type of mould per home as there are numerous different forms of mould, 
with different forms associated with different reactions such as allergic and disease 
activity (Chapman, 2005). Additionally, the study only focused on current homes and 
therefore does not consider mould involvement at earlier stages of their life or whether 
their place of work has mould, for example Bush et al. (2006) states hypersensitivity 
pneumonitis requires a high-dose or prolonged exposure and as such is linked to 
occupation. Terceli et al. (2011) findings warrant further research into the effects of 
mould within patient’s homes and whether this is a trend reported across geographical 
locations, a limitation of this research however is the lack of genetic evaluation 
involved, as the onset of sarcoidosis has been suggested as being from a combination 
of genetic and environmental factors (Luisetti et al., 2000).  Participants employment 
for full/part time stood at 59.03% with a further 13.89% retired, 18.06% were 
unemployed and receiving disability living allowance or equivalent. Of note, 41.55% 
of participants reported changing or stopping jobs due to their sarcoidosis (table 4). 
While the majority of those with the condition worked, the odds of receiving disability 
payments was only marginally better than 1 in 5 (18.06%; table 4) and thus suggests 
a disabling effect of the disease. It is worth noting, however, that it was not reported 
whether the disability living allowance was being received exclusively for sarcoidosis 
or not and participants may have had other conditions limiting their ability to work. 
As such, this area requires further research. 
 
 
5.5.4. Quality of life /Depression  
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Quality of life and depression was measured via SHQ and CES-D, respectively. The 
mean SHQ score was 3.41, although males scored higher (3.58) than females (3.34), 
which agrees with previous research showing that females with sarcoidosis have a 
lower quality of life than their male counterparts (De Vries et al., 1999). Females also 
scored slightly lower for depressive symptoms, although there was no significant 
difference (P>0.05) for both quality of life and CES-D, in addition to the quality of 
life sub-scales (Table 7). A multiple regression was carried out to investigate whether 
number of types & symptoms, fatigue, age and depressive score (CES-D) could 
significantly predict participants quality of life. The results indicated CES-D and 
number of symptoms account for 50.9% of the variance and that the model was a 
significant predictor of quality of life, F(2,142) = 73,66, P = 0.001. Both CES-D (B = 
.043) and number of symptoms (B = .208) significantly contributed to the model (P = 
0.001). There are likely to be numerous reasons for this, depression is associated with 
a reduced quality of life much like a number of sarcoidosis symptoms such as fatigue, 
dyspnoea and reduced exercise capacity (Korenromp et al., 2011; Drent et al., 2014; 
Saligan, 2014). These same reasons for a reduction in quality of life are also likely to 
contribute to higher depressive scores. Chang et al. (2001) found increased dyspnoea 
was a predictor of depression within sarcoidosis. Nowik et al. (2017) reported 
improvements to depression scores within sarcoidosis following pulmonary 
rehabilitation including at one year follow up. Nowik et al. (2017) findings highlights 
the potential benefit of pulmonary rehabilitation within sarcoidosis alongside 
improvements to exercise capacity, dyspnoea, fatigue and quality of life shown within 
asthma (Trevor et al., 2015), idiopathic pulmonary fibrosis (Swigris et al., 2011) and 
COPD (Reis et al., 2007; Spencer & McKeough, 2010). As we as highlighting the 
complexity and interaction of this multifactorial condition (sarcoidosis), additionally 
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participants within the current study and previous others (Korenromp et al., 2014; 
Saligan, 2014) reported low levels of physical activity and thus demonstrates scope 
for improvement. 
5.5.5. Limitations/Future Directions 
The mean number of types of sarcoidosis (2.83) and symptoms (3.79) experienced by 
patients highlights the diverse complexity of the condition and warrants further 
research into the interactions between different types of sarcoidosis and their 
associated symptoms with regards to quality of life and treatment guidelines (De Vries 
& Drent, 2008). Another limitation and area for future research is the genetic element 
of the disease. Genetic analysis is key to better understanding this disease and knowing 
the genetic makeup of the participants would better enable the understanding of the 
formation and development of sarcoidosis. For example, environmental factors such 
as exposure to organic dust or airborne agents, have been linked to the increased 
inflammatory response and resultant progression of pulmonary sarcoidosis (Stopinsek 
et al., 2016), however this has not been looked at alongside the genetics of sarcoidosis 
patients and whether certain genes such as HLA are more susceptible to select 
environment factors (i.e Insecticides) compared to others (Dardiotis et al., 2013). 
5.6. Conclusions 
In conclusion, participant feedback has highlighted the diverse nature of the condition 
and the barriers they face receiving patient care such as lack of knowledge regarding 
the condition and poor integration between different areas of medical care despite the 
multifactorial nature of sarcoidosis. Patient feedback has also highlighted areas for 
greater focus such as stress and anxiety reduction as well as the role of lifestyle factors 
on management of the condition and quality of life. This feeds back into the 
quantitative data reported, with CES-D and number of symptoms indicated as 
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predictors for quality of life while quality of life, number of symptoms and fatigue 
predictors of physical activity levels. The onset of sarcoidosis has also been shown to 
detrimentally affect physical activity levels alongside personal and professional life, 
and as such lifestyle (diet, physical activity, smoking status, sleep etc.) was identified 
as an area with potential beneficial improvements to symptoms and quality of life. 
There is still a wide range of different areas requiring research that could lead to 
improvements across the population however, overall two areas are prominently 
identified, the role and effects of lifestyle on sarcoidosis, including the number of types 
and severity of the disease, in addition to depression and quality of life, particularly 
considering potential benefits of stress and anxiety reduction through taught coping 
methods such as mindfulness.  
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6. CHAPTER SIX 
6.1. A Epidemiological Study into Sarcoidosis: Physical Activity Levels in 
Relation to Symptom Severity. 
6.1.1. Chapter six Abstract 
Background: There is a large body of research supporting staying physically active 
and as such is often suggested within pulmonary sarcoidosis. However, individuals 
with sarcoidosis are at risk of numerous mental and physical detriments compared to 
their healthy counterparts such as fatigue, dyspnoea and deconditioning. In addition to 
this, relatively little is known regarding the impact physical activity on the condition, 
hence this requires further research. An online cross-sectional observation survey 
investigating physical activity levels and fatigue within sarcoidosis. 
Methods: The study involved an online survey using Qualtrics, comprising of 
validated questionnaires measuring physical activity and fatigue, in addition to closed 
quantitative questions to obtain anthropometric data and information on types of 
sarcoidosis and time since diagnosis.  
Results: The majority of participants (92.59%) reported fatigue, with 22.22% 
reporting extreme fatigue via the fatigue assessment scale (FAS).  Obese BMI (25+) 
accounted for the majority of participants 44.64%, despite 49.06% reporting high 
levels of physical activity via the IPAQ. Fatigue, gender and sitting time explained 
37.5% of the variance within the IPAQ physical activity data. 
Conclusions: The analysed population was diverse with regards to physical activity 
and anthropometrics. Nonetheless, fatigue is a major issue within the population and 
is moderately correlated to dyspnoea, another important symptom.  
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6.2. Introduction 
Physical activity (PA) is recommended across all ages and health conditions. Physical 
activity descriptions range from “Miracle Cure” (NHS, 2015b) to “the best buy for 
public health” (MacAuley et al., 2015), highlighting the importance of physical 
activity. The current U.K. guidelines for adult’s physical activity are 150 minutes of 
moderate or 75 minutes of high intensity and/or a combination of the two is recommended per 
week with a minimum of two days involving strengthening exercises of all major 
muscle groups (Department of Health, 2011), General benefits of regular physical 
activity include decreased risk of osteoarthritis (Borer, 2005) depression and non-
communicable diseases (NHS, 2015b) as well as an important role in the prevention 
and management of hypertension (Diaz & Shimbo, 2013). While within chronic 
obstructive pulmonary disease (COPD) regular physical activity has been linked to 
reduced all-cause mortality (Garcia-Aymerich et al., 2006) and reduced risk of 
exacerbations within asthma (Garcia-Aymerich et al., 2009). Despite the known wide-
ranging benefits to physical activity; much like diet, there is no known average 
physical activity level among sarcoidosis patients. This is an important area that 
requires further investigation for a number of reasons including the better 
understanding of the role their disease plays with physical activity, understanding their 
risk profile both specific and non-specific to sarcoidosis and also allow for a better 
integrated health plan and thus care of patients. Within sarcoidosis itself, Saligan 
(2014)’s research found sarcoidosis patients had lower physical activity levels than 
age and race matched, sedentary controls, with daily energy expenditure of 1324 kcal 
(sarcoidosis) and 1748kcal (control), although BMI was significantly different 
(P<0.05) for the two groups, 34 for sarcoidosis and 25 for controls, which may in part 
explain the differences. A small number of studies have shown improvements to 
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primary and secondary symptoms including quality of life and fatigue following the 
completion of an exercise program within sarcoidosis (Marcellis et al., 2015; 
Strookappe et al., 2015; Naz et al., 2018). However, exercise adherence, especially 
long term and within disease populations is notoriously difficult for a range of reasons 
including baseline physical fitness, marital status, fatigue level, exercise self-efficacy 
and history of PA, as well as mood disturbance due to treatment (Neupert et al., 2009; 
Shang et al., 2012; Nam et al., 2013). For example, pulmonary rehabilitation within 
mild COPD has been shown to significantly improve exercise capacity and quality of 
life (Jacome & Marques, 2014), however despite this, Heerema-Poelman et al. (2013) 
found COPD patients following a home care maintenance exercise program post 
completion of pulmonary rehabilitation had a dropout rate of 36.7% within the first 
year, which highlights the difficulties of maintenance for exercise prescription. A 
better understanding of the populations’ typical physical activity and variances to this 
may allow for the creation of specifically tailored programmes and thus improve 
adherence and with-it long-term results, for example, older persons (64 ± 4.5 years) 
have been shown to have increased exercise adherence when receiving a behavioral 
programme alongside their exercise prescription (Azizan et al., 2013). Physical 
activity/exercise has been linked to numerous benefits within sarcoidosis including 
improved quality of life (Drent et al., 2014; Saligan, 2014; Naz et al., 2018) and 
aerobic capacity/exercise performance (6MWD) (Marcellis et al., 2015; Strookappe 
et al., 2015; Naz et al., 2018) as well as reductions to fatigue (Marcellis et al., 2015; 
Strookappe et al., 2015; Naz et al., 2018) and depression (Naz et al., 2018).  
Additionally, understanding a population’s physical activity levels provides a wide 
range of other benefits such as the ability to calculate their risk of other conditions 
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associated inactivity and therefore lead to a better understanding of what sarcoidosis 
directly and indirectly influences. 
Therefore, the aim of this study is to identify trends in physical activity levels in a 
sarcoidosis patient population and investigate relationships between fatigue and 
physical activity. 
6.3. Methodology 
6.3.1. Participants 
An online survey of 56 participants with self-reported sarcoidosis completed an 
online survey. Participants were voluntarily recruited via online sarcoidosis 
forums and support groups. Exclusion criteria extended to anyone with an 
additional interstitial lung disease such as asthma and chronic obstructive 
pulmonary disease (COPD) as well as those unable to give consent. The study 
consisted of 18 males, 38 females and one other(non-specified), ethnicity was also 
recorded (n = 54 Caucasian, n = 1 Black African, n = 2 Mixed Caucasian and 
Black-Caribbean). There was a drop-out of 24 participants, participants results 
were removed from analysis if they had completed less than 50% of part A. 
6.3.2. Design, Equipment and Procedures 
The study design was a cross-sectional online observation study that consisted of an 
online survey (Appendix 6). The participants firstly had to read and accept the 
informed consent for the study, which then lead them onto anthropometric and 
demographic questions including age (Years) mass (kg), stature (cm), gender(sex), 
BMI (body mass index) and ethnicity. Following this they answered validated 
questionnaires relating to physical activity via the International physical activity 
questionnaire (IPAQ; Craig et al., 2003) a questionnaire comprised of 27 items across 
five activity domains asked independently. One example question is “Think about only 
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those physical activities you did for at least 10 minutes at a time. During the last 7 
days, on how many days did you do vigorous physical activities like aerobics, running, 
fast bicycling, or fast swimming in your leisure time?” (Appendix 3). Fatigue was 
measured via Fatigue assessment scale (FAS; Michielsen et al., 2003), a 10-item 
questionnaire with a 5-point likert scale, split into 5 physical fatigue and 5 mental 
fatigue questions with an example question being “I get tired very quickly” (Appendix 
7), with answers ranging from “never” to “always”. Dyspnoea was measured via the 
MRC dyspnoea scale (MRC; Fletcher et al., 1959), consisting of five grades ranging 
from 1 (not troubled by breathes except on strenuous exercise) to 5 (too breathless to 
leave the house, or breathless when dressing/undressing) (Appendix 8). 
6.3.3. Data Analysis 
The data were analysed via SPSS 24.0 (IBM Corp, Armonk, New York). An 
exploratory data analysis (EDA) was first completed; the data were normally 
distributed and therefore met parametric assumptions. Following this, a multiple 
regression was conducted, P value was set at <0.05. 
6.4. Results 
6.4.1. Participant characteristics 
Table 13 displays the characteristic data of the participants who partook in the study. 
No participants were aged under 30 while the most populous age range was 51-60 
years. Females accounted for more than twice the male participation within the study 
and the vast majority of participants self-identified as Caucasian. The two biggest 
groups for time since diagnosis were less than two years and more than five years, 
with only a difference of five participants between the two groups. 
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Table 13. Characteristics of Subjects (n=57, unless otherwise stated). 
Age (Yrs) No. Percentage (%) 
31-40 8 14.04 
41-50 17 29.82 
51-60 25 43.86 
61+ 7 12.28 
Gender   
Male 18 31.58 
Female 38 66.67 
Ethnicity   
Caucasian 54 95.00 
Black African 1 2.00 
Mixed Caucasian & Afro-
Caribbean 2 4.00 
Time since Diagnosis*   
Less than 2 years 26 46.43 
3-5 years 9 16.07 
More than 5 years  21 37.50 
* = 56 participants 
Table 14 highlights the anthropometric characteristics (mass, stature and BMI) of 
participants including their gender breakdown. Overall 91-100kg was the most 
selected category however males most selected was 100+kg while females most 
selected was at the opposite end at 51-60kg and no one reported being under 50kg. 
The majority of participants selected 161-170cm as their stature and this was the same 
for both genders (38.89 & 55.26%, respectively).  No participants calculated their BMI 
to be under 18.5, with a BMI of 30+ being the most selected (44.64%).  
Table 14. Mass, Stature, Body mass index and participant selected types of 
sarcoidosis. 
 All* Male Female 
Mass (kg) No. 
Percenta
ge (%) No. 
Percent
age (%) No. 
Percen
tage 
(%) 
51-60 8 14.04 0 0.00 8 21.05 
61-70 7 12.28 1 5.56 5 13.16 
71-80 8 14.04 2 11.11 6 15.79 
96 
 
81-90 11 19.30 4 22.22 7 18.42 
91-100 12 21.05 5 27.78 7 18.42 
100+ 11 19.30 6 33.33 5 13.16 
Total 57 100.00 18 100.00 38 100.00 
Stature (cm)       
Under 150 2 3.51 0 0.00 2 5.26 
151-160 7 12.28 1 5.56 6 15.79 
161-170 28 49.12 7 38.89 21 55.26 
171-180 12 21.05 3 16.67 9 23.68 
181-190 7 12.28 6 33.33 0 0.00 
191-200 0 0.00 0 0.00 0 0.00 
200+ 1 1.75 1 5.56 0 0.00 
Total 57 100.00 18 100.00 38 100.00 
BMI       
18.5-25 15 26.79 1 5.88 13 34.21 
25-30 16 28.57 4 23.53 12 31.58 
30+ 25 44.64 12 70.59 13 34.21 
Total 56 100.00 17 100.00 38 100.00 
BMI = Body Mass Index. 
 
Table 15 shows all participants who partook within this study selected pulmonary 
sarcoidosis (100%) with Lymph nodes being the second most common (34.55%), the 
mean number of types of sarcoidosis a participant selected as having was above two, 
standing at 2.41. 
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Table 15. Sarcoidosis types with the mean, median and mode for the number of types. 
Types of Sarcoidosis       
Pulmonary 55 100.00 18 100.00 37 100.00 
Skin 11 20.00 4 22.22 7 18.92 
Lymph nodes 19 34.55 6 33.33 13 35.14 
Bone/joint 12 21.82 4 22.22 8 21.62 
Eye 16 29.09 5 27.78 11 29.73 
Nervous system 5 9.09 3 16.67 2 5.41 
Endocrine 3 5.45 3 16.67 0 0.00 
Organ 7 12.73 2 11.11 5 13.51 
Total 55 100.00 18 100.00 37 100.00 
Number of types of 
Sarcoidosis       
Mean 2.41  2.56  2.34  
Median 2.00  2.00  2.00  
Mode 1.00  1.00  1.00  
 
Table 16 displays the validated questionnaires and scale results of the participants. 
Only four participants (7.41%) were classified as non-fatigued via the fatigue 
assessment scale (FAS) and, grade 2 was the most populous answer for the MRC 
dyspnoea scale, followed by grades 3 and 4. Physical activity levels, as determined by 
the IPAQ showed the “high” classification being the most common (49.06%) however 
results varied by gender, where females self-reported physical activity classified as 
high (63.89%), while males self-reported physical activity classified as moderate for 
the majority (58.82%). As well as lower levels of physical activity, males recorded 
higher levels of sitting per day than their female counterparts (375mins.p/d & 
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352mins.p/d, respectively) however females reporting low levels of physical activity 
recorded the highest amount of sitting (515mins.p/d). 
Table 16. Fatigue status, MRC dyspnoea, physical activity level and mean minutes 
sitting per day. 
 All* Male Female 
Fatigue Status No. 
Percen
tage 
(%) No. 
Percen
tage 
(%) No. 
Percen
tage 
(%) 
No Fatigue 
(Scored 21 or 
under) 4 7.41 2 11.76 2 5.41 
Fatigued 
(Scored 22-34) 38 70.37 10 58.82 28 75.68 
Extreme 
Fatigued 
(Scored 35 or 
above) 12 22.22 5 29.41 7 18.92 
Total 54 100.00 17 100.00 37 100.00 
MRC Dyspnoea 
Scale       
Grade 1 5 9.09 3 16.67 2 5.41 
Grade 2 21 38.18 6 33.33 15 40.54 
Grade 3 13 23.64 3 16.67 10 27.03 
Grade 4 13 23.64 4 22.22 9 24.32 
Grade 5 3 5.45 2 11.11 1 2.70 
Total 55 100.00 18 100.00 37 100.00 
Physical 
Activity Level       
Low  9 16.98 4 23.53 5 13.89 
Moderate 18 33.96 10 58.82 8 22.22 
High  26 49.06 3 17.65 23 63.89 
Total 53 100.00 17 100.00 36 100.00 
Mean minutes 
sitting/per day       
Low 456±172  375±158  555±157  
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Moderate 414±163  414±182  415±136  
High 289±126  303±89  287±130  
All 360±164  375±158  352±166  
Low = Failure to meet other categories; Moderate = Moderate 5 or more days of any combination of walking, moderate-intensity 
or vigorous intensity activities achieving a minimum of at least 600 MET-min/week; High = 7 days of any combination of 
walking, moderate- or vigorous- intensity activities accumulating at least 3000 MET-minutes/week; Grade 1 = Not troubled by 
breathless except on strenuous exercise; Grade 2 = Short of breath when hurrying on a level or when walking up a slight hill; 
Grade 3 = Walks slower than most people on the level, stops after a mile or so, or stops after 15 minutes walking at own pace; 
Grade 4 = Stops for breath after walking 100 yards, or after a few minutes on level ground; Grade 5 = Too breathless to leave the 
house, or breathless when dressing/undressing. * = 56 Participants. 
 
 
Table 17 highlights the results of a multiple regression into predictors of IPAQ 
physical activity categories.  Fatigue measured via FAS, gender and average time 
spent sitting per day (mins) were found to be significant predictors, explaining 37.5% 
of the variance within the data. 
Table 17.  Multiple regression predictors of IPAQ physical activity categories. 
Model R2 B Sig. 
1    
Constant  3.95 .001 
FAS .192 -.06 .001 
2    
Constant  3.03 .001 
FAS  -.05 .001 
Gender .293 .52 .012 
3    
Constant  3.19 .001 
FAS  -.04 .008 
Gender  .51 .009 
Sitting Time .375 -.01 .017 
FAS = fatigue assessment scale, sitting time = time spent sitting per day. Dependent variable = IPAQ derived physical activity 
categories. 
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FAS = Fatigue assessment scale. 
Figure 4. Correlation between MRC dyspnoea scale and the fatigue assessment scale. 
 
 
1 = low physical activity, 2 = moderate physical activity, 3 = high physical activity. 
Figure 5. Correlation between physical activity level and fatigue assessment scale. 
 
6.5. Discussion 
6.5.1. Participant characteristics  
All participants within this study self-reported pulmonary sarcoidosis, but many 
reported multiple types of the disease, with the mean number of forms/types of 
sarcoidosis being above 2 (Table 15). This highlights the diverse and complex nature 
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of the condition and the need for consideration of treatment guidelines for the affected 
population as there are numerous different combinations and interactions between the 
different forms, in addition to varying levels of severity. A limitation of this study, 
however, was not collecting data on the severity of all symptoms. The majority of 
participants reported having been diagnosed less than two years ago (46.43%), which 
fits with the current views of sarcoidosis being acute in the majority of cases (NHS, 
2015a), Judson et al. (2003) states 80% are likely to improve over the first two years 
of the condition’s diagnosis, similarly, Mana et al. (1994) found only 22% with 
sarcoidosis over 2 years. However, this still leaves a large proportion of the population 
with chronic sarcoidosis, where the disease is unlikely to resolve (Judson et al., 2003). 
Hunninghake et al. (1999) states 10-30% with the condition have chronic sarcoidosis 
and within this study 37.5% selected being diagnosed more than five years ago. The 
reason for this is unclear, one possible reason to explain the levels of chronic 
sarcoidosis reported may be increased incentive on behalf of those with chronic 
sarcoidosis to help improve the understanding of the condition and aid the current 
body of knowledge due to frustration with the daily issues that accompany the 
condition for many. For example, current treatment does not improve progression 
chances of the condition (Rissmiler & James, 2017). Treatment currently focuses on 
symptomatic management and is associated with numerous side-effects such as weight 
gain (Liu et al., 2013). The top two selected age groups within the study were 41-50 
and 51-60 years, which may partly explain the high chronic levels of sarcoidosis 
reported as the onset of sarcoidosis has been associated with those aged 20-40 years 
old (Brenitz & Storm, 1983) although Baughman et al. (2001) found 35-45 years old 
to be the peak age for sarcoidosis onset. A limitation of this study is the lack of depth 
on the specific ages of participants, with greater depth, the peak onset reported by 
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Baughman et al. (2001) may have also been obtainable within this study however it is 
not possible to say based on the structure of the data recorded. Ungprasert et al. (2017) 
found the age women were diagnosed was significantly higher than their male 
counterparts, 48.3 versus 42.8 years old respectively, and therefore the age ranges 
observed within this study may be influenced by the increased female participation 
compared to male (n=38 versus. n= 18 participants). The body mass index (BMI) 
(please see Table 14) was split relatively evenly (1 participant difference) between 
18.5-25 (normal), 25-30 (overweight) and 30+ (obese) for female participants, while 
males were predominantly obese (70.59%). The reasons for this are likely to be many 
and consist of sarcoidosis and non-sarcoidosis factors, one possible attribute may be 
related to the suggested later onset of sarcoidosis in females (Ungprasert et al. 2017), 
as sarcoidosis is associated with decreased levels of physical activity (Korenromp et 
al., 2011; Saligan, 2014) and weight gain is associated with the primary medication 
prescribed (prednisolone; Liu et al., 2013). Therefore, the weight gain difference may 
be linked to time with the condition. The condition is associated with deconditioning 
related to major symptoms including fatigue, dyspnoea and chronic cough 
(Baughman, 2013) and as such has been suggested to lead to decreased physical 
activity levels. A multiple regression was carried out to investigate whether gender, 
sitting time, fatigue (FAS), dyspnoea, number of types or BMI could significantly 
predict participants IPAQ physical activity. The results of the regression indicated that 
FAS, gender and sitting time explained 37.5% of the variance and that the model was 
a significant predictor of IPAQ physical activity, F(3,47) = 9.39, P = 0.001. While all 
three variables contributed significantly to the model (B = -.04, .51, -.001, P < 0.05, 
respectively). Korenromp (2011) found self-reported fatigued sarcoidosis patients had 
reduced levels of physical activity against non-fatigued participants with the condition 
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and both groups were reduced compared to a healthy control. Gosse (2014) found BMI 
when self-reported tend to be underestimated with misclassification increasing with 
BMI score, additionally, sarcoidosis is associated with muscular atrophy (Cremers et 
al., 2013) and thus can lead to lower BMI scores. 
 
 
 
 
6.5.2. Physical activity/sitting hours p/d 
There is severely limited physical activity research within sarcoidosis at present, 
however some preliminary research is starting to form a baseline understanding. 
Korenromp et al. (2011) found higher levels of inactivity for those with the condition 
compared to healthy controls, with those reporting as fatigued reporting lower levels 
of activity than non-fatigued patients. Our findings remain unclear as non-fatigued 
participants reported higher levels than those reported as extremely fatigued for Mets-
mins/week (3112.5±442.71 & 1847.83±2905.85) however fatigued participants 
reported the highest Mets-mins/week of all groups (6325.33±6205.82), although this 
group showed a very large standard deviation, suggesting some fatigued individuals 
have high levels of physical activity and bring up the mean for the group overall, there 
is also a limitation of different group size (Table 16) and therefore may be not a fair 
representation of their group as a population. In addition to Koremromp et al. (2011) 
findings, Saligan (2014) found sarcoidosis participants had lower functional 
performance outcomes, more fatigue and were less physically active than age, gender 
and ethnically-matched sedentary healthy controls. Although Saligan’s (2014) 
research highlights key information regarding physical activity, for example greater 
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levels of physical activity than already sedentary controls, it fails to offer depth due to 
the exclusion of activity levels of physically active healthy controls and normative 
values for age and gender matched data. Additionally, Saligan (2014) only recorded 
during weekdays whilst Korenromp researched both weekdays and weekends and 
found a sharp drop in activity over the weekend, with fatigued participants reducing 
activity the most despite being the most inactive. Garcia-Aymerich et al.’s (2006) 
research highlights the potential benefits of physical activity and found COPD patients 
even with “low” self-reported physical activity had fewer hospital admissions and 
lower mortality rate than those reporting “very low”. Low was classified as engaging 
in light physical activity including walking or biking for less than two hours per week, 
while very low was classed as sedentary activities such as sitting during working hours 
and no leisure time activity, jogging or cycling. This study utilised the IPAQ and found 
83% reported moderate-high levels of physical activity, with 49% recording high 
levels of physical activity based on the IPAQ’s guidelines (Table 14). It is worth noting 
that there were clear differences between genders, where males recorded 17.65% as 
being highly active while 63.89% of females recorded as high. A limitation is the self-
reported aspect, where disadvantages include external factors such as social 
desirability and the need to rely on memory recall, in addition to being less robust in 
measuring light and moderate physical activity (Sylvia et al., 2015). Validity could be 
increased through the use of accelerometers to record real world physical activity data 
(Prince et al., 2008). Although, the IPAQ has shown moderate validity in comparison 
to accelerometer data (Wanner et al., 2016), it is worth noting that the IPAQ has been 
shown to produce repeatable data and been stated as being as good as other established 
self-reported physical activity questionnaires (Cora et al., 2003).  
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Mean minutes sitting per day decreased as the physical activity level increased, with 
the exception being moderate activity males who sat 39 minutes more than low activity 
males, however, all groups have sizeable standard deviations (Table 14) and thus 
highlights the volatility despite being within the same physical activity threshold. This 
is an area wide issue as based on current UK guidelines (Department of Health, 2010) 
it is possible to meet both the sedentary and physically active thresholds. There are 
numerous implications for being sedentary for too long, despite being active outside 
of this, and this is a growing area of research. Owen et al. (2010) states prolonged 
bouts of sitting compromises metabolic health irrespective of an individual’s physical 
activity levels. Prolonged bouts of sedentary behaviour including sitting has been 
associated with a range of detrimental health risks including type 2 diabetes and 
premature mortality (Dunstan et al., 2012). Korenromp et al. (2011) previously found 
fatigue was associated with reduced activity levels however physical activity is a 
complex issue, and will consist of numerous reasons, such as environmental factors 
including lack of affordability and childcare as well as social factors including peer 
and family support (Seefeldt et al., 2002) although based on the current findings, 
improving fatigue may be beneficial for improving physical activity levels 
(Korenromp et al., 2011; Saligan, 2014). Additionally, improving participants 
dyspnoea score may also improve activity levels in addition to other variables such as 
quality of life. Dyspnoea is a major symptom of sarcoidosis (Baughman, 2013), and 
has been suggested as being important within the deconditioning process and thus 
reduced activity levels as well as increased dyspnoea predicted depression as a 
sarcoidosis factor (Chang et al., 2001).  
6.5.3. Fatigue/MRC dyspnoea scale 
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Only four participants (7.41%) were identified as non-fatigued via the FAS within this 
study, while only five (9.09%) selected grade 1 on the MRC dyspnoea scale (i.e. only 
felt breathless during strenuous exercise; Table 14). This data highlights the significant 
effect of fatigue and dyspnoea on sarcoidosis patients and its importance for 
understanding the condition and development of future treatment options. Extreme 
fatigue, signified by a score above 35 on the FAS, was reported in 22.22% of 
participants, while 37 participants (85.46%) selected grade 2-4, with 5.45% selecting 
grade 5 (reported as being too breathless to leave the house, or breathless when 
dressing/undressing). This highlights the impact the disease can have on someone’s 
life and once again the complexity of physical activity as patients may wish to have 
higher levels of physical activity however their MRC dyspnoea score may be a limiting 
factor to this as well as their everyday life. A multiple regression was undertaken to 
check if any were predictors of the MRC dyspnoea scale, nothing was found to be a 
predictor. The reason for this remains unclear but may be due to how the scale is 
reported and the differences with how the other variables are measured. Improved 
understanding of the interaction between fatigue and dyspnoea is required, as well as 
their role in affecting physical activity, deconditioning and quality of life in sarcoidosis 
as well as greater understanding with regards to the potential benefits of better targeted 
treatment of these symptoms and the wider effect this would have on a sarcoidosis 
patient. 
6.6. Conclusions and Future Directions 
One future direction would be isolating the different combinations of the condition 
and severity scores, such as pulmonary and skin sarcoidosis and pulmonary and 
bone/joint sarcoidosis and looking into greater depth at their effects on BMI, physical 
activity, fatigue and other key variables. Gaining greater depth and understanding of 
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the different correlated variables such as physical activity, FAS and dyspnoea and the 
interactions between them is vital, a large cohort of diverse (geographical and 
demographically) sarcoidosis patients looking at this longitudinally is required.  
Based on the current study’s findings, sarcoidosis patients are a diverse population not 
dissimilar to the general population. The key symptoms of dyspnoea and fatigue do 
moderately correlate with each other while higher levels of self-reported physical 
activity have been linked with reduced FAS scores. 
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7.  CHAPTER SEVEN 
7.1. The Relationship Between a Direct Measure of Physical Activity Against 
Self-Reported Physical Activity, Muscle Strength, Quality of life and 
Exercise Capacity. 
7.1.1. Chapter seven Abstract 
Background: Physical activity is frequently suggested as beneficial within sarcoidosis 
however little is currently known about physical activity patterns within the condition 
as well as its role and effect on other key physiological and mental variables. 
Additionally, self-reported measures such as the IPAQ are regularly utilised within 
research due to their ease of use and low cost however their validity and accuracy 
within sarcoidosis in comparison to an objective measure (tri-axial accelerometer) is 
currently unknown. 
Methods: A lab-based approach was utilised with participants visiting twice to validate 
their variable measurements. Participants undertook exercise capacity (6MWT), lung 
function (FEV1, FVC, PEF), muscle strength (HGS, QPT, HPT, EFMS), quality of life 
(SHQ) and fatigue (FAS) tests in addition to wearing a tri-axial accelerometer for five 
days between visits. 
Results: Participants recorded above recommended levels of physical activity via the 
accelerometer (109mins MVPA per day) and reported a large difference via the IPAQ 
(43 minutes), neither were predictors of each other, however Calories burned per day 
and BMI were found to be predictors of accelerometer MVPA (R2 =.968). Handgrip 
strength reported strong bivariate correlations with gender (.809), body fat percentage 
(.794), elbow flexor muscle strength (.961) and forced vital capacity (.865) although 
only elbow flexor muscle strength was found to be a predictor (R2=.913). 
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Conclusions: Physical activity patterns are diverse within sarcoidosis much like the 
general public, while physical activity’s relation to other variables appears limited 
although the variables are multi-faceted. Handgrip strength and six-minute walk 
distance may be a good indicator of a range of other key variables within the condition. 
7.2. Introduction  
Physical activity (PA) is recommended across all ages and health conditions, albeit at 
different intensities and durations. For adults (19-64 years) in the U.K. 150 minutes of 
moderate exercise, 75 minutes of high intensity exercise or a combination of the two 
is recommended per week (Department of Health, 2011). Descriptions of Physical 
activity range from “Miracle Cure” (NHS, 2015b) to “the best buy for public health” 
(MacAuley et al., 2015), which highlights the perceived importance of physical 
activity, further backed up by reports that physical inactivity is the fourth biggest killer 
across the world’s population (Kohl et al., 2012). Unfortunately, the physical activity 
guidelines are not met by everyone. In the UK 2015/16 26% of adults (16+ years) were 
classified as inactive i.e. less than 30 minutes of physical activity a week (NHS Digital, 
2017) with physical inactivity being worse in those with interstitial lung diseases 
(ILD) such as asthma, chronic obstructive pulmonary disease (COPD) and Sarcoidosis 
(Watz et al., 2009; Korenromp et al., 2011; Drent et al., 2014; Saligan, 2014), despite 
the known public health benefits for both healthy and chronically ill populations. For 
example, regular physical activity within COPD has been shown to reduce not just 
admission to hospital but also all-cause mortality as well as specifically respiratory 
mortality (Garcia-Aymerich et al., 2006). Physical activity has frequently been 
suggested as beneficial for sarcoidosis patients (NHS, 2015a). This is due to a host of 
specific and non-specific benefits to those with the condition, such as the overall 
improvement to health including decreased levels of non-communicable diseases as 
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well as lower risk of depression (NHS, 2015b). Although anyone can suffer from 
depression, sarcoidosis patients have been shown to have increased levels (Hinz et al., 
2012). Physical activity also helps not only to slow and stop deconditioning, a major 
issue within sarcoidosis (Fleischer et al., 2014), but also aids the reversal of this 
process (Strookappe et al., 2015). Despite the known wide-ranging benefits of 
physical activity, there is no reported average physical activity level among 
sarcoidosis patients, with the few studies that have been undertaken showing 
decreased levels of normative values compared to healthy-aged match controls 
through both self-reported real world (accelerometer) methods (Korenromp et al., 
2011; Vasudevan et al., 2013; Saligan, 2014).  Self-reported measures of physical 
activity such as the International physical activity questionnaire (IPAQ) are important 
tools in better understanding the physical activity levels across large population sizes 
due to their ease of use and low costs (Biddle et al., 2011). Although they are useful 
in gaining knowledge within a population, especially one that has limited data such as 
sarcoidosis, the evidence obtained can only be utilised to the benefit of research and 
the population if the data is valid for that population. As such, the IPAQ and other 
self-reported measures need to be validated against the tri-axial accelerometer to 
understand their validity and justify their use in further studies. Craig et al. (2003) 
found the IPAQ to be a valid tool to measure adults’ (18 -65 years) physical activity, 
with similar correlation strength (.43 for UK population) to other self-reported 
measures. The weak-moderate correlation found between IPAQ and accelerometer 
within a healthy population further highlights the need to quantify both self-reported 
and objective measure of physical activity. To the IPAQ’s benefit Carlos et al. (2012) 
found the IPAQ did reveal some metabolic and cardiovascular disease risk factors thus 
underlying self-reported measures do have a place within research, however it did not 
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reveal them all in comparison to accelerometer derived physical activity and as such 
implementation of only the IPAQ could therefore lead to the underestimation and 
missing of some disease risk factor relationships. Furthermore, Dyrstad et al. (2014) 
found participants reported increased vigorous activity and less sedentary time via the 
short form-IPAQ than their accelerometer measurements. The inhibiting factors for 
the reported decreased levels of physical activity remain unclear too, although it is 
likely attributed to the symptoms of the condition and other lifestyle factors that the 
U.K’s whole population faces as well as regular comorbidities for sarcoidosis such as 
hypertension, thyroid disorders and obesity (Martuseqicz-Borors et al., 2015). The 
distribution of these factors on the effect of physical activity levels remains unknown 
and is an area for future research, as knowing this, is vital for the development of a 
disease-specific treatment plan. Sarcoidosis currently lacks specific guidelines, unlike 
similar conditions such as COPD and asthma (ACSM, 2014; National Institute of 
Health and Care Excellence (NICE), 2016). Due to this, sarcoidosis patients are often 
given advice on exercise and other forms of physical activity such as walking or 
dancing that are not underpinned by specific research of their condition and as such 
are potentially less effective or irrelevant for the condition. Holland et al. (2015) states 
the unique presentation of ILD, including sarcoidosis, requires modifications of 
exercise prescription for individuals and this was also noted as a key issue by 
Strookappe et al. (2016) in a systematic review of physical activity and training in 
Sarcoidosis.  
The effect of pulmonary sarcoidosis on exercise capacity and strength in comparison 
to a healthy population is limited and needs further research. Reductions to both 
exercise capacity and muscle strength indicated by lower results than normative 
values, are known primary symptoms of Sarcoidosis (Spruit, 2005a; Hildebrand et al., 
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2012; Baughman, 2013), which continue to get progressively worse with the onset of 
secondary symptoms such as deconditioning (Mitchell et al., 2012; Fleischer et al., 
2014). The symptoms of sarcoidosis in tandem with the varied manifestations (Skin, 
liver, heart etc. (Saidha et al., 2012)) of the disease alongside pulmonary, make it 
incredibly hard for accurate, appropriate suggestions for physical activity, especially 
when considering the current lack of evidence. This is highlighted by the role of 
fatigue within sarcoidosis, which is recognised as a major factor within the disease 
(Baughman, 2013) and therefore needs considering when creating an exercise 
prescription plan. In addition to this, pulmonary impairment has been reported via 
exercise testing despite normal pulmonary function results (Miller et al., 1995), while 
Delobbe et al (2002) also found limited maximal exercise capacity within sarcoidosis 
patients despite no signs of pulmonary or cardiac impairment at rest. Additionally, 
vital components of any exercise programme seeking to achieve physical benefits 
include duration, frequency and intensity (Spruit et al., 2005a; Swigris et al., 2011; 
Boots et al., 2011; Strookappe et al., 2 015). 
Hence, increased understanding of the effects of pulmonary sarcoidosis in relation to 
physical activity and fitness is required as well as comparison to a healthy age matched 
normative values to allow for the data to be considered alongside other ILD’s. This is 
vital as Kohl et al. (2012) states instead of an individualised behavioral science 
approach, focus is needed on populations as well as the complex interactions with 
physical inactivity factors. Further research into this area is required as exercise 
training has been shown to be in some cases just as, or more, effective than medical 
treatment across a wide range of chronic conditions (Pedersen & Saltin, 2015). Within 
Sarcoidosis, Marcellis et al. (2013a) argues rehabilitation should be utilised alongside 
any pharmacological treatment despite the need for future research on potential 
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benefits while Strookappe et al. (2016) also state that, although further randomised 
controlled trials are needed, the effects of physical training seem promising from the 
current limited research.  
Therefore, the primary aim of this study was to ascertain physical activity patterns in 
those with pulmonary sarcoidosis with regards to perceived physical activity and 
actual physical activity. The secondary aim of the study was to understand the effect 
of pulmonary sarcoidosis in relation to muscle strength and exercise capacity against 
physical activity and lung function as well as how these differ from normative values. 
7.3. Methodology 
7.3.1. Participants 
Participants with medically diagnosed pulmonary sarcoidosis were selected. They 
were recruited through support groups and online forums. A diagnosis of sarcoidosis 
was accepted provided the participant had been clinically diagnosed with pulmonary 
sarcoidosis, ascertained by self-reporting. The study consisted of 8 participants (n = 3 
male, n = 5 female) of whom seven were Caucasian and one was mixed Caucasian and 
Afro-Caribbean. Participants mean age (± standard deviation) was 50±8 years with 
mass and stature 81± 17.94kg & 172± 10.33cm, respectively. 
7.3.2. Exclusion Criterion 
Exclusion criterion included contraindications to (not able to perform) physical tests 
or exercise testing - e.g. unstable cardiovascular disease, oncological, cardiac, 
neurological or orthopaedic history making them unable to participate, , or an injury 
in the past 6 months that inhibits ability to perform exercise testing, both determined 
via a sub-maximal fitness screening form (appendix 1). Additionally, patients with a 
concurrent and predominant diagnosis of another significant respiratory disorder (for 
example: asthma, COPD, cystic fibrosis, or lung cancer) were excluded. Other reasons 
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for exclusion included pregnancy, physical disability (non-ambulatory patient e.g. 
wheelchair or bed-bound), inability to obtain informed consent and cognitive failure 
making them unable to give consent or understand questionnaires or instruction.  
7.3.3. Design, Equipment and Procedures 
The study used a prospective cross-sectional observational design with no 
intervention. Observational exercise testing included both endurance exercise and 
muscle strength. Patients participating in this study were treated according to current 
guidelines (Costabel & Hunninghake, 1999). As such, diagnostic procedures or 
current treatment was not postponed or impacted on by participation in this study. 
Participants were invited to attend the laboratory for testing on two occasions 
separated by a minimum of 6 days and maximum of 14 days to measure physical 
activity, fatigue, aerobic fitness and muscular strength with exercise testing at the 
Human Performance laboratory, Kingston University, London to establish the 
influence on symptoms, physiological and psychological outcomes. Exercise testing 
followed standardised guidelines (ACSM, 2016). Appropriate health and risk 
stratification screening was performed via a sub-maximal exercise screening form 
based on a PAR-Q (appendix 1). During visit one, participants signed an informed 
consent form (appendix 9) and had any questions answered before continuing. They 
were then put through a screening process beginning with physical examination: 
characteristics such as anthropometric data (stature, mass, heart rate (HR), blood 
pressure, age, BMI, fat% (Bodpod, Cosmed/ Bioelectric Impedance Analysis (BIA), 
Tanita) were collected. Following this, participants conducted a lung function test via 
computer spirometery (Oxycon Pro, VIASYS GmbH, Eric Jaeger, Hoechberg, 
Germany). Their predicted results were corrected for ethnicity (Bellamy, 2005), where 
Afro-Caribbean predicted results were decreased by 13% (Bellamy, 2005). 
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Participants then conducted muscle strength testing using an isokinetic dynamometer 
(Biodex System 4, Biodex Corporation, NY, USA); tests included: elbow flexor 
muscle strength (EFMS), quadriceps peak torque (QPT) and hamstring peak torque 
(HPT), in addition to this handgrip strength (HGS) was also assessed via handgrip 
digital dynamometer (Accord Medical Products). A minimum rest period of 20 
minutes followed (Vainshelboim et al., 2014) based on exercise-based pulmonary 
rehabilitation research. Heart rate (bpm) was checked at the end of this period and in 
two-minute intervals until HR returned to baseline as per ACSM (2014) guidelines, 
physical testing did not take place until this return to baseline. Following the rest 
period, participants conducted a six-minute walk test (6MWT). During the test, 
participants were measured for Borg rate of perceived exertion and Borg Dyspnoea at 
2-minute intervals and at completion of the test. Oxygen saturation levels of 
participants were recorded during the 6MWT via a portable pulse oximeter at the same 
intervals as the perceived exertion and dyspnoea. Once the 6MWT had been 
completed, participants completed three questionnaires, the fatigue assessment scale 
(FAS; De Vries et al., 2004), international physical activity questionnaire (IPAQ; 
Ekelund et al., 2003) and Sarcoidosis Health Questionnaire (SHQ; Cox et al., 2003). 
Before leaving, participants were given tri-axial accelerometers (GT3X+ 
accelerometer, ActiGraph, Pensacola, Flordia), which were used to measure the 
participants physical activity for five days, to establish habitual physical activity levels 
and compare against the results of the IPAQ.  
During the second lab visit, participants returned their accelerometers and followed 
the same pattern of testing from the first visit, excluding the questionnaires (SHQ, 
FAS & IPAQ) and anthropometric information. The order of testing followed ACSM 
(2016) guidelines.  
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Six Minute Walk Test: Performed along a straight flat 30 metre course indoors, 
participants walk at their own pace for 6 minutes (Butland et al., 1982). No warm-up 
is required however participants rest in the seated position 10 minutes before the test 
in accordance with American Thoracic Society (2002) guidelines. 
Sarcoidosis Health Questionnaire (SHQ): The questionnaire comprised of 29 
questions separated into three categories daily functioning, physical functioning and 
emotional functioning and is based on a 7-point Likert scale (Cox et al., 2003). 
International Physical Activity Questionnaire (IPAQ): IPAQ comprises of 27 items 
across five activity domains asked independently. 
Fatigue Assessment Scale (FAS): - FAS is a 10-item questionnaire with a 5-point likert 
scale, it is split into 5 physical fatigue and 5 mental fatigue questions. 
Borg rate of perceived exertion and Borg Dyspnoea: The Borg rate of perceived 
exertion scale (Borg RPE) allows participants to express how exerted they feel via a 
numbered scale (Borg, 1982), modified Borg Dyspnoea scale (Borg DS) allows 
participants to express their shortness of breath (Borg, 1982). 
Oxygen saturation levels (SpO2): Oxygen saturation levels of participants was 
recorded during the 6MWT via a portable pulse oximeter, the device was fitted to the 
participants finger and checked every 30 seconds throughout. 
Isokinetic Dynamometer: A Biodex system was utilized to look at dominant upper and 
lower limb strength via elbow flexor muscle strength (EFMS), quadriceps peak torque 
(QPT) and hamstring peak torque (HPT) tests, with rest periods of 60 seconds between 
repeated tests as per Parcell et al. (2002) research findings. 
Hand Dynamometer: Utilised to measure hand grip strength following ACSM (2014) 
guidelines. 
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Accelerometer: Participants kept this on their persons (right hip) for five days, starting 
the morning following their lab visit to measure real world physical activity. Set up 
included initializing the device and setting the sample rate to 100Hz, inputting start 
and end time as well as participant information (gender, stature, mass, age, ethnicity) 
in addition to location of the device (right hip) and whether this was their dominant 
side. Participants were required to wear the device for a minimum of seven hours per 
day, for a minimum of four days over the five-day wear period. 
7.3.4. Data analysis 
The data were analysed via SPSS 24.0 (IBM Corp, Armonk, New York). An 
exploratory data analysis was first completed; the data was normally distributed and 
therefore met parametric assumptions, a paired samples t-test was utilized in addition 
to a bivariate correlation between the different variables. Bivariate correlation strength 
was based on Evans (1996) guide (weak = .2 - .39, moderate = .4 - .59, strong = .60+). 
Data are presented as mean and standard deviation (SD). In addition to this, multiple 
regression was carried out to look for predictors of the different variables such as 
accelerometer MVPA. Analysis of the raw accelerometer data was conducted through 
Actigraph (ActiGraph, Pensacola, Flordia), Freedson VM3 (2011) (Sasaki et al., 2011) 
was used for energy and cut-point calculations before being exported to excel and 
transferred for analysis within SPSS.  
7.4. Results 
Of the eight participants who undertook the study, there were no drop-outs. Table 18 
displays the characteristics of the participants who partook in the study. The age range 
of participants was 36-61 years, with body fat range 10.30-60.00%, males fell within 
lean (6-17%) and normal (18-22%) while three females fell within overweight (32-
39%) and two within obese (40%+). This is in contrast to participants BMI score, three 
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participants were reported as obese (30+) via the BMI scale (National institute for 
health and care excellence, 2014), one as overweight (25-29.9) and four were a healthy 
weight (18.5-24.9). 
Table 18. Characteristics of Subjects. 
Characteristics All (n=8) Male (n=3) Female (n=5) 
Age (yrs) 50±8 46±10 53±6 
Stature (cm) 172.01±10.33 182.53±7.49 165.70±5.56 
Mass (kg) 81.32±17.94 72.63±3.19 86.53±20.89 
Body fat (%) 32.63±15.17 15.91±4.05 42.66±9.50 
 
Table 19 highlights the recorded measurements for both first and second visit, in 
addition to any statistically significant differences between them. Both hamstring peak 
torque and percentage of predicted FVC were found to be significantly different 
between visits (P<0.05). 6MWD mean changed by 34.25m however no significant 
statistical difference was observed (P>0.05), while EFMS & QPT results showed a 
small but non-significant increase non-significant (P>0.05). 
Table 19. Mean, standard deviation and statistical significance of lung function, six-
minute walk test, borg exertion & dyspnoea as well as muscle strength, including 
significance between visits. 
Measurement First Visit Second Visit Sig. 
FEV1 (L) 2.60±0.80 2.68±0.87 .107 
% FEV1 (%) 84.10±14.28 86.52±13.73 .114 
FVC (L) 3.00±0.93 3.36±1.25 .057 
%FVC (%) 80.87±14.82 88.92±12.70 .037* 
PEF (L/m) 6.74±1.84 6.45±1.19 .510 
6MWD (m) 565.63±88.55 599.88±69.34 .069 
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Borg RPE 11±1 10.5±2 .313 
Borg Dys 2.5±1 2.5±1 .856 
EFMS (N·m) 22.63±6.46 26.26±7.87 .065 
QPT (N·m) 56.81±23.84 74.81±16.47 .075 
HPT (N·m) 25.50±11.05 36.69±11.35 .015* 
HGS (kg) 34.75±14.39 32.75±12.98 .082 
Asterisk (*) = Significant difference (P<0.05); Borg RPE = Borg rating of perceived exertion; Borg Dys = Borg scale of dyspnoea; 
HGS = handgrip strength; HPT = hamstring peak torque; QPT = quadricep peak torque; EFMS = elbow flexor muscle strength; 
6MWD = six minute walk distance; PEF = peak expiratory flow; %FVC = percentage of forced vital capacity; = FVC = forced 
vital capacity; %FEV1 = percentage of forced expiratory volume in one second; FEV1 = forced expiratory volume in one second. 
Table 20 shows the reported quality of life for both genders. The overall mean for 
SHQ was 4.26, with males scoring higher in total and every sub-scale (EF, PF & DF) 
than their female counter parts. Mean score for fatigue was 27.88, with females self-
reporting higher levels of fatigue (28.60), with one extreme fatigued and four fatigued 
in comparison to males (26.67), with one extreme fatigued and two non-fatigued. 
There was no significance difference between the genders for any of the variables 
reported in the table (P>0.05). 
Table 20. Showing mean and standard deviation of quality of life, fatigue (no 
statistical difference between the genders P > 0.05). 
Variables All Male Female 
SHQ 4.26±0.90 4.77±0.95 3.96±0.70 
EF 4.08±0.81 4.57±1.00 3.78±0.74 
PF 4.31±1.04 5.06±1.00 3.87±0.78 
DF 4.40±1.04 4.67±1.19 4.24±0.90 
FAS    
Fatigue Score 27.88±9.32 26.67±13.89 28.60±4.67 
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No Fatigue 2 2 0 
Fatigued 4 0 4 
Extreme Fatigue 2 1 1 
SHQ = Sarcoidosis Health Questionnaire; EF = Emotional functioning; PF = Physical Functioning; DF = Daily Functioning; FAS 
= Fatigue Assessment Scale. 
Table 21 shows self-reported physical activity via IPAQ and measured physical 
activity via accelerometer. Four self-identified as high physical activity status, with 
two each in low and moderate categories. Moderate and vigorous physical activity 
(MVPA) per day was 152mins for self-reported (IPAQ). The male participants 
reported higher amounts of MVPA than their female counterparts (309 & 57 mins, 
respectively; P = 0.768). In addition, sitting time per day was reported as 448mins per 
day, participants sat for just under three times their reported MVPA. However, the 
table included two male outliers (reported excessive MVPA, up to 23 hours per day) 
without their inclusion the mean met-minutes/week were 2078±1798 while MVPA 
per day was 55±64, a substantial difference.  The outliers would have been excluded 
completely if the sample size was bigger as their reported MVPA was not 
representative of achievable within daily hours. The accelerometer data recorded 
MVPA as 109mins per day over a five-day period, where males recorded higher levels 
of MVPA than females (118 & 104, respectively) albeit with a smaller difference than 
IPAQ MVPA (14min difference, P = 0.946). Accelerometery also reported smaller 
standard deviations than the IPAQ for example IPAQ MVPA per day SD was 182 
compared to 44 for the accelerometer. No statistical difference was reported between 
the genders for accelerometer MVPA or IPAQ MVPA (P>0.05), or any of the other 
variables (Met-minutes/week, Kcals per day, sitting per day and steps per day). 
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Table 21. Highlighting the differences between self-reported physical activity and real 
world physical activity. 
Physical activity 
status IPAQ 
All Male Female 
Low 2 0 2 
Moderate 2 1 1 
High 4 2 2 
Mets-Minutes/week# 6755±8467 14171±9861 2305±1886 
7 Day MVPA 
(mins)# 
1061±1274 2163±1410 400±487 
MVPA per day 
(mins)# 
152±182 309±201 57±70 
Sitting per day 
(mins) 
448±117 397±123 478±102 
Accelerometer    
5 Day MVPA (mins) 503±239 568±237 463±231 
MVPA per day 
(mins) 
109±44 118±42 104±45 
Moderate Activity 
per day (mins) 
82±32 86±21 79±33 
Vigorous Activity 
per day (mins) 
27±13 32±12 24±13 
Average Kcals per 
day 
824±399 789±271 844±458 
Steps per day 7258±2199 7734±2666 6973±1804 
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IPAQ = International physical activity questionnaire; MVPA = moderate to vigorous physical activity; # = including two male 
outliers. 
Table 22 highlights the results of a multiple regression into predictors of accelerometer 
MVPA.  Calories burned per day and BMI were found to be significant predictors, 
explaining 96.8% of the variance within the data. 
Table 22.  Multiple regression predictors of accelerometer MVPA. 
Model R2 B Sig. 
1    
Constant  34.24 .183 
Kcals per day .783 .09 .019 
2    
Constant  83.209 .011 
Kcals per day  .12 .003 
BMI .968 -2.53 .025 
Kcals per day = calories burned per day. BMI = body mass index. Dependent variable = accelerometer MVPA. 
 
Table 23 highlights the results of a multiple regression into predictors of fatigue.  Only 
quality of life findings via the SHQ was found to be a significant predictor, explaining 
79.7% of the variance within the data. 
Table 23.  Multiple regression predictors of the fatigue assessment scale 
Model R2 B Sig. 
1    
Constant  49.93 .001 
SHQ .797 -5.38 .017 
SHQ = Sarcoidosis health questionnaire. Dependent variable = Fatigue (Fatigue assessment scale). 
 
Table 24 highlights the results of a multiple regression into predictors of the distance 
walked in the six-minute walk test (6MWD).  Gender and BMI were found to be 
significant predictors, explaining 99.1% of the variance within the data. 
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Table 24.  Multiple regression predictors of the six-minute walk distance 
Model R2 B Sig. 
1    
Constant  980.10 .001 
Gender .880 -220.10 .006 
2    
Constant  1014.295 .001 
Gender  -177.02 .001 
BMI .991 -3.809 .009 
BMI = body mass index. Dependent variable = Six-minute walk distance 
 
Table 25 highlights the results of a multiple regression into predictors of fatigue.  Only 
elbow flexor muscle strength was found to be a significant predictor, explaining 91.3% 
of the variance within the data. 
Table 25.  Multiple regression predictors of the Handgrip strength 
Model R2 B Sig. 
1    
Constant  -7.04 .283 
EFMS .913 1.62 .003 
EFMS = elbow flexor muscle strength. Dependent variable = Handgrip strength. 
 
Table 26 highlights the results of a multiple regression into predictors of fatigue.  Only 
hamstring peak torque found to be a significant predictor, explaining 87.3% of the 
variance within the data. 
Table 26.  Multiple regression predictors of the quadricep peak torque  
Model R2 B Sig. 
1    
Constant  17.60 .135 
HPT .873 1.53 .006 
HPT = Hamstring peak torque Dependent variable = Quadricep peak torque. 
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7.5. Discussion 
The primary aim of this study was to ascertain physical activity patterns and 
understand differences between perceived physical activity and actual physical 
activity in pulmonary sarcoidosis patients. Furthermore, in order to gain greater insight 
and understanding into the effect of pulmonary sarcoidosis on physical activity, 
muscle strength, quality of life, exercise capacity, lung function and oxygen saturation 
were also measured. 
7.5.1. Physical activity self-reported and real world 
The main findings of this study highlight the differences between perceived and actual 
physical activity levels as well as issues surrounding self-reported physical activity in 
addition to growing the body of knowledge within the clinical population of 
pulmonary sarcoidosis. Four participants self-reported high levels of physical activity 
with two each in moderate and low. Males self-reported higher Met-minutes/week 
(14171) than females (2305), a difference of 11866 met-minutes/week. However, 
those data include the two male outliers and without their inclusion the one other male 
reported 918 compared to the female mean of 2305. The two outliers were included as 
participants, both reported up to a possible 23 hours day of physical activity, much of 
it moderate or vigorous, excluding sleep or sitting time). This highlights issues 
associated with self-reported questionnaires, for example within the IPAQ the 
questions are open-ended for activity levels across a range of situations (work, 
commuting, leisure) and as such the hours are unlimited for each scenario. Although 
it is worth noting due to the format of the questionnaire, it is impossible to say which 
day of the week involved which activity. This is a key limitation of the IPAQ and 
should be addressed by changing the question from asking how many days per week 
to having separate and defined boxes for each day of the week and their relevant 
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physical activity for each category. This way researchers would be able to break down 
and rank their physical activity to each day of the week. In addition to between genders 
within genders there was also a large variation in reported Met-minutes/week with 
standard deviation being 9861(males) and 1886 (females), the male’s standard 
deviation is inflated by the outliers however the female’s standard deviation is still 
high. These large differences highlight the limitations associated with self-reported 
physical activity such as being less robust at measuring light-moderate activity, over- 
and under-estimation of activity levels and requiring participant recall of past events 
(Sylvia et al., 2014) and as such is highlighted by the outliers met-minute/week totals 
of 17037 and 24558. The two outliers are extreme examples of limitations associated 
with the IPAQ as well as the effect of a small sample size (n=8). In addition to the lack 
of clear days of the week being reported within the IPAQ, the number of working 
hours and how many days per week worked being specified by a participant was also 
a shortcoming too. For example, the first outlier reported four hours of walking five 
days per week, six hours of moderate activity four days per week and six hours of 
vigorous activity one day per week for just their work physical activity. They also 
reported high levels of activities at home (5 hours of house chores twice per week). 
While the other four hours of walking five days per week, six hours of moderate 
activity five days per week and eight hours of vigorous activity twice per week, 
Hastromer et al. (2005) also found similar outliers with extremely high levels of 
physical activity such as five hours cycling to and from work daily and a minimum of 
60-120 minutes of vigorous activity at work daily. The outliers may arise through a 
misunderstanding of the questions asked, these overestimations may have been 
avoided if participants were required to state how many days they worked in the last 
seven weeks and their number of hours worked before progressing to levels of activity. 
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Further, improvements could be made by highlighting the guidance that the IPAQ only 
wants activities that lasted a minimum of ten minutes at a time, much like it’s current 
highlighting of only involving the last seven days. Another adjustment to improve the 
accuracy of the IPAQ would be to include an example completed IPAQ beforehand 
involving their answers and a description of their day/week such as moderate/vigorous 
activity being less than the requested minimum length and as such not being included 
within their answers. It is worth noting dyspnoea is a major issue within sarcoidosis 
(Baughman, 2013) and may in-part explain the overestimation of MVPA within the 
IPAQ, as vigorous activity is described as making you breathe much harder than 
normal while moderate activity should make you breath somewhat harder than normal. 
Therefore, the IPAQ may need to be modified specially for sarcoidosis to ensure 
accurate results. 
The current guidelines recommendation of 600 met-minutes/week (Kyu et al., 2016) 
have been argued as being set too low. Disease risk including diabetes, breast & colon 
cancer and stroke events have recorded major reductions with physical activity up to 
3000-4000 met-minutes/week (Kyu et al., 2016) with further reductions noted at 
higher amounts too, albeit at a lower percentage rate (Kyu et al., 2016). Through the 
IPAQ, both genders reported above minimum met-minutes/week (14171 & 2305, 
respectively), although females (n =5) are missing potential health benefits compared 
to their male counterparts (n=3). Kyu et al. (2016) meta-analysis found those reported 
as highly active (>8000 met-minutes/week) had risk reductions of 21% for colon 
cancer, 28% for diabetes and 26% for stroke events compared to inactive individuals 
(< 600 met-minutes/week). However, it is worth noting the limitations of self-reported 
data, for example moderate-vigorous physical activity (MVPA) per day within the 
IPAQ was recorded as 152mins with a higher standard deviation (182) and thus 
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highlights the issue, further demonstrated by the accelerometer MVPA per day 
(109±44) being 39% less than self-reported with a much smaller deviation, although 
which does include the outliers. Males (including the two outliers) reported 252 more 
MVPA minutes per day than females (57 minutes) via the IPAQ, despite only 
recording a mean difference of 32 minutes (12%) more via the accelerometer, which 
implies males over-report their physical activity and shows the accelerometer to have 
increased validity against the self-reported IPAQ. The males (including two outliers) 
reported a 62% reduction on their IPAQ accelerometer MVPA compared to their self-
reported data while females under-reported their MVPA via the IPAQ by 28%. The 
two outliers mean difference between accelerometer MVPA and IPAQ is a 74% 
overestimation while interestingly when excluding the outlier’s participants under-
reported their IPAQ MVPA with a 91% difference between MVPA IPAQ and 
accelerometer. This again highlights the serious limitations and issues with self-
reported measures and specifically the IPAQ as the adjusted participants real world 
physical activity nearly doubles (91%) their reported levels. Interestingly, the outlier 
participants were closer to their real physical activity levels than the adjusted 
remaining participants. In addition to the issues stated above regarding the outlier’s 
discrepancies, greater details with regards to the types of activities that are included 
within moderate and vigorous activity may help reduce levels of under-reporting. 
Additionally, discrepancies such as the 91% under-reporting may arise due to the 
different methods applied between the IPAQ and accelerometer. For example, the 
IPAQ only wants moderate/vigorous activity reported that lasted at least 10 minutes 
while an accelerometer records all activity while worn and therefore MVPA bouts of 
five minutes for example would not be reported if following the IPAQ correctly which 
in turn may build up across a day/week if a participant conducts numerous short bouts 
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of MVPA. Dyrstad et al. (2014) reported a 47% difference between males and females 
via self-reported IPAQ results compared with difference between the genders from the 
accelerometer data. Hagstromer et al. (2010) suggests participants field of work may 
affect the efficiency of the accelerometer such as manual activities which is generally 
a male occupation and thus is partly behind the discrepancies in addition to differential 
bias between education groups. Unfortunately, the lack of data on job & educational 
level within our study does not allow us to understand or adjust for these confounding 
factors. Numerous collected variables within chapter seven such as MVPA IPAQ, age, 
gender, HGS, EFMS, QPT, HPT, FAS, SHQ, calories burned per day, BMI, steps per 
day and body fat percentage were utilised within a multiple regression to investigate 
whether any were significant predictors of accelerometer MVPA. The results showed 
only calories burned per day and BMI were predictors, explaining 94.7% of the 
variance within the data. Both variables were significant contributors to the model 
calories burned per day (B = .118, P = 0.001) and BMI (B = 2.528, P = 0.025). 
Accelerometer MVPA and IPAQ MVPA were found not to be predictors of each other 
within the study’s findings, there was a difference of 39% between accelerometer 
MVPA and IPAQ MVPA, which highlights a difference between people’s perception 
and/or memory recall with real world activity. However, it is worth noting the sample 
size for this analysis was very small (n=6) which was made smaller by the removal of 
outliers. The issue of people’s perception of physical activity is exemplified by the 
two outliers due to their 74% overestimation and the other participants under-reporting 
(91%). Calories burned per day was found only to be a predictor of accelerometer 
MVPA (R2 = .783) and not IPAQ MVPA, BMI was however found to be a predictor 
of calories burned per day. Therefore, further research should be contacted regarding 
the usefulness/accuracy & validity of using the IPAQ within Sarcoidosis. Raask et al. 
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(2017) found a correlation of .31 between short form IPAQ and accelerometer in 
adolescent boys, vastly different to this study’s findings. Interestingly the boys 
underreported their MVPA similar to this study’s finding however the boys 
underreported by 13 minutes compared to 43 minutes within the current study, a 
marked difference. Raask et al. (2017) states that to use self-reported questionnaires 
as a measure of meeting guidelines than greater accuracy is required in addition to 
correlational agreement such as the large difference of 43 MVPA minutes per day 
within the current study. Adults have been shown to typically overreport their activity 
levels via the IPAQ in comparison to accelerometer data (Boon et al., 2008; Ottevaere 
et al., 2011; Benefitez-Porress et al., 2013; O’Neill et al., 2017). Boon et al. (2008) 
found a seven-day overestimate of 583 minutes for the IPAQ against the accelerometer 
data, one strength of Boon et al. (2008) research was the immediate IPAQ testing 
following the completion of the seven-day accelerometer wear time. A limitation of 
the current study methods was that participants self-reported physical activity was 
recorded on their first visit, following which they then wore the accelerometer and due 
to this the results may vary slightly as activity does week to week and is not a direct 
measure covering the IPAQ’s timeframe. Furthermore, the population in use may 
affect the accuracy and validity of the IPAQ. For example, O’Neill et al. (2017) found 
IPAQ under-reported sedentary but over-reported MVPA for Bronchiectasis patients 
against an accelerometer. While Sievi et al. (2017) reported an intraclass correlation 
of .40 for time spent in moderate physical activity (>MET) between accelerometer and 
self-reported physical activity with a 44.5% difference within COPD patients. 
Although, Sievi et al. (2017) utilised the German Physical Activity Questionnaire (G-
PAQ-50+), which may in part explain the differences between this study and their 
findings, however it does highlight the lack of accuracy between self-reported physical 
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activity and accelerometer data within a respiratory condition. O’Neil et al. (2017) 
suggested that the IPAQ is not an accurate measure within the bronchiectasis 
population and therefore this may be the case for the Sarcoidosis population too, 
however more research within this area is required for a greater understanding, 
including the validation of the IPAQ within sarcoidosis. A systematic review by Lee 
et al. (2011) found no studies met minimal acceptable standard of correlation (.50) 
with the studies ranging from .09-.39 for total physical activity level. Whilst a 
systematic review into direct versus self-reported physical activity (Prince et al., 2008) 
found correlations were typically low-moderate and highlighted there is no clear 
pattern for mean differences. The current study’s findings following a multiple 
regression show IPAQ MVPA do not predict real world physical activity levels, 
however further research is required with a much larger sample size. Self-reported 
methods resulted in higher physical activity levels measurements (Boon et al., 2008; 
Ottevaere et al., 2011; Benefitez-Porress et al., 2013; O’Neill et al., 2017), similar to 
the current chapter’s findings. Da Silva et al. (2017) suggests both accelerometry and 
self-reported physical activity are complementary of one another and should be 
utilised in combination. It is worth noting participants’ physical activity within this 
study are well above current guidelines for physical activity (150mins moderate or 
75mins of vigorous/combination of both; Department of Health, 2011) with the 
equivalent of 137 minutes of physical activity per day when vigorous activity is 
adjusted (one-minute vigorous activity equals two minutes of moderate activity 
according to current guidelines (Department of Health, 2011). This implies that they 
surpass the weekly guidelines by 809 adjusted minutes but somehow fall below the 
10,000 steps per day (Tudor-Locke & Bassett, 2004). This data subverts the current 
understanding of physical activity within the sarcoidosis population, with Korenromp 
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et al. (2011) and Saligan (2014) both finding physical activity reduced to normative 
figures as well as age, gender and ethnicity-matched healthy sedentary controls 
(Saligan. 2014). The reason behind this is unclear however a sample size (n=8) can be 
considered one potential reason for these findings and highlights the need for further 
research into physical activity as there are no clear patterns for the sarcoidosis 
population as a whole. Another possible reason may be due to the combination of the 
complexity of physical activity and its associated factors (Kohl et al., 2012). In 
addition to the diverse nature of sarcoidosis (Baughman, 2013) and therefore creates 
a wide range of potential interactions between the two. Such as, high levels of drive 
and self-efficacy for physical activity/exercise within an individual coupled with 
severe fatigue and dyspnoea, or sarcoidosis limiting the patient’s ability to work and 
thus effects their socio-economic status and ability to partake in their preferred 
activities. These diverse possible interactions may be leading to extremely varied 
physical activity patterns across the disease. Currently, the effect of sarcoidosis on 
physical activity is not known and may be less influential than other factors associated 
to physical activity such as lifestyle. Fatigue has previously been associated with 
reduced activity levels (Korenromp et al., 2011; Saligan, 2014) while the current 
chapter following a multiple regression found only the SHQ was a predictor of FAS 
from the study’s variables (R2 = .797). Interestingly, Bahmer et al. (2018) found there 
to be a weak correlation (.254) between physical activity (classified as steps per day) 
and fatigue (MFI-20). While none of the other variables were found to be predictors 
of steps per day within this current study. The variances between the research are not 
clear but the two different measures of fatigue may play a role as well as the 
complexity and diverse nature of physical activity and the condition mentioned above. 
Interestingly, both accelerometer and IPAQ MVPA were not predictors of QOL  and 
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thus highlights the multifaceted nature of quality of life and people’s perception of 
what is beneficial to their QOL. Moreover, 6MWD, hand grip strength, elbow flexor 
muscle strength, quadricep peak torque and hamstring peak torque were also not found 
to be predictors of accelerometer MVPA. One potential reason for this may be because 
MVPA does not stipulate what activity is being conducted i.e. strength 
training/running/cycling etc. and therefore it is certain activities conducted and not 
simply physical activity itself that influences these variables. Additionally, MVPA 
only takes up a small amount of time within an individual 24-hour day cycle 
(Rosenberger et al., 2016), the current study finding of 109 minutes per day only 
represent 8% of their 24-hour cycle and therefore light intensity physical activity may 
also play an influential role.  Furthermore, despite females meeting and surpassing 
current physical activity guidelines they recorded above recognised acceptable levels 
of body fat (42.66%; Jeukendrup & Gleeson, 2010). Much like the rest of this disease 
the reasons behind this are unclear and there are likely multiple reasons playing a part. 
One factor may be steps per day, females recorded a daily mean of 6973 steps, 30.27% 
lower than the recommendation of 10,000 (Tudor-Locke & Bassett, 2004).  This 
suggests despite participants undertaking higher than suggested MVPA, their 
movement levels outside of this are reduced and/or limited, this may be due to many 
factors such as type of work or other lifestyle factors of participants. Furthermore, 
although participants within this study were found to be surpassing physical activity 
guidelines, outside of physical activity and MVPA of an individual prolonged sitting 
has been noted as having detrimental cardiovascular and metabolic effects (Hamilton 
et al., 2008). This study found participants sat for more than 7 hours per day 
(448mins). Owen et al. (2010) states prolonged bouts of sitting compromises 
metabolic health despite reaching recommended physical activity levels across the 
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duration of the day/week. Dunstan et al. (2012) states prolonged sedentary behaviour 
such as sitting is associated with numerous health outcomes including type 2 diabetes 
and premature mortality rates. It is worth noting however breaks in sedentary time has 
been associated positively with reduced metabolic risk independent of total sedentary 
time and MVPA (Healy et al., 2008). The area is continuing to build a body of 
knowledge, however research focusing on children aged between 8-11 years has 
shown frequent breaks in sedentary time and sedentary bouts lasting 1-4 minutes have 
been associated with reduced metabolic risk and BMI scores in comparison to longer 
bouts of sedentary behavior (Saunders et al., 2013). Future findings from this area will 
be able to address issues with both sarcoidosis and public health.  
7.5.2. Exercise Capacity 
Participants recorded a 6MWD of 565.63m (visit 1) and 599.88m (visit 2) with no 
significant difference between the two visits (P>0.69). Their mean across the two visits 
was 582.75±81.35m, which is 11.75m further than Casanova et al. (2011) mean of 
healthy subjects. Although it is worth noting Casanova et al. (2011) had a much larger 
sample size (n=444) and conducted the research with people ranging from 40-80 years 
of age with a distance covered range of 380-782m and therefore may help explain the 
mean score as age has been shown to be linked with 6MWD (Chetta et al., 2006) with 
the effect of age more prominent in those >60years of age (Casanova et al., 2011). 
Additionally, Casanova et al. (2011) found 69% of participants walked further in their 
second test and this may part explain the increased distance between visits one and 
two, potentially due to familiarisation with the procedure or a desire to better their 
previous distance. However, the current study’s finding may not be representative of 
the population as a whole due to the limited number of participants and their physical 
activity levels within the study compared to previous research (Korenromp et al., 
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2011; Saligan, 2014). Sarcoidosis has been associated with decreased 6MWD when 
compared against a healthy population previously (Baughman et al., 2007). Baughman 
et al. (2007) found 51% walked < 400 metres whilst 22% walked <200 metres 
compared to a healthy population with a mean of 571 metres (Casanova et al., 2011). 
A combination of reasons has been suggested for this. Kallianos et al. (2015) 
associated ventilatory and cardiocirculatory issues such as arrhythmias and advanced 
heart block (Doughan & Williams, 2006). Whilst, Bourbonnais and Samvati (2008) 
found those with sarcoidosis- associated pulmonary hypertension had lower 6MWD 
than sarcoidosis patients without, supporting ventilatory and cardiocirculatory 
problems as delimitating factors (Kallianos et al., 2015). Wallaert et al. (2011) 
reported impaired heart rate and circulatory impairment as mechanisms for limiting 
exercise capacity following cardiopulmonary exercise testing at lower radiographic 
stages of sarcoidosis (I & II) however the research also suggests the latter stage (IV) 
limitations are influenced greater by ventilatory and gas exchange impairments. Thus, 
there appears to be a greater dynamic nature to the mechanisms behind this reduction 
to exercise capacity than currently understood, therefore ventilatory and 
cardiocirculatory cannot be thought of as the only explanation. Within the current 
study however radiographic stage was not recorded and as such it is unclear the role 
radiographic stage played on the results. For example, it is unknown whether 
recruitment and participation involved more motivated individuals who in turn are 
more active and take more care due to the condition and thus were able to walk further 
compared to others with progressed levels of sarcoidosis with other underlying health 
issues. Exercise intolerance is the impaired ability to perform physical exercise in 
comparison to normative values (Kitzman & Groban, 2011). Exercise intolerance is 
multi-factorial (Kitzman & Groban, 2008) and includes factors such as muscle 
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weakness and poor lung function, both of which are often compounded by the effects 
of deconditioning (Strookappe et al., 2015). Garin et al. (2009) states regarding 
interstitial lung disease (ILD), 6MWD analysis should consider vascular, pulmonary 
and musculoskeletal exercise limitations. Additionally, Quesada-Rodriguez et al. 
(2014) states pulmonary rehabilitation is underutilised within ILD including 
sarcoidosis despite participants benefiting as much as other groups such as COPD 
(Pitta et al., 2008; Puhan et al., 2011) which have a much higher rate of pulmonary 
rehabilitation. Benefits include improvements to dyspnoea, QOL and functional 
exercise capacity (6MWD) (Holland et al., 2008) although long term effects need 
further research (Holland et al., 2008), Ryerson et al. (2014) found improvements to 
physical activity, depression score and QOL were significantly better at 6 months 
follow-up than pre-pulmonary rehabilitation, although Egan et al., (2012) found 
despite pulmonary rehabilitation in COPD improving exercise capacity, physical 
activity remained unchanged from baseline and thus highlights the complex nature of 
physical activity. It is worth noting that V̇O2max has been shown to improve following 
resistance training in non-clinical subjects with low scores (≤25ml/kg/min and 
≤40ml/kg/min) in older (60 years+) and young (20-40 years), respectively; (Ozaki et 
al., 2013). The effect of resistance training for improving V̇O2max in clinical 
populations such as ILD is currently unknown. Delobbe et al. (2002) states V̇O2max 
is typically impaired 25-30% in sarcoidosis although the studies did not differ between 
those with normal and impaired pulmonary or muscle function. Delobbe et al. (2002) 
suggested impaired heart rate response to exercise, alongside the ventilatory issues 
within pulmonary sarcoidosis. Additionally, there are also musculoskeletal issues, 
such as, decreased muscle strength (Strookappe et al., 2015) affecting patients in a 
wide range of ways; exercise capacity & tolerance, QOL and deconditioning to name 
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a few (Mitchell et al., 2012; Fleischer et al., 2014; Marcellis et al., 2013a; Strookappe 
et al., 2015).  
 
The 6MWD following a multiple regression of this study’s variables was found only 
to be predicted by gender and BMI (R2 = .985). The findings indicated that the model 
explained 98.5% of the variance and that the model was a significant predictor of 
6MWD, F(2,3) = 166.47, P = .001. Gender (B = -177.02, P = 0.001) and BMI (B = -
3.809, P = 0.009) contributed significantly to the model. Marcellis et al. (2013b) 
findings of a low correlation (.39) between QOL (World Health Organization quality 
of life – Brief; WHO-B) and 6MWD% predicted although it is worth noting a different 
QOL questionnaires was used (WHO-B & SHQ) as well as the slightly different 
variable. Although maximal testing such as the V̇O2max, which is utilised to measure 
the amount of oxygen the body can consume and use aerobically when performing 
maximal intensity exercise therefore defining the upper limits of the cardiorespiratory 
system (Hawkins et al., 2007), is considered safe within healthy populations, those 
with underlying disease (i.e. Sarcoidosis) have an increased risk of complications and 
adverse effects (Roca et al., 1992) such as exacerbating symptoms including chronic 
cough and dyspnoea. Therefore, another method of testing is required; this leads us to 
VO2peak prediction models, however there are numerous known limitations to these 
including limited gender and age representation as well as lack of adjustment for 
varying fitness levels (Tsiaras et al., 2010; Kendall et al., 2012; Lamberts & 
Davidowitz, 2014). Prediction models are only useful within a very limited range of 
participants similar to those used when creating the model (Malek et al., 2005).  
Previously, fat free mass and BMI has been associated with 6MWD within obese 
individuals (de Souza et al., 2009; Correia de Faria Santarem et al., 2015), while 
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Olufunke et al. (2014) only found a weak correlation (.356) within healthy 
participants. Interestingly however Rastogi et al. (2012) found that in asthmatic 
adolescents, a condition sarcoidosis is often mistaken for (Kalkanis & Judson, 2013), 
BMI was a significant predictor of 6MWD for obese participants whilst percent 
predicted FEV1 predicted 6MWD in normal weight participants. Neither were found 
to be predictors within the current study’s findings although this may be due to a small 
sample size (n=8). Zieleznik et al. (2015) found fatigue not to be correlated to 6MWD 
(.01), a similar finding to this study’s results, therefore despite fatigue being perceived 
as highly disabling, its effect may be separate to exercise performance. One possibility 
is although fatigue is self-reported as highly disabling it not the key factor for exercise 
performance due to the range of other issues such as cardiovascular, pulmonary and 
musculoskeletal and because of this performance is inhibited before fatigue can play 
a role (Zieleznik et al., 2015). There is still a great amount of research required to fully 
understand the different variables and how they interact with each other as well as the 
extent of their interactions.  
Based on Alangari and Al-Hazzaa’s (2004) research of isokinetic peak torque in young 
male adults as normative values (QPT = 67.4 N·m; HPT 41.9 N·m) participants 
recorded 97.64% and 74.22% of their predicted QPT and HPT. A limitation of using 
these values is the population as they were young adult males and therefore do not 
accurately represent the participants within our study, another limitation of our study 
was the lack of an age, gender matched healthy control group to use for normative 
values. Cremers et al. (2013) found 25% of sarcoidosis participants within their study 
suffered from muscle atrophy, Spruit et al. (2005a) found participants scored 87% & 
67% of their predicted hand grip strength (HGS) and quadricep peak torque (QPT) 
respectively, while Marcellis et al. (2011) found scores of 96% for handgrip and 
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79.3% for QPT against an age and gender matched control. Participants mean score 
from two visits was 62.85 N·m for QPT and 48.35 N·m for HPT, in comparison to this 
study’s findings of 65.81 N·m for QPT and 31.10 for HPT. The difference in HPT 
observed may partly explain the reduced 6MWD (mean = 582m) of participants in this 
study against Marcellis et al. (2011) sarcoidosis participants (618m). Strookappe et al. 
(2015) used Marthiowetz et al. (1986) handgrip scores to calculate percentage of HGS 
within their study, based on this method this current study’s results show participants 
scored 93.77% in comparison to Strookappe et al. (2015) findings of 89.6% pre-
intervention, it is worth noting however that HGS normative scores were based on 19 
years of age participants and therefore may not accurately represent the clinical 
population’s true predicted HGS, nonetheless these findings once again highlight the 
differences across sarcoidosis patients and as such reinforce the complexity of the 
issue. Marcellis et al. (2011) also reported percent of population with muscle strength 
reductions recording HGS (15%), EFMS (12%), QPT (27%) and HPT (18%). This 
highlights the prominence of reduced muscle strength across the population although 
it is too simplistic to state sarcoidosis as the only cause for the reported reductions, 
due to this we need greater research to understand the role of the disease with regards 
to muscle strength. Physical inactivity (disuse) is one confounding factor for muscle 
strength with both sarcoidosis and non-disease aspects, while others factor non-
specific to the disease include age and gender. This is a very important area within 
sarcoidosis as muscle weakness is associated with increased all-cause mortality in all 
populations, specifically the elderly (Rantanen, 2003; Clark & Manini, 2010). Ruiz et 
al. (2008) found the association between muscle strength and all-cause mortality 
continues following adjustment for cardiorespiratory fitness. Therefore, one future 
direction is for major muscle groups across the body to be looked at in both isolation 
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and together to further understand the reasons behind the increased mortality rates. 
Swallow et al. (2006) found quadricep strength in COPD predicts mortality, whilst 
Bohannon (2008) argues hand-grip strength measured via a dynamometer should be 
considered a vital measure, Norman et al. (2011) states hand grip strength can predict 
short and long-term mortality, thus further research is required to gain a greater 
understanding of the role and effect of muscle strength within sarcoidosis. 
Additionally, further research is needed between exercise performance and the effects 
of delimitating factors on exercise capacity and whether it is relevant to adjust the 
results of these tests such as V̇O2max. Strookappe et al. (2016) found lower limb 
strength correlated closer to 6MWD than upper limb, likely due to the physiological 
demands of walking as the findings are as expected within sarcoidosis and healthy 
populations too. Strookappe et al. (2016) muscle strength test of chair rise time (CRT) 
measuring quadricep strength was less correlated (.48) than the current study’s QPT 
(.843, P = 0.009). The discrepancy may arise from the differences of testing, isokinetic 
QPT isolates the quadriceps strength while CRT relies upon a number of other muscles 
such as glutes and hamstrings. And thus, weaknesses elsewhere or issues with balance 
may affect the outcome, leading to an untrue representation of muscle strength. 
Currently it is not clear in sarcoidosis patients the degree to which muscle weakness, 
cardiocirculatory and ventilatory issues affect exercise capacity. For example, the 
current body of knowledge does not identify whether improving muscle strength to 
normative levels improves patients VO2max or whether the ventilatory issues limit the 
capacity before muscle strength becomes a delimiting factor. Although, it is worth 
noting Delobbe et al. (2002) found reduced maximal exercise capacity within 
sarcoidosis patients without impaired pulmonary function. Despite these current short-
comings, there is a growing area of literature of exercise rehabilitation within 
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sarcoidosis including both cardiovascular activities as well as weight bearing exercises 
(Marcellis et al., 2015; Strookappe et al., 2015; Naz et al., 2018). At present only three 
studies have researched exercise rehabilitation as a treatment and management method 
to improve symptoms and QOL (Marcellis et al., 2015; Strookappe et al., 2015; Naz 
et al., 2018) although results thus far have been promising with statistically significant 
(P < 0.05) improvements recorded for muscle strength, exercise performance, fatigue 
scores and QOL. Each study had a different rehabilitation program however, of the 
three, Strookappe et al. (2015) had the largest improvement for 6MWD (70m) and 
FAS (decrease of 3.8). Strookappe et al. (2015) also recorded a significant (P < 0.05) 
improvement to EFMS of 7.8% predicted value, whereas Marcellis et al. (2015) 
reported only a non-significant improvement (P > 0.05) although Marcellis et al. 
(2015) did report a significant (P < 0.05) improvement of 10.7kg in weight lifting 
strength of the quadriceps. The difference of results is likely attributed to the 
difference in training methods, Marcellis et al.’s (2015) weight lifting exercises started 
at 40% maximum multiple repetition and increased progressively by 3%, while 
Strookappe et al. (2015) utilized patient feedback and aimed for an intensity of 13-15 
on the Borg scale, reassessing and adjusting after every session, Naz et al. (2018) also 
utilized patient feedback however they used the Borg modified dyspnea scale aiming 
for 4-6. Therefore, future research must focus on optimising exercise as a 
rehabilitation method, likely personalised to each undergoing patient due to the 
complexity of the condition.  
 
Handgrip strength is already utilised across different populations and conditions due 
to its correlations with mortality (Oksuzyan et al., 2017) and test-retest ability 
(Haward & Griffin, 2002). Following a multiple regression involving this study’s 
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variables, only EFMS was found to be a significant predictor of HGS (R2 = .913, 
F(1,4), P = .003). While HGS reported significant (P < 0.05) strong bivariate 
correlations with gender (.809, P = 0.015), FEV1 (.885, P = 0.003), FVC (.865, P = 
0.006), PEF (.921, P = 0.001) and body fat percentage (.794, P = 0.019)  The findings 
warrant further investigation into the predictor values of HGS within pulmonary 
sarcoidosis, Jeong et al. (2017) found COPD patients QOL was associated with their 
HGS although this study’s data reported a weak bivariate correlation of .193 (P > 0.05) 
for HGS and SHQ. Holmes et al. (2017) found elder people (>70 years of age) with a 
strong HGS were associated with a better PEF, while the current study’s findings 
found a strong positive bivariate correlation between HGS and PEF (.921, P = 0.001) 
although following a multiple regression PEF was not found to be a predictor of HGS. 
QPT and HPT were the only predictors of each other (R2 = .873, F(1,4), P = 0.006). 
While HGS and EFMS were the only predictors of each other too (R2 = .913, F(1,4), 
P = .003), the reasons for this are not known but may be likely due to being utilised 
within the same activation phases/tasks. The findings suggest muscle strength is 
relatively stable across the body for sarcoidosis patients and that the condition does 
not prevalently isolate one specific muscle group. 
7.6. Conclusions and Future Directions 
Accelerometer MVPA was found to be predicted by calories burned per day and BMI, 
there was a large difference (43 minutes) between accelerometer and IPAQ MVPA. 
Only met minutes per week was a predictor for IPAQ MVPA. Participants scored 
below their predicted for muscle strength tests, HGS (93.77%), QPT (97.64%) and 
HPT (74.22%). Overall, the complexities and diverse nature of sarcoidosis was 
highlighted across the wide-ranging variables and there remains numerous questions 
to be answered. An increase in sample size is required, future focus on 6MWD and 
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HGS may be appropriate due to their bivariate correlations, potentially allowing the 
greater management and treatment of the disease. Exercise rehabilitation involving 
both cardiovascular and strengthening exercises shows promise within Sarcoidosis 
and further research must be conducted to understand not only the optimal exercise 
programme but also the long-term effects of rehabilitation and adherence once home-
based. COPD and other ILD’s rehabilitation research may work as a base for the 
expansion of this area. Physical activity patterns remain uncertain but represent an 
area which requires greater focus due to the known issues with inactivity. One future 
direction would be a larger sample sized study to allow for the distinguishing of 
separate and distinctive physical activity groups (low/moderate/high) and how their 
other variables (muscle strength, fatigue, lung function etc.) match up as well as 
greater information gathering on the forms of physical activity performed. 
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8. GENERAL DISCUSSION 
 
8.1. Physical Activity 
Physical activity was investigated at across chapters four, five, six and seven Methods 
for understanding physical activity ranged from a simple non-validated multiple 
choice closed-ended question focusing on how often they thought they were 
throughout a typical week, the international physical activity questionnaire and a tri-
axial accelerometer. Interestingly, when asked through the multiple choice (chapter 
five) the majority of participants (65.52) reported no physical activity or less than two 
bouts per week of physical activity however when questioned on physical activity 
through the IPAQ within chapter six, only 16.98% fell within the low category. 
Although exact numbers are unknown it is likely many participants completed both 
chapter five and six dues to the same recruitment methods being employed. The 
reason(s) for this stark change remain unclear but may be attributed to firstly a 
misunderstanding of the question within chapter five such as an oversight of what 
physical activity is and/or an overestimation of activity levels within the IPAQ when 
asked separately. Allender et al. (2006) states activities such as gardening and 
housework are not traditionally thought of as physical activity and as such participants 
may have ignored these activities when answering chapter five’s question. Listing 
common traditional and non-traditional forms of physical activity may help combat 
any potential issue. On the other hand, physical activity levels within sarcoidosis has 
been shown to be diverse and the change in participants involved may explain the 
difference (Korenromp et al., 2011; Saligan, 2014, Morton-Holtham et al., ndB). For 
example, within chapter six participants reported 360 minutes of sitting per day 
compared to 448 minutes per day within chapter seven despite exceeding current 
physical activity guidelines derived from a tri-axial accelerometer (MVPA = 109mins 
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per day), the IPAQ derived MVPA was not found to be a predictor of accelerometer 
MVPA although a strong bivariate correlation was found (.875, P = 0.022) despite a 
large difference (43 minutes overreported per day via IPAQ) between the two 
instrument findings, which raises questions of accuracy and validity further coupled 
by the two outliers that reported a possible 23 hour day made up of walking plus 
moderate and vigorous activity excluding sleep and sedentary time. With regards to 
chapter six it is worth noting chapter six did not use an accelerometer and thus 
participants may have had higher real world MVPA than chapter seven participants. 
Additionally, reduced sitting time may relate to light physical activities and as such 
not be represented by MVPA. The current projects findings of above guideline MVPA 
was opposite to previous accelerometer research within sarcoidosis (Korenromp et al., 
2011; Saligan, 2014) and thus highlights the diverse patterns across the population 
although the lack of consistency with weekend testing within the current study 
(Morton-Holtham et al., ndA) may help explain part of the difference as Korenromp 
et al. (2011) found a drop in physical activity at weekends, additionally Korenromp et 
al. (2011) study focussed on those with sarcoidosis in clinical remission. As physical 
activity patterns are diverse, an area that requires further focus is activity change 
following diagnosis/onset of symptoms. Chapter five reported 73.79% of participants 
decreased physical activity following diagnosis with a further 41.55% of the study’s 
participants changing or stopping work due to issues related to the condition. These 
findings are novel and of interest as currently change from no sarcoidosis to onset of 
the condition has not been looked at. The findings imply sarcoidosis has a major direct 
effect on the daily functioning of patients and future research should look at 
minimising these detrimental effects as well as how employers can best support their 
employee’s. 
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8.2. Muscle Strength 
Due to the online approach of chapter five and six, only chapter seven directly 
measured muscle strength (QPT, HPT, EFMS and HGS) while chapter four findings 
into muscle strength were used as baseline measures for the condition. In line with 
previous research participants reported lower than predicted levels of strength, HGS 
(93.77%), QPT (97.64%) and HPT (74.22%). The reasons for the reduced score 
remain unclear although the deconditioning process has previously been stated 
(Mitchell et al., 2012; Fleischer et al., 2014). Based on chapter seven’s findings it is 
likely other factors also play an important role as participants met and exceeded 
current physical activity guidelines (table 21), a potential important factor regarding 
the guidelines could be type of activity carried out. For example, the physiological 
effects of brisk walking/running vary from the effects of weight training. Therefore, 
the type of activity being conducting during MVPA may be vital in maintain muscle 
strength and limiting deconditioning. Hand grip strength was found to have strong 
bivariate correlations with numerous variables such as lung function (FEV1, FVC, 
PEF), gender, body fat percentage, muscle strength (EFMS, QPT, HPT) and 6MWD 
however only EFMS was found to be a predictor. HGS is a useful indicator of 
functional ability in numerous populations (Burtin et al., 2015; Leong et al., 2016) and 
thus needs further research within sarcoidosis. 
8.3. Quality of life and Fatigue 
Quality of life and fatigue were key variables throughout the project. Fatigue was the 
most selected symptom within chapter five (92.62%) however a limitation was the 
lack of measuring the severity such as via the FAS and therefore it remains unknown 
the level of fatigue per participant, as some may have been found to be non-fatigued 
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against the FAS’s validated scale (Michielsen et al., 2003; De Vries et al., 2004). 
However, chapter six and seven found 92.59% and 75% of participants were fatigued 
or extremely fatigued via the FAS. This thesis therefore highlights the significance of 
fatigue within sarcoidosis and the importance of improving and managing the 
symptoms of fatigue in this population. Exercise rehabilitation within sarcoidosis has 
been shown to improve fatigue scores (Marcellis et al., 2015; Strookappe et al., 2015; 
Naz et al., 2018) and therefore is an area that must be taken forward with further 
research. Quesada-Rodriguez et al. (2014) highlights lack of awareness as the reason 
for lower levels of pulmonary rehabilitation within ILD, Holland et al. (2013) states 
this non-pharmacological treatment needs to become more prominent among chest 
physicians to increase the referral rates and care of patients with ILD’s. An issue that 
could be improved with greater emphasis and evidence from future research into other 
ILD’s, this problem highlights the multifaceted nature of long-term care offered to 
those with chronic conditions such as pulmonary sarcoidosis. 
  
Quality of life was measured via the SHQ within chapter five and seven. Participants 
scored a mean 3.41 and 4.26 within chapter five and seven, respectively. Within both 
studies’ females scored worse 3.34 (chapter five) and 3.96 (seven) than compared to 
their male counterparts 3.58 (five) and 4.77 (seven) although there was no significant 
difference (P>0.05) for either study. Quality of life has been shown to be 
multifactorial, being affected by numerous factors including depression score (CES-
D), number of symptoms, 6MWD, HPT and exercise rehabilitation. Therefore, the 
reason behind the difference reported between chapter five and seven is likely to be 
made up of multiple factors too, although both accelerometer and IPAQ MVPA were 
found not to be predictors of quality of life, the types of activities undertaken during 
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MVPA such as weight lifting and aerobic activities; much like those conducted within 
exercise rehabilitation programs may explain the difference in quality of life in part. 
Another possible factor is the number of symptoms per participant, chapter five found 
a CES-D and number of symptoms were predictors of quality of life, chapter five 
participants reported a mean of over 3 (3.79) symptoms while chapter seven did not 
record number of symptoms and therefore the participants may have had less than their 
chapter five counterparts. Additionally, as previously mentioned chapter seven had a 
lower number of fatigued participants (75%) than those reporting the symptom within 
chapter five (92.62%). 
8.4. Patient Views 
The inclusion of open-ended qualitative questions within chapter five was a novel and 
extremely important aspect of the project and sarcoidosis research overall. Participants 
revealed often feeling overlooked and ignored by the very people that treated them 
highlighted by the quote “Consultants, I never get to see the same one and I always 
feel that they are winging it”. The key themes highlighted via the content analysis were 
sarcoidosis causing the ‘limiting of activities’ (“The slightest effort results in 
struggling to breathe”), the ‘benefits of exercise, physical activity and diet’ (“light 
exercise seems to help improve some of my pain”), the ‘detrimental effect of poor 
lifestyle choices’ (“smoking and I don’t know how to quit”), ‘lack of understanding 
by friends, family and employers’ (“family’s lack of understanding can be awful as 
are doctors”), ‘the role of medicine’ (“the higher dose of steroids but would rather not 
take them cause of the side effects”), ‘importance of sleep’ (“feel that if I could sleep 
properly I would feel better able to cope”) and ‘anxiety and stress’ (“stress has major 
impact on my Sarcoid symptoms”). This feedback can be beneficial in formulating 
new areas of research such as the role of mindfulness-based training (Merkes, 2010) 
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and also justify current and future research areas by providing real-life views on a 
situation, such as the effect of fatigue on their daily life. For example, fatigue is a self-
reported measure and has not be linked to clear physiological mechanisms within 
sarcoidosis yet chapter seven found fatigue strongly correlated to the SHQ (.812, P = 
0.014) but not 6MWD (.385, P>0.05). Therefore, the role of fatigue requires further 
investigation. 
 
8.5. Limitations and Strengths 
 
Although the current thesis has identified important findings, there are several 
limitations that cannot be dismissed. One limitation to the current work is the vast 
nature of sarcoidosis and its ability to affect almost any part of the body (Saidha et al., 
2012). This may make comparisons between participants difficult as their conditions 
can vary (NHS, 2015a) and currently the effects of different forms of sarcoidosis 
(pulmonary, skin, organ) has not been isolated. Additionally, severity of the disease 
can vary despite sharing the same radiographic stage exemplified by the lack of 
correlation between stages and lung function (Criado et al., 2010). Another limitation 
is due to the low incidence rate of sarcoidosis (1 in 10,000; NHS, 2015a) where 
participants are sparsely spread throughout the country therefore increasing the 
difficulty of recruitment, exemplified through the small sample size of chapter seven 
(n=8). In addition to this, many aspects of chapters five, six and seven comprise of 
self-reported measures including SHQ, IPAQ, CES-D, FAS, MRC etc. therefore 
participants may intentionally and unintentionally alter their answers causing a under 
or over statement of their symptoms/physical activity levels etc (Swann et al., 2005; 
Sylvia et al., 2014). With regards to the physical tests, prior practice and 
familiarisation was also a concern as it can lead into an increase in performance and 
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alter the results (Casanova et al., 2011) although Dias et al. (2005) argues 
familiarisation allows for more accurate results. Outside of the population size and 
tests utilised across the project, a lack of depth in some key areas has limited the 
analysis and understanding of results. On reflection, one key example would be the 
lack of the actual age of participants on diagnosis and participants own estimates on 
when they noticed the onset of symptoms. This would have been useful as the data 
could have been checked against previously suggested age groups for onset of the 
condition, as well as a better understanding the progression of the disease over-time. 
While wrongly diagnosed participants is also a concern, up to 40% of chronic 
beryllium disease cases has been misdiagnosed as sarcoidosis (Muller-Quernheim et 
al., 2006). In addition to the limitations of the three experimental studies there were 
also delimitations, these included the extensive use of closed-ended Likert scale 
questionnaires although likert scales have been shown to be valid indicators of levels 
of agreement and are quantifiable (Joshi et al., 2015), the use of a limited amount of 
possible options limits the participants to ticking the most appreciate box as opposed 
to expressing how they truly feel (Hartley, 2014), however open-ended qualitative 
questions were included in chapter five to combat this delimitation (Kelley et al., 
2003). Another delimitation was the self-reported home-based approach to chapter 
five and six, as participants could have altered their responses from the reality of their 
lives although the home-based approach also has benefits such as no time pressure or 
constraints on participants, allowing for greater detail with regards to the qualitative 
questions and honesty throughout due to the confidential nature of completing at home 
on their personal computer and reduced social desirability factors. Despite the 
limitations and delimitation above, there was also numerous strengths and new 
insights gained by conducting this thesis. One key strength was being the first known 
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research allowing patient feedback on highly regarded patient areas of care such as 
barriers faced and what improves/worsens the condition. Patients reported feeling 
isolated and overlooked by doctors and other medical professionals despite a lack of 
faith in their ability to treat the condition. The inclusion of their thoughts and ideas 
can help improve both short-term and long-term care and quality of life of patients 
through making adjustments such as further training for relevant doctors or improved 
integration between the services as well as allowing for better planning for future 
research via evidence-led co-creation as a pathway to impact. Greenhalgh et al. (2016) 
states co-creation is a growing trend and it has the potential to reduce beneficial 
research not being implemented or utilised within the real world. For example, 
lifestyle choices and the management of stress and anxiety were important themes 
emphasised by patients and thus highlights the potential of future research into these 
areas. Another strength was the inclusion of physical activity patterns within the 
condition, as there is currently little known but is a developing area of interest. For 
example, chapter seven helped to show the reliability and validity of the IPAQ in 
relation to pulmonary sarcoidosis against the gold standard of a tri-axial accelerometer 
as well as the correlation of real-world physical activity against key variables such as 
quality of life, fatigue and muscle strength. 
 
8.6. Future Directions 
Due to the vast and varied nature of the condition coupled with a shortage of research, 
there remains numerous avenues for future research. This project was always designed 
to establish trends and gain baseline information on a range of key aspects of 
sarcoidosis and due to this would not provide definitive answers but aid future research 
into key areas such as the improvement to quality of life and functional ability. 
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Therefore, three future areas for research would be to expand on the three experimental 
studies conducted within this project with regards to sample size and depth, as per the 
mentioned limitations (e.g. age at onset of sarcoidosis). An increase in sample size 
would aid in the establishment of trends and patterns (e.g. physical activity/sedentary 
behaviour) within sarcoidosis (Hajian-Tilaki, 2011), similar research in asthma 
utilised 5000 participants (Subbarao et al., 2010) while another utilised the 
combination of 27 different datasets obtained via national health surveys and routine 
health and social care datasets. This highlights the differing approaches to sample size 
and methods for gathering data within epidemiological research. In addition, findings 
from this project have also highlighted new/under-researched areas for improving the 
treatment and management of sarcoidosis. One future direction based on the findings 
of chapter four would be to further establish the benefits of an exercise rehabilitation 
program including its effect on long-term measures as this has not currently been 
looked at. As well as the effectiveness and ease of implementation of a home-based 
method, as at present all research into exercise rehabilitation has been conducted 
under-supervision and thus could limit the benefit to a proportion of the population if 
only recommended as a class/event which required attendance (Dalal et al., 2010). 
Another interesting future direction would be the effect of mindfulness-based training 
in sarcoidosis in relation to stress, anxiety and quality of life etc. Quality of life is 
known to be reduced within those with sarcoidosis (Hinz et al., 2012; Heer et al., 2013; 
Drent et al., 2014). While mindfulness-based training has been shown to be a relatively 
fast method (eight-week program) of providing a clinically significant improvement 
to quality of life within asthma even at a 12 month follow up (Pbert et al., 2012). Other 
chronic conditions including chronic fatigue syndrome, rheumatoid arthritis and type 
2 diabetes have shown benefits from the training (Merkes, 2010) and was noted as 
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beneficial for a participant via the content analysis of chapter five ‘s open-ended 
qualitative questions. Based on the findings of chapter seven, future research is 
required to understand physical activity patterns within sarcoidosis and any sub-sets 
of the population, this should be extended beyond simple sedentary, light, moderate 
and vigorous activity times and include the types of activity conducted such as strength 
training, running, vacuuming etc. and the effect of type of activity against key 
variables including quality of life, fatigue, muscle strength, depression, exercise 
performance etc. This is of importance as greater understanding of the effects of 
different types of exercise and/or physical activity would aid in the development and 
establishment of guidelines specific to sarcoidosis and therefore lead to improvements 
of patient care. An alternative area with limited but promising research within 
sarcoidosis and other ILD’s is inspiratory muscle training (IMT). IMT is a method of 
breathing exercises for pulmonary rehabilitation (Hill, 2006; Shaji et al., 2013), it has 
been shown to have several beneficial outcomes (Karadalli et al., 2016) in a range of 
conditions including asthma (Silva et al., 2013), COPD (Gosselink et al., 2011) and 
cystic fibrosis (Houston et al., 2013) as well as sarcoidosis (Karadalli et al., 2016). 
These benefits include decreases in dyspnoea as well as increasing exercise capacity 
in COPD and sarcoidosis (Gosselink et al., 2011; Karadalli et al., 2016), while another 
key benefit shown within healthy populations is the improvement of rate of perceived 
recovery (McConnel, 2011). When considering exercise as a treatment for sarcoidosis, 
improving perceived recovery could potentially increase the benefits of the treatment 
through not only greater effort on the part of the participant but lower dropout rates as 
the perceived difficulty of training would decrease too, however this would need to be 
researched further. 
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 Although techniques for IMT do differ, threshold loading is the most commonly used 
and involves breathing through a spring-loaded device, with individualised intensity 
(Gloeckl et al., 2013).  Based on current literature threshold loading for 15-20 minutes 
daily is recommended (Langer et al., 2009), Enright and Unnaithan (2011) state 
training at 80% of maximum inspiratory pressure led to increases in lung volume, wok 
capacity and perceived exertion in healthy population, with high intensity workloads 
being labelled as optimal for maximizing effectiveness (Brilla, 2012). 
8.7. Impact and application  
The impact of this project was to influence the development of specific 
recommendations for exercise and physical activity aimed to improve clinical care 
pathways for pulmonary sarcoidosis as an adjunct to pharmacological treatment. The 
findings will help characterise patients with pulmonary sarcoidosis to help establish 
modifiable lifestyle habits with tailored exercise, physical activity. This project will 
aid in the development of current guidelines to inform future service planning, 
treatment provision and support for patients with the condition. 
8.8. Conclusions 
The novel and key findings from the current thesis are firstly, exercise rehabilitation 
appears to improve the effects of deconditioning and symptoms within sarcoidosis. 
Quality of life has been shown to be affected by the number of symptoms reported and 
depression score as well as discontent with quality of care on the patient’s behalf due 
to a perceived lack of knowledge by doctors (both GP and specialists) and a lack of 
integration between the different services. Sarcoidosis physical activity patterns being 
diverse across the population much like the condition itself. Although muscle strength 
does appear to be reduced across the population based on this project and previous 
research findings. Handgrip strength had numerous moderate and strong bivariate 
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correlations but only elbow flexor muscle strength was found to be a predictor, further 
research is required into the possibility of handgrip strength being a useful indicator 
for a range of key. The content analysis shows an appetite for information regarding 
beneficial lifestyle changes relevant to the condition such as diet, smoking cessation 
and exercise programs. Overall it can be stated that physical activity is diverse and not 
always reduced within the population, fatigue is a major issue and the effect 
sarcoidosis has on work needs further investigation. 
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10.1. Appendix 1) Physical Activity Questionnaire (PAR-Q) 
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10.2. Appendix 2) Chapter five Survey 
Study 1: Establishing the existence of 
multifactorial patterns within 
Sarcoidosis. 
 
 
Start of Block: Information and informed consent 
 
Q1.1 Information Sheet: Establishing the existence of non-pharmacological 
multifactorial patterns within Pulmonary Sarcoidosis.   Ethics Code: 1617/028  
Thank you for considering being a participant in this project.  Below you will find a 
short background to our work, and an outline of what you will be required to do as a 
participant in this study.  The aim of this study is to establish the existence of any 
patterns or traits within pulmonary sarcoidosis specifically looking at the interaction 
of multiple factors and their combined outcome.  Unfortunately Sarcoidosis has a 
chronic shortage of research. This lack of research is coupled with current researchers’ 
focus solely on results of tests such as lung function, at the expense of patient feedback 
on the condition, despite lung function being shown to be a poor indicator of overall 
health including primary and secondary symptoms within sarcoidosis. Therefore, 
the purpose for the current study and its future findings are driven by informed patient 
experience from a wide range of patients from numerous geographical locations and 
backgrounds.   
 Am I eligible to take part in the study?   You are eligible to take part in the study 
if you have been diagnosed with pulmonary sarcoidosis (this can be in addition to 
other forms of sarcoidosis and conditions) and over the age of 18 years.   
What is expected of me?  The study will involve you completing an electronic 
questionnaire comprised of four validated surveys, with closed ended questions such 
as gender & age as well as open questions including your experiences and views on 
what improves/worsens your symptoms.  The procedure involves completing an 
online survey that will take approximately 30 minutes. Your responses will be 
confidential and we do not collect identifying information such as your name, email 
address or IP address.   
What are the benefits of taking part?  The benefits of this study will be to investigate 
the possible existence of non-pharmacological multifactorial patterns within 
Pulmonary sarcoidosis. The study will not only add knowledge to the current body of 
research but also help identify future areas of relevant research that may have been 
overlooked before or lacked scientific support.  
 What are the risks of taking part?  No identified risks other than those of typical 
computer use and minor emotional distress.  Some questions might cause minor 
emotional distress, although this risk is very low, as most of the questions are general 
(e.g. type of sarcoidosis) and not personalised. In cases where participants find some 
of the questions upsetting, they will have the option to skip them or exit the 
questionnaire at any time. Risks associated with using display screen equipment e.g. 
PC, Laptops, include upper limb disorders, back ache, fatigue, stress and temporary 
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eye strain or headaches. Ensure you are positioned correctly and the questionnaire will 
only take a maximum of 30 minutes to complete. However, take short pauses and 
breaks if necessary.  
 What if I have a question or a query?   We are happy to answer any queries that 
you may have regarding the study. In the event of having any health concerns, we will 
advise you to contact your GP for further screening and advice.   
What if I decide to withdraw?  Participants are permitted to withdraw from the study 
at any time and data from them will not be used.   
What about my Confidentiality?  Any information given to us by you will remain 
confidential and all data will be kept anonymous. All data will be coded and saved as 
encrypted password protected files on a PC. Results of testing and analysis along with 
age, gender will be recorded. Participants will remain anonymous throughout the 
research, including the publication of the research which may result in availability of 
the research at the University Learning Resources Centre, through scientific journals 
and conference presentation. Any hard copy versions will be kept in locked 
offices/cabinets of lead applicant.  The only personnel authorised to access the data 
will be the researcher, principal investigator and the project participants (their 
individual data only).   
 If you have any questions or problems, please do not hesitate to contact the 
researchers or project supervisor:  Name of Researcher: Luke Morton-Holtham  
Email: K1214556@kingston.ac.uk       Name of Supervisor: Dr Hannah Moir  Email: 
H.Moir@kingston.ac.uk  Tel: 020 8417 2876                
 Thank you for your time & contribution to this study.      
ELECTRONIC INFORMED CONSENT:  
    By clicking agree, you are agreeing to participate in this study, acknowledging that 
you understand that you can withdraw at any time, and understand that all the data 
collected will be confidential and stored securely in line with the Data Protection Act 
(2003).   
 It is important to mention that you will not need to provide your name, as this study 
is anonymous. However, you will need to provide basic demographic background 
information which will remain confidential. There are no risks of taking part in the 
study, but if you have any concerns whilst answering the questions, withdrawal from 
the study is permitted at any time, and the data collected up to that point will not be 
used. Please contact the researchers if you have any queries.   
 Statement by Participant  By clicking on the "agree" button below indicates that 
you consent to the following statements:    I confirm that I have read and 
understood the information sheet/letter of invitation for this study. I have been 
informed of the purpose, risks, and benefits of taking part.  "Establishing the 
existence of non--pharmacological multi-factorial patterns within Pulmonary 
sarcoidosis."   I understand what my involvement will entail and any questions have 
been answered to my satisfaction.   I understand that my participation is entirely 
voluntary, and that I can withdraw at any time without prejudice. I understand that all 
information obtained will be confidential. I agree that research data gathered for the 
study may be published provided that I cannot be identified as a subject. Contact 
information has been provided should I (a) wish to seek further information from the 
investigator at any time for purposes of clarification (b) wish to make a complaint.   
Statement by investigator     I have explained this project and the implications of 
participation in it to this participant without bias and I believe that the consent is 
informed and that he/she understands the implications of participation.   Name of 
investigator: Luke Morton-Holtham 
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 By clicking on the "agree" button below indicates that you consent to the following 
statements:    I confirm that I have read and understood the information sheet/letter 
of invitation for this study. I have been informed of the purpose, risks, and benefits of 
taking part.  "Establishing the existence of non--pharmacological multi-
factorial patterns within Pulmonary sarcoidosis."     I understand what my 
involvement will entail and any questions have been answered to my satisfaction.    I 
understand that my participation is entirely voluntary, and that I can withdraw at any 
time without prejudice.  I understand that all information obtained will be 
confidential.  I agree that research data gathered for the study may be published 
provided that I cannot be identified as a subject.  Contact information has been 
provided should I (a) wish to seek further information from the investigator at any 
time for purposes of clarification (b) wish to make a complaint.    
 Statement by investigator     I have explained this project and the implications of 
participation in it to this participant without bias and I believe that the consent is 
informed and that he/she understands the implications of participation.     
 Name of investigator: Luke Morton-Holtham 
  
 Signature of investigator:      23/06/17 
  
 Luke Morton Holtham 
   Signature of investigator:                         23/06/17     
 
 If you do not wish to participate in the research study, please decline participation by 
clicking on the "disagree" button      
o Agree  (1)  
o Disagree  (2)  
 
Skip To: End of Survey If Information Sheet: Establishing the existence of non-pharmacological 
multifactorial patterns with... = Disagree 
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End of Block: Information and informed consent 
 
Start of Block: Study one - Part one 
 
Q2.1 Please indicate your age range (years): 
o 20 or Under  (1)  
o 21-30  (2)  
o 31-40  (3)  
o 41-50  (4)  
o 51-60  (5)  
o 61+  (6)  
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Q2.2 Please indicate your ethnicity: 
o White (English / Welsh / Scottish / Northern Irish / British/Irish/Gypsy 
Traveller  (1)  
o Black Caribbean  (2)  
o Black African  (3)  
o Black British  (4)  
o Mixed White & Black-Caribbean  (5)  
o Mixed White & Black African  (6)  
o Mixed White & Asian  (7)  
o Asian/Asian British  (8)  
o Indian  (9)  
o Pakistani  (10)  
o Bangladeshi  (11)  
o Japanese  (12)  
o Chinese  (13)  
o Arab  (14)  
o Other (please describe):  (15) 
________________________________________________ 
 
 
 
Q2.3 Please select your gender: 
o Male  (1)  
o Female  (2)  
o Other (please specify):  (3) 
________________________________________________ 
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Q2.4 Please select your nationality / citizenship: 
o United Kingdom  (1)  
o Poland  (2)  
o India  (3)  
o Pakistan  (4)  
o Republic of Ireland  (5)  
o Germany  (6)  
o France  (7)  
o Romania  (8)  
o Portugal  (9)  
o United States of America  (10)  
o Spain  (11)  
o Other (please specify):  (12) 
________________________________________________ 
 
 
 
Q2.5 Thinking about your sarcoidosis, please select how you were first diagnosed: 
o GP  (1)  
o Consultant  (2)  
o Specialist  (3)  
o Other (please specify):  (4) 
________________________________________________ 
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Q2.6 Please select how long you have been diagnosed with sarcoidosis: 
o Less than two years  (1)  
o 3-5 years  (2)  
o 5 years or more  (3)  
 
 
 
Q2.7 Considering your condition, select the type(s) of sarcoidosis you have.  
Please select all that apply. 
▢ Pulmonary  (1)  
▢ Skin  (2)  
▢ Heart  (3)  
▢ Eye  (4)  
▢ Endocrine system  (5)  
▢ Nervous system  (6)  
▢ Bone/Joint  (7)  
▢ Lymph nodes  (8)  
▢ Organ (spleen/liver/kidney)  (9)  
▢ Other (please specify):  (10) 
________________________________________________ 
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Q2.8 Considering your condition, on average, what are the main symptoms you 
experience.   Please select all that apply. 
▢ Fatigue  (1)  
▢ Persistent Cough (dry cough)  (2)  
▢ Shortness of breath (trouble breathing, wheezing, or pain)  (3)  
▢ Painful Joints or bones  (4)  
▢ Rashes / red bumps on the skin  (5)  
▢ Sore eyes  (6)  
▢ Other (please specify):  (7) 
________________________________________________ 
 
 
 
Q2.9 Please select your current medication. 
▢ Prednisolone  (1)  
▢ Methotrexate  (2)  
▢ Leflunomide  (3)  
▢ Hydroxchloroquine  (4)  
▢ Other (please specify):  (5) 
________________________________________________ 
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Q2.10  
Thank you for your responses.   
    
The next section will feature lifestyle factors associated with sarcoidosis, specifically 
smoking status, physical activity and diet. Please click next to continue.   
    
If you do not wish to complete this section please select skip. 
o Skip  (1)  
 
Skip To: End of Block If Thank you for your responses.   The next section will feature lifestyle factors 
associated with S... = Skip 
 
Page Break  
  
192 
 
 
Q2.11 Please select your current smoking status: 
o Smoker  (1)  
o Ex-smoker  (2)  
o Non-smoker  (3)  
 
Skip To: Q2.13 If Please select your current smoking status: = Non-smoker 
 
 
Q2.12 Please select the appropriate range for amount of cigarettes smoked per day: 
o 1-4  (1)  
o 5-9  (2)  
o 10-14  (3)  
o 15-19  (4)  
o 20-24  (5)  
o 25+  (6)  
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Q2.13  
Thank you for your responses. The following section relates to physical activity and 
diet.   
    
Please click next to continue. 
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Q2.14 What are your current physical activity levels? 
o Inactive  (1)  
o Less than twice a week  (2)  
o 3-5 times a week  (3)  
o 5+ times a week  (4)  
 
 
 
Q2.15  Considering your physical activity levels since being diagnosed with 
sarcoidosis, please select the most relevant option: 
o Increased physical activity levels  (1)  
o Decreased physical activity levels  (2)  
o Stayed the same  (3)  
 
 
 
Q2.16 Has physical activity been mentioned to you as an option for improving your 
symptoms by a physician / GP ? 
o Yes  (1)  
o No  (2)  
 
 
 
Q2.17 Has a change in diet been mentioned to you for improving your symptoms by 
a physician / GP? 
o Yes  (1)  
o No  (2)  
 
 
Page Break  
  
195 
 
End of Block: Study one - Part one 
 
Start of Block: Quality of life (Sarcoidosis Health Questionnaire) 
 
Q3.1  
The following questions relate to the sarcoidosis Health Questionnaire (Cox, 2003)   
    
This questionnaire is designed to allow people with sarcoidosis to describe how 
sarcoidosis affects their daily lives. Please read each question carefully and select the 
option that best represents how you feel. Answer each and every item, thinking back 
about how you have felt over the past 2 weeks. All questions within this section must 
be answered. Please do not skip any questions! There are 29 questions in total. Thanks 
for your time.    
    
If you do not wish to complete this section please select skip. 
o Skip  (1)  
 
Skip To: End of Block If The following questions relate to the Sarcoidosis Health Questionnaire (Cox, 
2003)   This questio... = Skip 
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Q98  
Answer each and every item, thinking back about how you have felt over the past 2 
weeks. 
 
 
During the past two weeks: 
 
 
 
Q3.2  
Been bothered by headaches? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time`  (7)  
 
 
 
Q3.3 Felt that you needed medications to function day to day? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.4 Felt that you were full of energy? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.5 Experienced mood swings? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.6 Been bothered by skin or hair problems related to sarcoidosis? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.7 Felt your breathing was completely comfortable during your normal daily 
activities? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.8 Worried about the amount of pain or discomfort you might have experienced?    
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.9 Felt that everything you did took a lot of effort or made you tire easily?   
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.10 Felt satisfied with the support you get from your family and friends?    
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.11 Had joint pains?    
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.12 Felt shortness of breath walking up stairs, the length of a city block, or up a 
small hill?   
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.13 Felt that you expect your health to be good in the future? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.14 Had a cough? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.15 Felt that your physical problems interfered in your social activities with family 
and friends? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.16 Felt that you accomplished all that you wanted? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.17 Been discouraged by recent weight gain? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.18 Felt bodily pain? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.19 Felt that you could concentrate easily? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.20 Felt that your emotional problems affected your relationships with family, 
friends, or co-workers? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.21 Felt that sarcoidosis controls your life? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.22 Had a good night’s sleep? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.23 Felt depressed? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
207 
 
Q3.24 Been bothered by problems with your eyes or eyesight? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.25 Felt satisfied with the appearance of your body? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.26 Experienced wheezing? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.27 Worried that your sarcoidosis might flare up or get worse? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.28 Felt confidence in yourself and your abilities? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
 
 
 
Q3.29 Felt that you were as healthy as others your age? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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Q3.30 Been discouraged by physical limitations in performing your normal daily 
activities or your job? 
o All of the time  (1)  
o Most of the time  (2)  
o A good bit of the time  (3)  
o Some of the time  (4)  
o A little bit of the time  (5)  
o Very little of the time  (6)  
o None of the time  (7)  
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End of Block: Quality of life (Sarcoidosis Health Questionnaire) 
 
Start of Block: Depression - CES-D 
 
Q4.1  
Thank you for your responses so far.   
The next section relates to the Center for Epidemiologic Studies Depression Scale 
(CES-D) (Radloff, 1977).  All questions within this section must be answered. There 
are 20 questions to complete.   
    
If you do not wish to complete this section please select skip. 
o Skip  (1)  
 
Skip To: End of Block If Thank you for your responses so far. The next section relates to the Center 
for Epidemiologic Stu... = Skip 
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Q101 Please read each question carefully, then circle one of the numbers to the right 
to indicate how you have felt or behaved during the past week, including today. 
 
 
 
Q4.2 I was bothered by things that don't normally bother me. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.3 I did not feel like eating; my appetite was poor. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.4 I felt that I could not shake off the blues even with help from my family or 
friends. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
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Q4.5 I felt that I was just as good as other people. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.6 I had trouble keeping my mind on what I was doing. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.7 I felt depressed. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.8 I felt everything I did was an effort. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
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Q4.9 I felt hopeful about the future. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.10 I thought my life has been a failure. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.11 I felt fearful. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
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Q4.12 My sleep was restless. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.13 I was happy. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.14 I talked less than usual. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.15 I felt lonely. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
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Q4.16 People were unfriendly. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.17 I enjoyed life. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.18 I had crying spells. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
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Q4.19 I felt sad. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.20 I felt people dislike me. 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
 
 
 
Q4.21 I could not get "going". 
o Most or all of the time (5-7 days)  (1)  
o Occassionally or a moderate amount of time (3-4 days)  (2)  
o Some or a little of the time (1-2 days)  (3)  
o Rarely or none (Less than 1 day)  (4)  
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End of Block: Depression - CES-D 
 
Start of Block: Study One - Part Two 
 
Q5.1  
Thank you for your responses.   
The next section relates to environment and employment.   
    
Please click next to continue. If you do not wish to complete this section please select 
skip. 
o Skip  (1)  
 
Skip To: End of Block If Thank you for your responses. The next section relates to environment and 
employment.   Please cl... = Skip 
 
Page Break  
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Q5.2 Please select the region you currently live in: 
o Wales  (1)  
o Scotland  (2)  
o Northern Ireland  (3)  
o North East England  (4)  
o North West England  (5)  
o Yorkshire & the Humber  (6)  
o East Midlands  (7)  
o West Midlands  (8)  
o East of England  (9)  
o South East England  (10)  
o South West England  (11)  
o London  (12)  
o Other (please specify):  (13) 
________________________________________________ 
 
 
 
Q99 How long have you resided in this region? 
o Less than 6 months  (1)  
o 6 months to 1 year  (2)  
o 1 to 3 years  (3)  
o 3 to 5 years  (4)  
o 5 to 10 years  (5)  
o Over 10 years  (6)  
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Q5.3 Does your property contain mold? 
o Sometimes  (1)  
o Never  (2)  
o Always  (3)  
 
 
 
Q5.4 What is your current employment status? 
o Employed full time  (1)  
o Employed part time  (2)  
o Unemployed looking for work  (3)  
o Unemployed not looking for work  (4)  
o Unemployed receiving disability living allowance or equvialent  (5)  
o Student  (6)  
o Retired  (7)  
 
Skip To: Q5.6 If What is your current employment status? != Employed full time 
Skip To: Q5.6 If What is your current employment status? != Employed part time 
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Q5.5 Please select your type of employment: 
o Manager, director, senior official (e.g. corporate, proprietors)  (1)  
o Professional (e.g. science, research, health, education, business, media)  (2)  
o Associate professional and technical (e.g. technicians, health and social care 
professional, culture, public service)  (3)  
o Administrative and secretarial  (4)  
o Skilled trades (e.g. agricultural, metal, electrical, construction, textiles)  (5)  
o Caring, leisure and other service (e.g. personal service, leisure & travel)  (6)  
o Sales and customer service  (7)  
o Process, plant and machine operatives (e.g. transport, machine operatives)  (8)  
o Elementary (e..g agricultural, administration, clearing, security, sales, storage, 
services)  (9)  
o Retired  (10)  
o Other (please specify):  (11) 
________________________________________________ 
 
 
 
Q5.6 Has your occupation changed since being diagnosed with sarcoidosis? 
o Stayed the same  (1)  
o Changed due to sarcoidosis  (2)  
o Changed non-related to sarcoidosis  (3)  
o Stopped working due to sarcoidosis  (4)  
 
 
Page Break  
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End of Block: Study One - Part Two 
 
Start of Block: Study one - Qualitative Questions 
 
Q6.1  
Thank you for your responses.This final section involves open ended qualitative 
questions.   
    
Please click next to continue. If you do not wish to complete this section please select 
skip. 
o Skip  (1)  
 
Skip To: End of Survey If Thank you for your responses.This final section involves open ended qualitative 
questions.   Plea... = Skip 
 
Page Break  
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Q6.2 How has sarcoidosis affected your life? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q6.3  
What barriers have you faced since being diagnosed with sarcoidosis? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q6.4  
What factors do you believe improves your sarcoidosis symptoms? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q6.5 What factors do you believe negatively affects your symptoms? 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
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________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q6.6 Please specify any ideas and/or area(s) in which you feel you could most benefit 
from additional support related to your condition. 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
________________________________________________________________ 
 
 
 
Q103 A follow-up interview and/or focus group may be conducted regarding the 
findings of study one and two. If you are willing to take part please leave your details.  
Thank you again for taking the time to participate in our project.  
o Name  (1) ________________________________________________ 
o E-mail  (2) ________________________________________________ 
 
 
 
Q102 End of survey.  
    
Please select the 'submit' button to save and submit your responses.   
    
Please note, once you submit, your responses can not be changed.   
  
   
o Submit  (1)  
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10.3. Appendix 3) International Physical Activity Questionnaire 
INTERNATIONAL PHYSICAL ACTIVITY 
QUESTIONNAIRE 
(October 2002) 
 
LONG LAST 7 DAYS SELF-ADMINISTERED FORMAT 
 
 
FOR USE WITH YOUNG AND MIDDLE-AGED ADULTS (15-69 years) 
 
The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires. Long (5 activity domains asked independently) and short (4 generic 
items) versions for use by either telephone or self-administered methods are 
available. The purpose of the questionnaires is to provide common instruments that 
can be used to obtain internationally comparable data on health–related physical 
activity. 
 
Background on IPAQ 
The development of an international measure for physical activity commenced in 
Geneva in 1998 and was followed by extensive reliability and validity testing 
undertaken across 12 countries (14 sites) during 2000. The final results suggest that 
these measures have acceptable measurement properties for use in many settings 
and in different languages, and are suitable for national population-based prevalence 
studies of participation in physical activity. 
 
Using IPAQ  
Use of the IPAQ instruments for monitoring and research purposes is encouraged. It 
is recommended that no changes be made to the order or wording of the questions 
as this will affect the psychometric properties of the instruments.  
 
Translation from English and Cultural Adaptation 
Translation from English is encouraged to facilitate worldwide use of IPAQ. 
Information on the availability of IPAQ in different languages can be obtained at 
www.ipaq.ki.se. If a new translation is undertaken we highly recommend using the 
prescribed back translation methods available on the IPAQ website. If possible please 
consider making your translated version of IPAQ available to others by contributing it 
to the IPAQ website. Further details on translation and cultural adaptation can be 
downloaded from the website. 
 
Further Developments of IPAQ  
International collaboration on IPAQ is on-going and an International Physical 
Activity Prevalence Study is in progress. For further information see the IPAQ 
website.  
 
More Information 
More detailed information on the IPAQ process and the research methods used in 
the development of IPAQ instruments is available at www.ipaq.ki.se and Booth, M.L. 
(2000). Assessment of Physical Activity: An International Perspective. Research 
Quarterly for Exercise and Sport, 71 (2): s114-20. Other scientific publications and 
presentations on the use of IPAQ are summarized on the website. 
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INTERNATIONAL PHYSICAL ACTIVITY QUESTIONNAIRE 
 
We are interested in finding out about the kinds of physical activities that people do 
as part of their everyday lives. The questions will ask you about the time you spent 
being physically active in the last 7 days. Please answer each question even if you 
do not consider yourself to be an active person. Please think about the activities you 
do at work, as part of your house and yard work, to get from place to place, and in 
your spare time for recreation, exercise or sport. 
 
Think about all the vigorous and moderate activities that you did in the last 7 days. 
Vigorous physical activities refer to activities that take hard physical effort and make 
you breathe much harder than normal. Moderate activities refer to activities that take 
moderate physical effort and make you breathe somewhat harder than normal. 
 
PART 1: JOB-RELATED PHYSICAL ACTIVITY 
 
The first section is about your work. This includes paid jobs, farming, volunteer work, 
course work, and any other unpaid work that you did outside your home. Do not 
include unpaid work you might do around your home, like housework, yard work, 
general maintenance, and caring for your family. These are asked in Part 3. 
 
1. Do you currently have a job or do any unpaid work outside your home? 
 
 Yes 
 
 No Skip to PART 2: TRANSPORTATION 
 
The next questions are about all the physical activity you did in the last 7 days as 
part of your paid or unpaid work. This does not include traveling to and from work. 
 
2.  During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, heavy construction, or climbing up stairs as part 
of your work? Think about only those physical activities that you did for at least 10 
minutes at a time. 
 
_____ days per week 
 
 No vigorous job-related physical activity Skip to question 4 
 
3. How much time did you usually spend on one of those days doing vigorous 
physical activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
4. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
physical activities like carrying light loads as part of your work? Please do not 
include walking. 
 
_____ days per week 
 
 No moderate job-related physical activity Skip to question 6 
227 
 
5. How much time did you usually spend on one of those days doing moderate 
physical activities as part of your work? 
 
_____ hours per day 
_____ minutes per day 
 
6. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time as part of your work? Please do not count any walking you did to travel to 
or from work. 
 
_____ days per week 
 
 No job-related walking Skip to PART 2: TRANSPORTATION 
 
7. How much time did you usually spend on one of those days walking as part 
of your work? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 2: TRANSPORTATION PHYSICAL ACTIVITY 
 
These questions are about how you traveled from place to place, including to places 
like work, stores, movies, and so on. 
 
8. During the last 7 days, on how many days did you travel in a motor vehicle 
like a train, bus, car, or tram? 
 
_____ days per week 
 
 No traveling in a motor vehicle Skip to question 10 
 
9. How much time did you usually spend on one of those days traveling in a 
train, bus, car, tram, or other kind of motor vehicle? 
 
_____ hours per day 
_____ minutes per day 
 
Now think only about the bicycling and walking you might have done to travel to and 
from work, to do errands, or to go from place to place. 
 
10. During the last 7 days, on how many days did you bicycle for at least 10 
minutes at a time to go from place to place? 
 
_____ days per week 
 
 No bicycling from place to place Skip to question 12 
228 
 
11. How much time did you usually spend on one of those days to bicycle from 
place to place? 
 
_____ hours per day 
_____ minutes per day 
 
12. During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time to go from place to place? 
 
_____ days per week 
 
 No walking from place to place Skip to PART 3: 
HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
13. How much time did you usually spend on one of those days walking from 
place to place? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR FAMILY 
 
This section is about some of the physical activities you might have done in the last 
7 days in and around your home, like housework, gardening, yard work, general 
maintenance work, and caring for your family. 
 
14. Think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, chopping wood, shoveling snow, or digging in the garden 
or yard? 
 
_____ days per week 
 
 No vigorous activity in garden or yard Skip to question 16 
 
 
15. How much time did you usually spend on one of those days doing vigorous 
physical activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
16. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
activities like carrying light loads, sweeping, washing windows, and raking in the 
garden or yard? 
 
_____ days per week 
 
 No moderate activity in garden or yard Skip to question 18 
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17. How much time did you usually spend on one of those days doing moderate 
physical activities in the garden or yard? 
 
_____ hours per day 
_____ minutes per day 
 
18. Once again, think about only those physical activities that you did for at least 
10 minutes at a time. During the last 7 days, on how many days did you do moderate 
activities like carrying light loads, washing windows, scrubbing floors and sweeping 
inside your home? 
 
_____ days per week 
 
 No moderate activity inside home Skip to PART 4: 
RECREATION, SPORT AND LEISURE-TIME PHYSICAL ACTIVITY 
 
19. How much time did you usually spend on one of those days doing moderate 
physical activities inside your home? 
 
_____ hours per day 
_____ minutes per day 
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL ACTIVITY 
 
This section is about all the physical activities that you did in the last 7 days solely 
for recreation, sport, exercise or leisure. Please do not include any activities you have 
already mentioned. 
 
20. Not counting any walking you have already mentioned, during the last 7 days, 
on how many days did you walk for at least 10 minutes at a time in your leisure 
time? 
 
_____ days per week 
 
 No walking in leisure time Skip to question 22 
 
21. How much time did you usually spend on one of those days walking in your 
leisure time? 
 
_____ hours per day 
_____ minutes per day 
 
22. Think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do vigorous physical 
activities like aerobics, running, fast bicycling, or fast swimming in your leisure time? 
 
_____ days per week 
 
 No vigorous activity in leisure time Skip to question 24 
 
23. How much time did you usually spend on one of those days doing vigorous 
physical activities in your leisure time? 
 
_____ hours per day 
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_____ minutes per day 
 
24. Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
physical activities like bicycling at a regular pace, swimming at a regular pace, and 
doubles tennis in your leisure time? 
 
_____ days per week 
 
 No moderate activity in leisure time Skip to PART 5: TIME 
SPENT SITTING 
 
25. How much time did you usually spend on one of those days doing moderate 
physical activities in your leisure time? 
_____ hours per day 
_____ minutes per day 
 
 
PART 5: TIME SPENT SITTING 
 
The last questions are about the time you spend sitting while at work, at home, while 
doing course work and during leisure time. This may include time spent sitting at a 
desk, visiting friends, reading or sitting or lying down to watch television. Do not 
include any time spent sitting in a motor vehicle that you have already told me about. 
 
26. During the last 7 days, how much time did you usually spend sitting on a 
weekday? 
 
_____ hours per day 
_____ minutes per day 
 
27. During the last 7 days, how much time did you usually spend sitting on a 
weekend day? 
 
_____ hours per day 
_____ minutes per day 
 
 
This is the end of the questionnaire, thank you for 
participating. 
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10.4. Appendix 4) Sarcoidosis Health Questionnaire 
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10.5. Appendix 5) Center for Epidemoiologic Studies Depression Scale 
(CES-D Scale) 
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10.6. Appendix 6) Chapter six Part A Survey 
Study 2 - Sarcoidosis 4 day food log 
incorporating symptom scales and 
physical activity levels. 
 
 
Start of Block: Information and informed consent 
 
Q67 Information Sheet: Establishing the existence of non-
pharmacological multifactorial patterns within Pulmonary Sarcoidosis  Study: 
Impact of diet and physical activity on symptom of pulmonary sarcoidosis.  
Ethics Code: 1617/028  Thank you for considering being a participant in this 
project.   Below you will find a short background to our work, and an outline of what 
you will be required to do as a participant in this study. 
   
 The aim of this study is to establish the effect of pulmonary sarcoidosis on a patient’s 
diet and physical activity levels and the influence on their symptoms to establish any 
trends. 
   
 Various recommendations are given to patients with pulmonary sarcoidosis to help 
manage the disease, including a healthy lifestyle, such as following a healthy diet or 
being as physically active as you can.   Anecdotally, foods high in antioxidants and 
anti-inflammatories have been suggested as an approach for managing the symptoms 
of sarcoidosis. Alongside this, exercise and physical activity are frequently 
recommended alongside any pharmacological treatment to improve symptoms and the 
overall health status of an individual.   Physical activity has been defined as any body 
movement that works your muscles and requires more energy than resting, examples 
include walking, running, dancing, swimming, yoga, and gardening.   However 
current research into diet, exercise and sarcoidosis is limited, therefore the aim of the 
current study is to establish physical activity and dietary patterns in pulmonary 
sarcoidosis. 
   
 Am I eligible to take part in the study?  
 You are eligible to take part in the study if you have been diagnosed with pulmonary 
sarcoidosis (this can be in addition to other forms of sarcoidosis and conditions) and 
over the age of 18 years. 
   
 What is expected of me?  The study comprises of two sections: 
   
 Section 1: Involves you completing an online electronic questionnaire comprised of 
validated surveys looking at physical activity, fatigue and symptoms. 
   
 The procedure involves completing an online survey that will take approximately 20 
minutes. Your responses will be confidential and we do not collect identifying 
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information such as your name, email address or IP address. 
   
 Section 2: Involves you completing a 7 day food and physical activity diary log. 
  
 You will be required to maintain your normal habitual lifestyle. You will then be 
asked to complete a food diary of what you consume on a daily basis for 7 days in a 
row, including timings, food types and quantity. Alongside this you will be required 
to log your physical activity (including length of time, type and intensity). This 
information will be collected via either a computer-based electronic file, or sent to you 
as a hardcopy, according to your preference.  You will be asked to provide your contact 
details at the end of the electronic questionnaire so that the researchers can send you 
the 7 day diary log with further instructions, please note, this information will not  be 
saved / linked with your responses to the online survey to maintain anonymity and 
confidentiality. 
  
 What are the benefits of taking part? 
 The benefits of this study will not only add knowledge to the current body of research 
but also help identify future areas of relevant research that may have been overlooked 
before or lacked scientific support. 
   
 What are the risks of taking part? 
 No identified risks other than those of typical computer use. Risks associated with 
using display screen equipment e.g. PC, Laptops, include upper limb disorders, back 
ache, fatigue, stress and temporary eye strain or headaches. Ensure you are positioned 
correctly and the questionnaire will only take a maximum of 30 minutes to complete. 
However, take short pauses and breaks if necessary. 
   
 What if I have a question or a query?  
 We are happy to answer any queries that you may have regarding the study. In the 
event of having any health concerns, we will advise you to contact your GP for further 
screening and advice. 
   
 What if I decide to withdraw? 
 Participants are permitted to withdraw from the study at any time and data from them 
will not be used. 
  
 What about my Confidentiality? 
 Any information given to us by you will remain confidential and all data will be kept 
anonymous. All data will be coded and saved as encrypted password protected files 
on a PC. Results of testing and analysis along with age, gender, stature and mass will 
be recorded. Participants will remain anonymous throughout the research, including 
the publication of the research which may result in availability of the research at the 
University Learning Resources Centre, through scientific journals and conference 
presentation. Any hard copy versions will be kept in locked offices/cabinets of lead 
applicant. 
 The only personnel authorised to access the data will be the researcher, principal 
investigator and the project participants (their individual data only). 
   
 If you have any questions or problems, please do not hesitate to contact the 
researchers or project supervisor: 
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 Name of Researcher: Luke Morton-Holtham 
 Email: K1214556@kingston.ac.uk    
   
 Name of Supervisor: Dr Hannah Moir 
 Email: H.Moir@kingston.ac.uk               
 Tel: 020 8417 2876    
   
 Thank you for your time & contribution to this study.  ELECTRONIC INFORMED 
CONSENT:  
    By clicking agree, you are agreeing to participate in this study, acknowledging that 
you understand that you can withdraw at any time, and understand that all the data 
collected will be confidential and stored securely in line with the Data Protection Act 
(2003).   
 It is important to mention that you will not need to provide your name, as this study 
is anonymous. However, you will need to provide basic demographic background 
information which will remain confidential. There are no risks of taking part in the 
study, but if you have any concerns whilst answering the questions, withdrawal from 
the study is permitted at any time, and the data collected up to that point will not be 
used. Please contact the researchers if you have any queries.  
  
 Statement by Participant  By clicking on the "agree" button below indicates that you 
consent to the following statements:    I confirm that I have read and understood 
the information sheet/letter of invitation for this study.   I have been informed of 
the purpose, risks, and benefits of taking part. "Establishing the existence of non--
pharmacological multi-factorial patterns within Pulmonary sarcoidosis."    I 
understand what my involvement will entail and any questions have been answered to 
my satisfaction.     I understand that my participation is entirely voluntary, and that 
I can withdraw at any time without prejudice.  I understand that all information 
obtained will be confidential.  I agree that research data gathered for the study may be 
published provided that I cannot be identified as a subject. Contact information has 
been provided should I (a) wish to seek further information from the investigator at 
any time for purposes of clarification (b) wish to make a complaint.   Statement by 
investigator     I have explained this project and the implications of participation in it 
to this participant without bias and I believe that the consent is informed and that 
he/she understands the implications of participation.  Name of investigator: Luke 
Morton-Holtham 
  
 Luke Morton Holtham  Signature of investigator:     23/06/17     
 If you do not wish to participate in the research study, please decline participation by 
clicking on the "disagree" button 
o Agree  (1)  
o Disagree  (2)  
 
Skip To: End of Survey If Information Sheet: Establishing the existence of non-
pharmacological multifactorial patterns with... = Disagree 
End of Block: Information and informed consent 
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Start of Block: Section one: 
 
Q1 Please select your age range (years): 
o 20 or under  (1)  
o 21-30  (2)  
o 31-40  (3)  
o 41-50  (4)  
o 51-60  (5)  
o 61+  (6)  
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Q2 Please indicate your ethnicity 
o White (English / Welsh / Scottish / Northern Irish / British/Irish/Gypsy 
Traveller  (1)  
o Black Caribbean  (2)  
o Black African  (3)  
o Black British  (4)  
o Mixed White &  Black Caribbean  (5)  
o Mixed White & Black African  (6)  
o Mixed White & Asian  (7)  
o Asian/Asian British  (8)  
o Indian  (9)  
o Pakistani  (10)  
o Bangladeshi  (11)  
o Japanese  (12)  
o Chinese  (13)  
o Arab  (14)  
o Other (Please specify)  (15) 
________________________________________________ 
 
 
 
Q4 Please select your gender: 
o Male  (1)  
o Female  (2)  
o Other (Please specify)  (3) 
________________________________________________ 
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Q3 Please select your weight range (kg):  
o Under 50  (1)  
o 51-60  (2)  
o 61-70  (3)  
o 71-80  (4)  
o 81-90  (5)  
o 91-100  (6)  
o 100+  (7)  
 
 
 
Q76 Please select your height range (cm): 
o Under 150  (1)  
o 151-160  (2)  
o 161-170  (3)  
o 171-180  (4)  
o 181-90  (5)  
o 191-200  (6)  
o 200+  (7)  
 
 
 
Q77 Please select your BMI Range. (If you do not know your BMI, you can calculate 
it by dividing your weight in kg by your height in meters and then dividing the answer 
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by your height (meters) again. For example for a person of 70kg weight and 1.8m 
height would be 70/1.8= 38.8 > 38.8/1.8 = 21.6 Therefore their BMI is 21.6 
o Under 18.5  (1)  
o 18.5-25  (2)  
o 25-30  (3)  
o 30+  (4)  
 
 
 
Q72 Please select how long you have been diagnosed with sarcoidosis: 
o Less than two years  (1)  
o 3-5 years  (2)  
o 5 years or more  (3)  
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Q73  
Considering your condition, select the type(s) of sarcoidosis you have. 
Please select all that apply. 
▢ Pulmonary  (1)  
▢ Skin  (2)  
▢ Heart  (3)  
▢ Eye  (4)  
▢ Endocrine system  (5)  
▢ Nervous system  (6)  
▢ Bone/Joint  (7)  
▢ Lymph nodes  (8)  
▢ Organ (spleen/liver/kidney)  (9)  
▢ Other (please specify):  (10) 
________________________________________________ 
 
End of Block: Section one: 
 
Start of Block: International physical activity questionnaire (IPAQ) 
 
Q5 Thank you for your answers so far.  
The next section involves the international physical activity questionnaire. 
 The International Physical Activity Questionnaires (IPAQ) comprises a set of 4 
questionnaires, with 5 domains.  The purpose of the questionnaires is to provide 
common instruments that can be used to obtain internationally comparable data on 
health–related physical activity. The questionnaire involves a maximum of 27 
questions and each question requires an answer.  
If you do not wish to complete this questionnaire please select 'skip' and you will be 
taken to the following section. 
o Skip  (1)  
 
Skip To: End of Block If Thank you for your answers so far.  The next section involves the international 
physical activity... = Skip 
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Q69 We are interested in finding out about the kinds of physical activities that people 
do as part of their everyday lives. The questions will ask you about the time you spent 
being physically active in the last 7 days. Please answer each question even if you do 
not consider yourself to be an active person. Please think about the activities you do 
at work, as part of your house and yard work, to get from place to place, and in your 
spare time for recreation, exercise or sport. 
Think about all the vigorous and moderate activities that you did in the last 7 
days. Vigorous physical activities refer to activities that take hard physical effort and 
make you breathe much harder than normal. Moderate activities refer to activities that 
take moderate physical effort and make you breathe somewhat harder than normal.  
 
 
 
Q35  
PART 1: JOB-RELATED PHYSICAL ACTIVITY  
 
The first section is about your work. This includes paid jobs, farming, volunteer work, 
course work, and any other unpaid work that you did outside your home. Do not 
include unpaid work you might do around your home, like housework, yard work, 
general maintenance, and caring for your family. These are asked in Part 3. 
Please select next to continue. 
 
 
 
Q6  
Do you currently have a job or do any unpaid work outside your home?   
 
o Yes  (1)  
o No  (2)  
 
Skip To: Q36 If Do you currently have a job or do any unpaid work outside your home? = No 
 
 
Q7 The next questions are about all the physical activity you did in the last 7 days as 
part of your paid or unpaid work. This does not include traveling to and from 
work.        During the last 7 days, on how many days did you do vigorous physical 
activities like heavy lifting, digging, heavy construction, or climbing up stairs as part 
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of your work? Think about only those physical activities that you did for at least 10 
minutes at a time.    
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q9 If The next questions are about all the physical activity you did in the last 7 days as part of 
your... = None 
 
 
Q8 How much time did you usually spend on one of those days doing vigorous 
physical activities as part of your work? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q9 Again, think about only those physical activities that you did for at least 10 minutes 
at a time. During the last 7 days, on how many days did you do moderate physical 
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activities like carrying light loads as part of your work? Please do not include 
walking. 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q13 If Again, think about only those physical activities that you did for at least 10 minutes at 
a time.... = None 
 
 
Q11 How much time did you usually spend on one of those days doing moderate 
physical activities as part of your work? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
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Q12 During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time as part of your work? Please do not count any walking you did to travel to 
or from work. 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q36 If During the last 7 days, on how many days did you walk for at least 10 minutes at a time 
as part o... = None 
 
 
Q13 How much time did you usually spend on one of those days walking as part of 
your work? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q36 PART 2: TRANSPORTATION PHYSICAL ACTIVITY  These questions are about 
how you traveled from place to place, including to places like work, stores, movies, 
and so on. 
Please select next to continue. 
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Q14 During the last 7 days, on how many days did you travel in a motor vehicle like 
a train, bus, car, or tram?    
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q17 If During the last 7 days, on how many days did you travel in a motor vehicle like a train, 
bus, car... = None 
 
 
Q15 How much time did you usually spend on one of those days traveling in a train, 
bus, car, tram, or other kind of motor vehicle? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q17 Now think only about the bicycling and walking you might have done to travel 
to and from work, to do errands, or to go from place to place. 
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 During the last 7 days, on how many days did you bicycle for at least 10 minutes at 
a time to go from place to place? 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q18 If Now think only about the bicycling and walking you might have done to travel to and 
from work, to... = None 
 
 
Q16 How much time did you usually spend on one of those days to bicycle from place 
to place? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
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Q18 During the last 7 days, on how many days did you walk for at least 10 minutes 
at a time to go from place to place? 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q37 If During the last 7 days, on how many days did you walk for at least 10 minutes at a time 
to go fro... = None 
 
 
Q19 How much time did you usually spend on one of those days walking from place 
to place? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q37 PART 3: HOUSEWORK, HOUSE MAINTENANCE, AND CARING FOR 
FAMILY This section is about some of the physical activities you might have done in 
the last 7 days in and around your home, like housework, gardening, yard work, 
general maintenance work, and caring for your family. 
Please select next to continue. 
 
 
 
Q20  
Think about only those physical activities that you did for at least 10 minutes at a time. 
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During the last 7 days, on how many days did you do vigorous physical activities like 
heavy lifting, chopping wood, shoveling snow, or digging in the garden or yard? 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q22 If Think about only those physical activities that you did for at least 10 minutes at a time. 
During... = None 
 
 
Q21 How much time did you usually spend on one of those days doing vigorous 
physical activities in the garden or yard? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q22 Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
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activities like carrying light loads, sweeping, washing windows, and raking in the 
garden or yard?    
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q25 If Again, think about only those physical activities that you did for at least 10 minutes at 
a time.... = None 
 
 
Q23 How much time did you usually spend on one of those days doing moderate 
physical activities in the garden or yard? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q25 Once again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
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activities like carrying light loads, washing windows, scrubbing floors and sweeping 
inside your home? 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q38 If Once again, think about only those physical activities that you did for at least 10 minutes 
at a... = None 
 
 
Q24 How much time did you usually spend on one of those days doing moderate 
physical activities inside your home? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q38  
 
 
PART 4: RECREATION, SPORT, AND LEISURE-TIME PHYSICAL 
ACTIVITY This section is about all the physical activities that you did in the last 7 
days solely for recreation, sport, exercise or leisure. Please do not include any 
activities you have already mentioned. 
Please select next to continue. 
 
 
 
Q26  
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 Not counting any walking you have already mentioned, during the last 7 days, on 
how many days did you walk for at least 10 minutes at a time in your leisure time?  
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q28 If Not counting any walking you have already mentioned, during the last 7 days, on how 
many days did... = None 
 
 
Q27  
How much time did you usually spend on one of those days walking in your leisure 
time? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q28 Think about only those physical activities that you did for at least 10 minutes at 
a time. During the last 7 days, on how many days did you do vigorous physical 
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activities like aerobics, running, fast bicycling, or fast swimming in your leisure 
time? 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q30 If Think about only those physical activities that you did for at least 10 minutes at a time. 
During... = None 
 
 
Q29 How much time did you usually spend on one of those days doing vigorous 
physical activities in your leisure time? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q30 Again, think about only those physical activities that you did for at least 10 
minutes at a time. During the last 7 days, on how many days did you do moderate 
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physical activities like bicycling at a regular pace, swimming at a regular pace, and 
doubles tennis in your leisure time? 
o 1  (1)  
o 2  (2)  
o 3  (3)  
o 4  (4)  
o 5  (5)  
o 6  (6)  
o 7  (7)  
o None  (8)  
 
Skip To: Q39 If Again, think about only those physical activities that you did for at least 10 minutes at 
a time.... = None 
 
 
Q31 How much time did you usually spend on one of those days doing moderate 
physical activities in your leisure time? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q39  
 
 
PART 5: TIME SPENT SITTING 
   
 The last questions are about the time you spend sitting while at work, at home, while 
doing course work and during leisure time. This may include time spent sitting at a 
desk, visiting friends, reading or sitting or lying down to watch television. Do not 
include any time spent sitting in a motor vehicle that you have already told me about. 
 
 
Please select next to continue. 
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Q40  
During the last 7 days, how much time did you usually spend sitting on a weekday? 
  
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q33 During the last 7 days, how much time did you usually spend sitting on a 
weekend day? 
o Hours per day  (1) 
________________________________________________ 
o Minutes per day  (2) 
________________________________________________ 
 
 
 
Q34  
Thank you for taking the time to complete the IPAQ questionnaire please click 'next' 
to continue. 
 
End of Block: International physical activity questionnaire (IPAQ) 
 
Start of Block: MRC breathlessness scale 
 
Q41  
The following survey item is a scale. Please select the most relevant statement for you. 
 
 
If you do not want to complete this item, please select 'skip'. 
 
 
Otherwise, please select next to continue. 
o Skip  (1)  
 
Skip To: End of Block If The following survey item is a scale. Please select the most relevant statement 
for you. If you d... = Skip 
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Q42 Select the statement most accurate to your current personal situation: 
o Not troubled by breathlessness except on strenuous exercise  (1)  
o Short of breath when hurrying on the level or walking up a slight hill  (2)  
o Walks slower than most people on the level, stops after a mile or so, or stops 
after 15 minutes walking at own pace.  (3)  
o Stops of breath after walking about 100 yards or after a few minutes on level 
ground.  (4)  
o Too breathless to leave the house, or breathless when undressing.  (5)  
 
End of Block: MRC breathlessness scale 
 
Start of Block: Fatigue assessment Scale 
 
Q43  
Thank you for your answers so far.   
    
Below are a number of questions about possible complaints. Please select the answer 
to each question that is applicable to you. Please give an answer to each question, even 
if you do not have any complaints at the moment. The aim of this questionnaire is to 
find out how you experience your complaints. There are no correct or incorrect 
answers. It is important that you are honest.   
    
If you do not wish to complete the fatigue assessment scale then please select Skip, 
otherwise please select next to continue. 
o Skip  (1)  
 
Skip To: End of Block If Thank you for your answers so far.   Below are a number of questions about 
possible complaints. P... = Skip 
 
 
Q70  
The following ten statements refer to how you usually feel.  
Per statement you can choose one out of five answer categories, varying from 'Never' 
to 'Always'. 
 
Please select the answer to each question that is most applicable to you. 
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Q44 I am Bothered by fatigue 
o Never  (1)  
o Sometimes  (2)  
o Regularly  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
Q46  
I get tired very quickly 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
Q48  
I don't do much during the day 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
257 
 
Q49 I have enough energy for everyday life 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
Q50  
Physically, I feel exhausted 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
Q51  
I have problems to start things  
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
258 
 
Q52  
I have problems to think clearly 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
Q53  
I feel no desire to do anything 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
 
 
Q54  
Mentally, I feel exhausted 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
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Q55  
When I am doing something, I can concentrate quite well. 
o Never  (1)  
o Sometimes  (2)  
o Regulary  (3)  
o Often  (4)  
o Always  (5)  
 
End of Block: Fatigue assessment Scale 
 
Start of Block: Section two: 
 
Q74  
Section two: 
 
If you are willing to participate in the second part of this study, please provide your 
name and email address below and the research team will be in touch with further 
information. 
 
 
If you would prefer to receive the second part of this study as a hardcopy, please 
provide your postal address. 
 
 
Additionally a follow-up interview and/or focus group may be conducted regarding 
the findings of study one and two. If you are willing to take part please leave your 
details and indicate in the relevant box. 
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Thank you again for taking the time to participate in our project.   
o Name  (1) ________________________________________________ 
o Email Address:  (2) 
________________________________________________ 
o Address (optional):  (3) 
________________________________________________ 
o Address 2  (4) ________________________________________________ 
o City  (5) ________________________________________________ 
o Postal code  (6) ________________________________________________ 
o Country  (7) ________________________________________________ 
o Telephone number (optional):  (8) 
________________________________________________ 
o Please state (yes/no) if would like to be part of a follow-up interview/focus 
group.  (9) ________________________________________________ 
 
 
 
Q71  
End of survey. 
 
 
Please select the 'submit' button to save and submit your responses. 
 
 
Please note, once you submit, your responses can not be changed. 
o Submit  (1)  
 
End of Block: Section two: 
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10.7. Appendix 7) Fatigue Assessment Scale (FAS) 
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10.8. Appendix 8) MRC Breathlessness Scale 
 
10.9. Appendix 9) Informed Consent 
I, the undersigned, do hereby acknowledge: 
• Consent to perform a health-related fitness appraisal consisting of the evaluation 
of (tick appropriate boxes): 
  Standing Height 
  Weight 
  Waist Circumference 
  Body fat percentage 
  Six-minute walk test 
  Quadricep/Hamstring Peak Torque 
 
• Consent to answer questions concerning my current levels of physical activity 
participation and my lifestyle; 
• Understanding that my heart rate and blood pressure will be measured prior to 
and at the completion of the appraisal; 
• Understanding that the results from my health-related fitness appraisal will assist 
in determining the type and amount of physical activity most appropriate for my 
level of fitness; 
  Hand Grip Strength (R/L) 
  Push-Ups (max #) 
  Sit and Reach 
  Vertical Jump/Leg Power 
  Lung Function 
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• Consent to perform a supervised exercise training session (if desired) based on 
the findings of my fitness appraisal, consisting of a warm-up, cardiovascular 
training, musculoskeletal training, flexibility exercises and a cool-down; 
• Consent to have my blood pressure and heart rate measured periodically during 
my supervised exercise training session(s);  
• Understanding that there are potential risks during exercise (i.e., episodes of 
transient light headedness, loss of consciousness, abnormal blood pressure, chest 
discomfort, leg cramps, and nausea), in rare instances heart rhythm disturbances 
or heart attacks, and that I assume willfully those risks;  
• Obligation to immediately inform the Investigator of any pain, discomfort, 
fatigue, or any other symptoms that I may suffer during and immediately after 
the appraisal and/or exercise training session; 
• Understanding that I may stop or delay any further exercise if I so desire and that 
the Investigator may terminate the exercise session upon observation of any 
symptoms of undue distress or abnormal response; 
• Understanding that I may ask any questions or request further explanation or 
information about the procedures at any time before, during, and after exercise; 
• That I have read, understood, and completed the Physical Activity Readiness 
Questionnaire (PAR-Q) and answered NO to all the questions and/or received 
clearance to participate in unrestricted physical activity/exercise from a 
physician. 
This form must be completed, signed and submitted to Investigator, along with the 
completed PAR-Q, at the time of the appraisal. The form must also be witnessed at 
the time of signing. 
 
I AGREE THAT I HAVE READ AND UNDERSTAND THIS DOCUMENT 
 
 
_________________________  __________________________ 
 ____________ 
     Printed Name of Client    Signature of Client            Date 
 
 
_________________________  __________________________ 
 ____________ 
     Printed Name of Witness             Signature of Witness             Date 
             (Investigator)         (Investigator) 
 
 
